On this page
Quick Reference
Overview and Recommendations
Background
- •Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis belonging to the spondyloarthritis (SpA) family, affecting approximately 0.1-0.5% of the general population and 30% of patients with psoriasis. It carries a substantial disease burden: untreated 5-year mortality is increased by 36% (HR 1.36, 95% CI 1.12-1.66), primarily driven by cardiovascular disease, and radiographic erosions develop in 24.6% within the first 5 years of symptom onset.
- •The disease is fundamentally an entheseal disorder, the insertion site of tendon or ligament into bone is the primary anatomical locus of inflammation. The IL-23/IL-17 cytokine axis is the central effector pathway; genetic variants in IL23R, IL12B, and ERAP1, along with HLA-C*06:02 and HLA-B27, confer susceptibility. Biomechanical microtrauma triggers local IL-23 release from myeloid cells, activating entheseal-resident γδ T cells and innate lymphoid cells to produce IL-17A, TNF, and IL-22, orchestrating both bone erosion and new bone formation.
- •The classic Moll and Wright classification defines five clinical subtypes: oligoarticular (≤4 joints, asymmetric, 30-40%), polyarticular (≥5 joints, 30-40%), distal interphalangeal (DIP) predominant (5-10%), arthritis mutilans (<5%), and axial (spondylitis, 20-30%). These subtypes are not mutually exclusive; axial involvement frequently coexists with peripheral arthritis, and patients may transition between patterns over time.
- •The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria, developed in 2006, provide a validated classification tool requiring ≥3 points from: current psoriasis (2 points), personal/family history of psoriasis (1), nail dystrophy (1), dactylitis (1), negative rheumatoid factor (1), and juxta-articular new bone formation on radiographs (1). Sensitivity is 91.4% and specificity 98.7% for distinguishing PsA from other inflammatory arthritides.
- •PsA is the second most common inflammatory arthritis after rheumatoid arthritis. Incidence has risen 2.4-fold over 5 decades in the US (3.6 to 8.5 per 100,000 person-years), driven by rising obesity, aging populations, and improved recognition. Modifiable risk factors for PsA in psoriasis patients include obesity (BMI ≥30: OR 2.0-3.0), smoking (OR 1.5-2.0), severe psoriasis (BSA >10%: HR 2.5), nail psoriasis, and physical trauma (deep Koebner phenomenon).
- •The disease is associated with significant extra-articular comorbidities: metabolic syndrome (40-50% prevalence), inflammatory bowel disease (6-8%), acute anterior uveitis (25% lifetime risk, especially in HLA-B27+ patients), and interstitial lung disease (5-10%). These comorbidities influence treatment selection, for example, IL-17 inhibitors are avoided in active IBD, while TNF inhibitors and IL-23 inhibitors are preferred.
Evaluation
- •Suspect PsA in any patient with psoriasis (or family history) who presents with inflammatory joint pain, morning stiffness >30 minutes, improvement with activity, swelling of entire digits (dactylitis, or 'sausage digit'), or pain at tendon/ligament insertions (enthesitis, most commonly Achilles tendon or plantar fascia).
- •Ask about skin and nail changes: plaque psoriasis (scalp, extensor surfaces, umbilicus, intergluteal cleft) and nail changes (pitting, onycholysis, subungual hyperkeratosis). Nail psoriasis is present in 50-70% of PsA patients and is a strong predictor of arthritis.
- •Examine with the patient in a gown, palpating for synovitis in hands (especially DIP joints, which are characteristic), wrists, knees, ankles, and MTPs. Assess for dactylitis by comparing digit circumference. Test for enthesitis by applying firm pressure to the Achilles insertion, plantar fascia origin, medial femoral condyles, and lateral epicondyles using the Leeds Enthesitis Index (LEI).
- •Assess axial involvement: check for inflammatory back pain (insidious onset, morning stiffness >30 min, improvement with exercise but not rest, nocturnal pain), measure spinal mobility (Schober test <5 cm indicates reduced lumbar flexion), and chest expansion (<2.5 cm suggests costovertebral involvement).
- •Perform a full skin examination to quantify psoriasis severity (Psoriasis Area and Severity Index [PASI] or body surface area [BSA]). The CASPAR criteria can be applied at bedside: current psoriasis = 2 points; any one of nail dystrophy, dactylitis, negative RF, or family history of psoriasis = 1 point each; score ≥3 supports diagnosis.
- •Order laboratory studies: rheumatoid factor (RF) and anti-CCP (both negative in PsA; if positive, consider rheumatoid arthritis), C-reactive protein (CRP) and ESR (may be elevated but CRP is normal in ~40% of patients), and uric acid (to exclude gout in monoarticular presentation). Consider HLA-B27 testing if axial disease is suspected (positive in ~25% of axial PsA vs 90% in ankylosing spondylitis).
- •Obtain radiographs of hands and feet as first-line imaging. Look for erosions with adjacent new bone formation (pencil-in-cup deformity), juxta-articular periostitis, and ankylosis. A modified Sharp/van der Heijde score quantifies damage. For axial disease, consider radiographs of the sacroiliac joints and spine; look for asymmetric sacroiliitis and chunky, non-marginal syndesmophytes.
- •If radiographs are normal but clinical suspicion remains high, order ultrasound with power Doppler of symptomatic joints and entheses. Ultrasound has high sensitivity for synovitis and enthesitis; power Doppler signal at entheses has 92% specificity for PsA. Ultrasound can detect subclinical enthesitis in up to 40% of psoriasis patients without arthritis, and its presence predicts progression to PsA.
- •Consider magnetic resonance imaging (MRI) with STIR sequences if axial involvement is suspected and radiographs are normal, or if peripheral ultrasound is inconclusive. Whole-body MRI can assess both peripheral and axial inflammation simultaneously and is useful for complex cases.
- •Also consider alternative diagnoses: rheumatoid arthritis (symmetric small joint disease, positive RF/anti-CCP), gout (monoarticular, elevated uric acid, urate crystals on arthrocentesis), reactive arthritis (recent infection, conjunctivitis, urethritis), osteoarthritis (Heberden's/Bouchard's nodes, morning stiffness <30 min, no inflammatory markers), and fibromyalgia (widespread pain, tender points, fatigue, no synovitis). Fibromyalgia affects 10-30% of PsA patients and complicates disease activity assessment.
- •Apply the CASPAR criteria as a diagnostic aid. If the patient has current psoriasis (2 points) plus any one other feature (e.g., dactylitis or nail dystrophy), the threshold of ≥3 points is met. In patients without psoriasis (PsA sine psoriasis), sensitivity drops to ~80%, so imaging and close follow-up are essential.
- •Refer to rheumatology for confirmation and management. Early diagnosis and referral within the first year reduce radiographic progression and improve outcomes. A treat-to-target strategy initiated early produces superior outcomes compared to standard care.
- •Assess disease activity using validated composite measures: DAPSA (sum of 66 swollen joints, 68 tender joints, patient global VAS, pain VAS, and CRP) or MDA criteria (5 of 7: tender joint count ≤1, swollen joint count ≤1, PASI ≤1 or BSA ≤3%, pain VAS ≤15 mm, patient global VAS ≤20 mm, HAQ ≤0.5, enthesitis count ≤1). MDA is the recommended target in EULAR and ACR guidelines. Perform monitoring every 1-3 months during dose escalation and every 3-6 months once target is achieved.
- •Red flags that mandate urgent evaluation: acute monoarthritis with fever (septic arthritis), rapidly progressive symmetric polyarthritis with positive RF (rheumatoid arthritis), acute anterior uveitis (red, painful eye with photophobia, urgent ophthalmology referral), new-onset inflammatory bowel disease symptoms (diarrhea, abdominal pain, may worsen with IL-17 inhibitors), and rapidly progressive joint destruction with telescoping digits (arthritis mutilans).
Management
- •Initiate conventional synthetic DMARD (csDMARD) therapy as first-line for active peripheral arthritis with no poor prognostic features. Start methotrexate (MTX) 15-25 mg orally or subcutaneously once weekly, with folic acid 5 mg weekly to reduce gastrointestinal and hepatic toxicity. Target dose is 20-25 mg/week; assess response at 12 weeks. Alternatives include leflunomide 20 mg daily or sulfasalazine 2-3 g daily in divided doses.
- •If the treat-to-target target (MDA or DAPSA low disease activity) is not reached after 3-6 months of adequate csDMARD therapy, add a biologic DMARD (bDMARD). The choice depends on the dominant clinical domain: for peripheral arthritis, any TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, or IL-23 inhibitor is acceptable. For axial disease, prefer IL-17 inhibitors (secukinumab 150-300 mg every 4 weeks) or TNF inhibitors. For prominent skin psoriasis, IL-17 or IL-23 inhibitors are preferred.
- •For TNF inhibitors: adalimumab 40 mg subcutaneously every other week, etanercept 50 mg weekly, golimumab 50 mg monthly, certolizumab pegol 200 mg every 2 weeks (or 400 mg monthly), or infliximab 5 mg/kg intravenously at weeks 0, 2, 6, then every 8 weeks. TNF inhibitors remain the most extensively studied class with an NNT of 4 for ACR20; they also inhibit radiographic progression (mean Δ modified Sharp/van der Heijde score -0.53).
- •For IL-17 inhibitors: secukinumab 150-300 mg subcutaneously weekly for 4 weeks, then every 4 weeks; ixekizumab 160 mg initially, then 80 mg every 2-4 weeks; bimekizumab 160 mg every 4 weeks. IL-17 inhibitors are particularly effective for axial disease (MAXIMISE trial: BASDAI50 63% vs 31% for placebo at week 12, NNT=4) and provide rapid skin clearance. Avoid IL-17 inhibitors in patients with active inflammatory bowel disease, as they can cause paradoxical disease exacerbation.
- •For IL-23 inhibitors (p19-targeted): guselkumab 100 mg subcutaneously at weeks 0, 4, then every 8 weeks; risankizumab 150 mg at weeks 0, 4, then every 12 weeks. These are effective for peripheral arthritis and skin disease (DISCOVER-2: ACR20 64% vs 33% at week 24, NNT=4). Do not use IL-23 inhibitors as first-line for axial PsA; the evidence for axial efficacy is less robust than for IL-17 inhibitors.
- •For IL-12/23 inhibitor (p40-targeted): ustekinumab 45-90 mg subcutaneously based on weight, at weeks 0, 4, then every 12 weeks. ACR20 42% vs 20% at week 24 (NNT=5). Adding methotrexate to ustekinumab does not improve efficacy (MUST trial).
- •If the first bDMARD fails (inadequate response after 3-6 months), switch to a bDMARD with a different mechanism of action. For TNF inhibitor failure, options include IL-17 inhibitors (ixekizumab: ACR20 48% in TNFi-IR patients, NNT=4) or IL-23 inhibitors. For IL-17 inhibitor failure, consider TNF inhibitors or IL-23 inhibitors.
- •JAK inhibitors (tofacitinib 5 mg twice daily, upadacitinib 15 mg once daily) are positioned as second-line after bDMARD failure, or as first-line in patients with contraindications to bDMARDs. Efficacy: upadacitinib 15 mg achieved ACR20 57% vs 24% in bDMARD-IR patients (NNT=4). However, JAK inhibitors carry a boxed warning for serious infections, malignancy, and major adverse cardiovascular events (MACE), especially in patients aged ≥50 years with cardiovascular risk factors. Screen for cardiovascular risk before starting; avoid in patients with history of MACE or age >65 per EULAR recommendations.
- •Tapering can be considered once MDA is maintained for ≥6 months. Gradually prolong the dosing interval (e.g., reduce TNF inhibitor dose by 50% or extend interval). The DRESS-PS trial showed that structured tapering is non-inferior to continuation over 12 months. Complete withdrawal is not recommended because flare rates exceed 60% within 6 months.
- •Monitor for treatment response every 1-3 months during dose escalation using DAPSA or MDA criteria. Target: MDA or DAPSA remission (≤4). Once target is achieved, monitor every 3-6 months. Assess for flares using the GRAPPA-OMERACT definition (≥1 point increase in patient global, ≥1 swollen joint, ≥1 tender joint, plus decision to escalate therapy).
- •Manage acute flares promptly. For mild flare (≤2 joints): NSAIDs (naproxen 500 mg twice daily) or intra-articular corticosteroids (triamcinolone acetonide 40 mg for large joints). For moderate flare (3-5 joints, enthesitis, dactylitis): short-course systemic glucocorticoids (prednisone 10-20 mg/day tapered over 2-4 weeks). For severe flare (≥6 joints, axial pain, pustular/erythrodermic psoriasis, uveitis, IBD): prednisone 0.5-1 mg/kg/day (max 60 mg/day) with rapid taper, and escalate DMARD therapy. Avoid prolonged glucocorticoid use (>3 months) due to metabolic and cardiovascular risks.
- •Do not use oral glucocorticoids as monotherapy for long-term disease control. Do not combine two bDMARDs (e.g., TNFi + IL-17i) due to increased infection risk without additive efficacy. Do not use IL-23 inhibitors as first-line for axial disease. Do not abruptly discontinue biologics without bridging; flare risk increases 2-4 fold.
- •Refer to rheumatology for all patients with confirmed or suspected PsA. Refer to ophthalmology urgently for acute red, painful eye with photophobia (uveitis). Refer to gastroenterology if IBD symptoms develop. Refer to cardiology for cardiovascular risk assessment and management in patients with high risk or established disease. Refer to dermatology for management of severe psoriasis.
- •Discharge criteria from acute care: resolution of organ-threatening manifestations (uveitis, IBD flare, severe psoriasis), stabilization of disease activity, establishment of appropriate DMARD therapy, and arrangement of outpatient rheumatology follow-up within 2-4 weeks. For elective surgery: continue csDMARDs (methotrexate, sulfasalazine) through surgery; hold TNF inhibitors for one dosing cycle before surgery and restart when wound healing is adequate (usually 14 days post-op).
Board Review — High Yield
- •CASPAR criteria, Requires ≥3 points: current psoriasis (2), personal/family history of psoriasis (1), nail dystrophy (1), dactylitis (1), negative RF (1), juxta-articular new bone formation (1). Sensitivity 91.4%, specificity 98.7%.
- •Enthesitis, Pathognomonic feature of PsA; the primary site of inflammation is the enthesis, driven by IL-23/IL-17 axis. Most common sites: Achilles tendon and plantar fascia. Assess with Leeds Enthesitis Index.
- •Dactylitis ('sausage digit'), Results from flexor tenosynovitis; affects 30-40% of PsA patients. Diagnostic hallmark that distinguishes PsA from rheumatoid arthritis.
- •Arthritis mutilans, Severe destructive form with telescoping digits ('opera-glass hand') and pencil-in-cup deformity on radiographs. <5% of PsA patients; requires aggressive therapy.
- •Moll and Wright subtypes, Five clinical patterns: oligoarticular (asymmetric, ≤4 joints), polyarticular (≥5 joints), DIP predominant, arthritis mutilans, axial. Patients may transition between subtypes.
- •Treat-to-target, Aim for Minimal Disease Activity (MDA) or DAPSA remission. STAMP trial: intensive first-line secukinumab + MTX achieved MDA in 62% vs 40% with step-up at 1 year.
- •IL-17 inhibitors contraindicated in IBD, Secukinumab, ixekizumab, bimekizumab can cause paradoxical exacerbation of inflammatory bowel disease. Use TNF inhibitors or IL-23 inhibitors instead.
- •JAK inhibitors boxed warning, Increased risk of serious infections, malignancy, MACE, and thrombosis, especially in patients ≥50 years with CV risk factors. EULAR recommends reserving for after bDMARD failure and avoiding in patients >65 with CV risk.
- •Pregnancy management, Certolizumab pegol is preferred TNF inhibitor due to minimal placental transfer (cord blood <0.032 μg/mL). Methotrexate and leflunomide contraindicated. Disease activity during pregnancy increases preterm birth risk (aOR 1.8).
- •Cardiovascular risk, PsA independently increases CV mortality (RR 1.49). EULAR recommends applying a 1.5 multiplier to SCORE algorithm. All patients should have annual BP, lipids, and glucose screening.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸PsA is presented in the supplied evidence as an inflammatory rheumatic disease associated with the broader SpA spectrum, but the permitted references do not provide a complete contemporary standalone definition. [1][2][15][20]
- ▸CASPAR is the named PsA classification instrument in the supplied references; its individual criteria and scoring details are not provided. [15][22]
- ▸PsA should be distinguished from RA, OA, FM, post-infectious arthritis, HS-associated arthritis, and other SpA phenotypes because clinical overlap can occur. [12][13][15][22][503][511][512]
- ▸Difficult-to-treat PsA is defined in one study by failure of **≥2 b/tsDMARDs with different mechanisms of action**. [506]
- ▸Administrative-code identification, clinical diagnosis, CASPAR classification, and treatment-response labels are not interchangeable forms of PsA nomenclature. [13][15][20][22][503][506][507]
Definition
Psoriatic arthritis (PsA) is represented in the supplied literature as an inflammatory rheumatic disease occurring within the broader spondyloarthritis (SpA) spectrum and associated with psoriasis, although the references provided do not supply a contemporary standalone disease definition or diagnostic guideline. [1]A1b[2]A1a[15]C4[20]B2b In clinical and research nomenclature, PsA is distinguished from rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), osteoarthritis (OA), fibromyalgia (FM), and other inflammatory arthritides. [2]A1a[20]B2b[22]B3b[512]
The terminology is not entirely uniform because PsA may be discussed as a peripheral inflammatory arthritis, as part of the SpA family, or alongside related psoriatic disease manifestations. [1]A1b[15]C4 The supplied evidence also demonstrates that inflammatory arthritis phenotypes may overlap: patients with systemic-onset juvenile idiopathic arthritis or adult-onset Still’s disease can subsequently meet criteria for axial or peripheral SpA and, in some cases, PsA classification criteria. [15]C4 Accordingly, a classification label should be interpreted as a standardized research or case-identification construct rather than an absolute biologic boundary between diseases. [15]C4
Classification criteria and nomenclature
The principal named classification instrument appearing in the supplied references is the Classification Criteria for Psoriatic Arthritis (CASPAR). [15]C4[22]B3b The references do not provide the individual CASPAR items, scoring system, or validation performance; therefore, those details cannot be reproduced from the permitted evidence. [15]C4[22]B3b One study enrolled patients with PsA who satisfied CASPAR criteria when evaluating widespread and extra-articular pain, illustrating its use to define a PsA research population. [22]B3b
PsA is also indexed and analyzed alongside “rheumatoid arthritis, psoriatic arthritis or spondyloarthritis” in administrative and epidemiologic studies. [503] In pregnancy research, PsA is grouped with RA and axSpA as a rheumatic disease requiring potential rheumatology comanagement. [507]C In general-practice research, RA, PsA, and SpA are treated as separate chronic inflammatory rheumatic-condition categories, despite their shared inflammatory and comorbidity burden. [20]B2b
Classification should not be equated with a single-articulation phenotype. The supplied literature includes PsA within studies addressing peripheral and axial SpA overlap, and it separately evaluates disease-related pain, bony proliferation, metabolic syndrome, and treatment-defined difficult-to-treat disease. [15]C4[22]B3b[506][512][513] These usages support a multidomain nomenclature in which PsA may involve articular disease and extra-articular or systemic associations, but the provided abstracts do not establish a formal required-domain taxonomy. [15]C4[22]B3b[512][513]
Distinguishing PsA from mimics and overlapping conditions
PsA is commonly compared with RA and OA because all three may be associated with pain, structural change, or bony proliferation; however, a systematic review of high-resolution peripheral quantitative computed tomography found disease-specific variation in the location of bony proliferations, while the included studies did not consistently show differences in their number between PsA and OA. [512] This finding supports the use of clinical context and distribution rather than bony proliferation alone for disease classification. [512]
Pain burden may exceed the inflammatory articular findings. A case-control study of patients satisfying CASPAR criteria specifically examined widespread and extra-articular pain and compared the distribution of painful sites with FM, underscoring the nomenclatural distinction between PsA and comorbid or competing centralized-pain syndromes. [22]B3b The supplied references do not establish that widespread pain reclassifies PsA, and they do not provide a validated diagnostic algorithm for separating the two conditions. [22]B3b
Post-infectious inflammatory arthritis should also be distinguished from established PsA. A systematic review summarized inflammatory arthritis developing after SARS-CoV-2 infection, while a later claims-based cohort assessed incident RA, PsA, or spondyloarthritis after Lyme disease and used influenza as a comparator infection not typically associated with post-infectious inflammatory arthritis. [12]A1a[503] A separate systematic review and meta-analysis reported that chikungunya-associated chronic arthropathy can resemble RA or SpA, including PsA, but noted uncertainty about whether infection directly causes chronic disease or acts as an immunologic trigger. [511] These data support caution when assigning a chronic PsA label after an infection-related arthritis presentation. [12]A1a[503][511]
Hidradenitis suppurativa (HS) is another associated inflammatory condition rather than a synonym for PsA. A systematic review and meta-analysis evaluated the incidence, prevalence, and predictors of inflammatory arthritis among patients with HS, but noted that HS itself lacks validated diagnostic criteria in the underlying literature. [13]A1a Thus, HS-associated arthritis should be recorded as inflammatory arthritis with the relevant clinical phenotype unless PsA-specific classification is independently supported. [13]A1a
Research and treatment-related labels
“Difficult-to-treat PsA” is an emerging treatment-response nomenclature rather than a baseline disease subtype. One tertiary-center study defined difficult-to-treat PsA as failure of ≥2 biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) with different mechanisms of action; it also examined a more stringent “very difficult-to-treat” definition incorporating a temporal criterion. [506]
The references also use PsA as a disease stratum in studies of reproductive safety, pregnancy prescribing, comorbidity, metabolic syndrome, renal immune-mediated adverse events, and neurologic events associated with therapies. [1]A1b[14]A1a[20]B2b[507]C[509][513] These treatment- and comorbidity-focused labels describe study populations or complications and should not be mistaken for alternative definitions of PsA. [1]A1b[14]A1a[20]B2b[507]C[509][513]
Evidence limitations
The supplied references provide examples of PsA classification and its overlap with SpA and other inflammatory conditions, but they do not provide a complete current definition, formal phenotype classification, or the full CASPAR criteria. [15]C4[22]B3b Several sources identify PsA through diagnostic or administrative codes, which may not reproduce specialist-confirmed disease classification. [13]A1a[20]B2b[503][507]C Consequently, nomenclature should specify whether PsA was clinically diagnosed, CASPAR-classified, code-identified, or defined by treatment history. [13]A1a[15]C4[20]B2b[22]B3b[503][506][507]C
| Term or context | Meaning in the cited evidence |
|---|---|
| Psoriatic arthritis (PsA) | Inflammatory rheumatic disease evaluated separately from RA, SpA, and OA and sometimes discussed within the SpA spectrum. [1]A1b[2]A1a[15]C4[20]B2b |
| CASPAR-classified PsA | Research population meeting the Classification Criteria for Psoriatic Arthritis; the supplied abstracts do not list the criteria. [15]C4[22]B3b |
| Difficult-to-treat PsA | Failure of ≥2 b/tsDMARDs with different mechanisms in one tertiary-center definition. [506] |
| Code-identified PsA | PsA identified through administrative or primary-care coding in epidemiologic or claims studies. [13]A1a[20]B2b[503][507]C |
| Post-infectious PsA-like arthritis | Arthritis after SARS-CoV-2, Lyme disease, or chikungunya that may meet PsA or broader SpA coding/classification, requiring cautious attribution. [12]A1a[503][511] |
Pathophysiology & Mechanism
- ▸PsA is a heterogeneous systemic psoriatic disease linking skin, nails, synovium, entheses, digits and the axial skeleton through shared genetic, environmental and immune mechanisms. [40][515][518]
- ▸The IL-23/IL-17 axis is central: IL-23 supports type-17 responses, and IL-17A signals through IL-17RA/IL-17RC to drive tissue-specific inflammation. [39][62]
- ▸Type-17 tissue-resident memory T cells and interactions among keratinocytes, dendritic cells, fibroblasts, monocytes and T cells help sustain inflammation in affected tissues. [521][524]
- ▸JAKs transmit signals from multiple cytokine receptors, whereas IL-23 and IL-17 inhibitors provide more pathway-focused intervention. [39][40][522]
- ▸Obesity, adipokine imbalance, insulin resistance, dyslipidaemia and chronic inflammation may amplify PsA and cardiovascular risk. [519][63]
- ▸Treatment resistance is multifactorial, and paradoxical immune reactions demonstrate that cytokine pathways have context-dependent effects. [26][38][59]
Disease spectrum and tissue interface
Psoriatic arthritis (PsA) is a heterogeneous, chronic, immune-mediated disease within the broader psoriatic disease spectrum, linking inflammatory skin, nail, entheseal, peripheral-joint, dactylitic and axial manifestations. [515]D[40]A1a Its pathogenesis reflects interactions among genetic susceptibility, environmental exposures, epithelial and stromal tissues, innate immunity, adaptive immunity and systemic metabolic inflammation. [515]D[518]D[521]D The skin–joint relationship is therefore best understood as inflammatory crosstalk rather than as two completely independent diseases. [518]D
Genetic risk is an important component of susceptibility; psoriasis is particularly associated with HLA-C*06:02, while broader genetic and multi-omic studies in PsA identify susceptibility loci and signaling pathways that may contribute to clinical heterogeneity. [515]D[524]D Environmental and host factors, including obesity and metabolic dysfunction, may amplify disease activity through shared inflammatory and immunometabolic pathways. [515]D[519]D[520]D Mendelian-randomization research has also examined potentially causal relationships between genetically predicted circulating levels of 25 nutrients and PsA, although these findings are best regarded as etiologic clues rather than established mechanisms or treatments. [61]B2c
IL-23/IL-17-centered inflammation
The IL-23/IL-17 axis is a central pathogenic pathway in psoriatic disease. [39]A1a[518]D IL-23 supports type-17 immune responses, while IL-17A acts as a major downstream proinflammatory mediator in psoriasis and PsA. [39]A1a[516]D[517]D[62]D5 IL-17A signals through the IL-17RA/IL-17RC receptor complex and promotes tissue-specific inflammation. [62]D5 The pathway provides a mechanistic explanation for shared skin and musculoskeletal inflammation and is a principal therapeutic target in PsA. [39]A1a[62]D5
Recent tissue and single-cell analyses have refined this model by identifying cell-type-specific interactions among keratinocytes, dendritic cells, T cells, fibroblasts, monocytes and other inflammatory populations in skin, synovium and entheses. [521]D Type-17 tissue-resident memory T cells are prominent in psoriatic synovium and may help sustain local, treatment-relevant inflammation. [521]D[524]D These findings support a model in which epithelial activation, antigen-presenting cells, resident lymphocytes and mesenchymal cells form self-reinforcing inflammatory circuits across anatomically connected tissues. [518]D[521]D
Synovio-entheseal and structural mechanisms
PsA commonly manifests through inflammation of the synovium and entheses, with additional involvement of digits and the axial skeleton. [40]A1a Enthesitis and dactylitis are therefore not merely secondary consequences of synovitis; they represent clinically distinctive components of the disease phenotype and are included among outcomes assessed in therapeutic trials. [40]A1a Animal models, spatial transcriptomics and proteomics have helped define inflammatory interactions in skin, synovium and entheses, although no single model reproduces the full heterogeneity of human PsA. [521]D
The resulting clinical phenotype varies substantially between patients, with different combinations of peripheral arthritis, enthesitis, dactylitis, axial disease, psoriasis and nail disease. [40]A1a[524]D This heterogeneity probably reflects differences in genetic background, tissue-resident immune populations, cytokine dependence, metabolic state and disease-specific cellular networks. [524]D[521]D It also contributes to delayed diagnosis and variable responses to treatment. [524]D
Intracellular cytokine signaling
Cytokine activity is transmitted through intracellular pathways, including Janus kinases (JAKs), which mediate signaling from multiple cytokine receptors. [40]A1a[522]D JAK inhibition consequently acts downstream of individual cytokines and can influence several inflammatory signaling programs at once. [40]A1a[522]D Randomized-trial evidence synthesized in network meta-analysis evaluates JAK inhibitors against outcomes spanning ACR20, ACR50, ACR70, PASI75, enthesitis resolution, dactylitis resolution and serious adverse events, illustrating the clinical breadth of pathways involved in PsA. [40]A1a
By contrast, IL-23 inhibitors target a more pathway-focused component of the type-17 response. A 2025 systematic review and meta-analysis of randomized controlled trials evaluated their effects on joint and skin outcomes, including ACR20/50/70 and psoriasis responses, while also characterizing complications. [39]A1a The clinical efficacy of these agents supports the biological importance of IL-23-dependent inflammation, but therapeutic response is not uniform, indicating that PsA is not mechanistically reducible to a single cytokine pathway. [39]A1a[524]D
Systemic inflammation, metabolism and cardiovascular risk
PsA is systemic rather than exclusively articular. Chronic cytokine-driven inflammation interacts with adipokine balance, insulin signaling and lipid metabolism, promoting metabolic abnormalities and accelerated atherogenesis. [63]D5 Psoriasis has a particularly strong association with cardiometabolic disease, and shared inflammatory mediators may connect cutaneous disease, PsA and vascular inflammation. [515]D[514][63]D5 Obesity is frequently linked with greater disease burden and may influence severity, treatment response and outcomes through shared inflammatory and metabolic mechanisms. [519]D
Potential disease-modifying mechanisms outside conventional immunosuppression remain investigational. Ketogenic or very-low-calorie ketogenic diets may affect immunometabolism, but direct clinical evidence in PsA remains preliminary and must be distinguished from indirect or ketosis-adjacent evidence. [520]D Vagus-nerve stimulation is proposed to activate the cholinergic anti-inflammatory pathway; systematic-review evidence has assessed inflammatory biomarkers and clinical outcomes across autoimmune diseases, but this does not establish a standard PsA mechanism or therapy. [60]B2a Phosphodiesterase inhibitors may modulate immune and vascular function through intracellular cAMP and cGMP signaling, although their relevance to PsA remains translational rather than definitive. [523]D
Mechanistic complexity and treatment resistance
A proportion of patients has an unsatisfactory response despite standard care; EULAR describes difficult-to-manage and treatment-refractory PsA as multifactorial problems involving disease, patient and treatment-related factors rather than a single biological defect. [26]A1c Therapeutic escape and incomplete target achievement remain important limitations even with biologic and targeted synthetic therapies. [516]D[517]D Paradoxical immune reactions further demonstrate pathway complexity: rare morphoea has been reported during ustekinumab therapy, suggesting that altering IL-12/IL-23 signaling can disturb cutaneous cytokine homeostasis in susceptible individuals. [59]C4 IL-17 inhibition has likewise been investigated in relation to paradoxical or treatment-associated systemic lupus erythematosus, underscoring that cytokine blockade may produce context-dependent immune effects. [38]B3a
Overall, PsA pathophysiology is best represented as a genetically and metabolically conditioned, tissue-specific inflammatory network centered on IL-23/IL-17 signaling but shaped by multiple cytokines, intracellular pathways and resident immune-cell populations. [39]A1a[40]A1a[515]D[518]D[521]D[524]D
| Domain | Mechanistic contribution | Supporting evidence |
|---|---|---|
| Genetic susceptibility | HLA-C*06:02 and other susceptibility loci contribute to risk and heterogeneity. | [515]D[524]D |
| Type-17 immunity | IL-23 supports type-17 responses; IL-17A drives tissue-specific inflammation through IL-17RA/RC. | [39]A1a[62]D5 |
| Tissue cellular networks | Keratinocytes, dendritic cells, T cells, fibroblasts, monocytes and resident memory T cells interact in skin, synovium and entheses. | [521]D |
| Intracellular signaling | JAKs transmit signals from multiple cytokine receptors and are therapeutically targetable. | [40]A1a[522]D |
| Immunometabolism | Obesity, adipokines, insulin signaling and lipid metabolism link inflammation with disease burden and vascular risk. | [519]D[63]D5 |
| Neuroimmune and second-messenger pathways | Cholinergic anti-inflammatory signaling and cAMP/cGMP modulation are investigational mechanistic approaches. | [60]B2a[523]D |
Epidemiology, Etiology & Risk Factors
- ▸In a selected cohort of adults with psoriasis receiving bDMARDs, **22%** developed PsA during follow-up; this is not a population-wide incidence estimate.[607]
- ▸A systematic review found no significant difference in incident PsA between bDMARD-treated and non-biologic treatment groups.[113]
- ▸A real-world cohort observed more PsA during TNF-inhibitor exposure than during IL-17, IL-23 or IL-12/23 inhibitor exposure, but confounding prevents causal interpretation.[607]
- ▸MHC class I expression and peptide presentation are altered in PsA, supporting an immunogenetic mechanism without identifying a single causal antigen.[608]
- ▸Treatment-related risks relevant to PsA include immunogenicity, tuberculosis, herpes zoster and malignancy concerns with selected advanced therapies.[112][525][534][605]
- ▸Persistent symptoms may reflect difficult-to-manage disease, central sensitization, comorbidity or non-inflammatory drivers rather than active inflammation alone.[118][533][606]
Epidemiologic overview
Psoriatic arthritis (PsA) is a systemic inflammatory arthritis occurring in the setting of psoriasis, but the supplied evidence base does not provide a new general-population prevalence estimate. Contemporary studies instead describe PsA across dermatology, rheumatology and biologic-treatment cohorts, highlighting substantial heterogeneity in clinical phenotype, comorbidity burden and treatment response.[113]A1a[118]B2b[532][606] In a retrospective cohort of 393 adults with psoriasis receiving biologic disease-modifying antirheumatic drugs (bDMARDs) for at least 6 months, 86 patients (22%) developed PsA during follow-up; this estimate applies to the selected treated cohort and should not be interpreted as population incidence.[607]
Comorbidity is an important component of PsA burden. A nationwide Polish claims analysis identified concurrent disorders at diagnosis in incident PsA and compared them with rheumatoid arthritis, using a ten-year look-back period; the study was designed to generate crude, relative and adjusted prevalence estimates, although the supplied abstract does not report the individual estimates.[532] Psoriasis itself is associated with cardiovascular and structural cardiac abnormalities: the PSOCADIA study compared 1,010 adults with psoriasis with 1,010 matched controls and assessed hypertrophy, valvular disease, systolic and diastolic dysfunction, and myocardial dysfunction defined by global longitudinal strain <16%.[528] These findings support cardiometabolic and cardiovascular assessment in patients with psoriasis or PsA, but they do not establish cardiac disease as a cause of PsA.[528]
Etiology and immunogenetic mechanisms
PsA is an immune-mediated disease involving genetically influenced antigen presentation and inflammatory pathways. A 2026 immunopeptidome study reported increased major histocompatibility complex class I expression on circulating immune cells in PsA and identified a high prevalence of nine-amino-acid peptides derived from intracellular proteins, consistent with altered MHC class I peptide presentation.[608] These findings provide mechanistic support for MHC-I-associated autoimmunity, but they do not establish a single causative antigen or prove that the observed presentation pattern precedes disease onset.[608]
MHC-I-related susceptibility may overlap with broader spondyloarthritis phenotypes. A retrospective study of HLA-B51-positive patients evaluated whether participants fulfilled criteria for Behçet disease, axial or peripheral spondyloarthritis, or PsA, and characterized extra-articular manifestations across these phenotypes; the abstract does not provide a PsA-specific causal association or a population-attributable risk estimate.[404]B3b Thus, HLA-B51 should not be treated as an established standalone PsA susceptibility marker on the basis of this study.[404]B3b
Psoriasis-to-PsA transition and treatment-related associations
The transition from psoriasis to PsA is clinically important, but whether treatment prevents it remains uncertain. A systematic review and meta-analysis of 18 studies evaluated csDMARDs, bDMARDs, phototherapy, topical therapy and no therapy; the primary analysis found no significant difference in incident PsA between bDMARD-treated and non-biologic treatment groups.[113]A1a In a separate real-world cohort of 393 biologic-treated patients, PsA occurred more frequently during TNF-inhibitor exposure than during exposure to IL-17, IL-23 or IL-12/23 inhibitors in the single-class analysis; after adjustment, the abstract reports that all non-TNF classes differed from TNF inhibitors, but does not provide the adjusted effect sizes.[607] These observational findings may reflect confounding by indication, treatment era, psoriasis severity or baseline musculoskeletal risk and do not demonstrate that TNF inhibition causes PsA or that other biologic classes prevent it.[607]
Treatment exposure as a modifier of risk
Biologic and targeted synthetic DMARD exposure creates clinically relevant safety considerations that may modify the risk profile of patients with PsA, although these are treatment-associated risks rather than causes of PsA. A systematic review of 28 studies evaluated anti-drug antibodies in adults with PsA receiving biologic DMARDs and assessed relationships with serum drug concentrations, efficacy and safety.[605] Immunogenicity may therefore contribute to loss of therapeutic response or treatment switching, but the supplied abstract excerpt does not provide pooled antibody prevalence or drug-specific estimates.[605]
Infection risk is also treatment- and geography-dependent. A systematic review examined new tuberculosis infection and latent tuberculosis reactivation in psoriasis or PsA treated with IL-23 inhibitors, including guselkumab, risankizumab and tildrakizumab, with particular attention to Asia-Pacific countries where tuberculosis prevalence is relatively high; the available abstract does not report the final event estimates.[112]B2a Patients receiving JAK inhibitors for immune-mediated inflammatory diseases, including PsA, were evaluated in a real-world cohort for herpes zoster incidence and associated factors, with incidence calculated per 100 person-years and predictors assessed by Cox regression.[534] Cancer risk has likewise been evaluated in a Bayesian network meta-analysis of randomized trials and long-term extensions of advanced therapies across immune-mediated inflammatory diseases, including psoriasis/PsA; the analysis was prompted by malignancy concerns with tofacitinib in rheumatoid arthritis and regulatory class warnings for JAK inhibitors.[525] These findings support individualized infection, vaccination and malignancy-risk assessment rather than attribution of these outcomes to PsA etiology.[525][534]
Factors associated with difficult or persistent disease
Treatment-refractory or difficult-to-manage PsA represents an important disease-modifying context. Five Nordic biologic registries studied patients initiating biologic or targeted synthetic DMARDs and examined definitions based on discontinuation of at least 2, 3 or 4 agents, with additional consideration of discontinuation reason and other framework components.[606] A separate ORCHESTRA cohort evaluated EULAR and GRAPPA definitions of difficult, complex or treatment-refractory PsA, emphasizing that persistent symptoms may arise from inflammatory disease, non-inflammatory drivers or comorbidity rather than uncontrolled synovitis alone.[118]B2b Central sensitization was assessed in 228 consecutive PsA patients after excluding fibromyalgia; the study examined prevalence, clinical correlates, multidimensional pain and therapeutic refractoriness, but the supplied abstract does not report the prevalence estimate.[533] These data caution against equating persistent pain with inflammatory progression.[118]B2b[533]
Other autoimmune or inflammatory conditions may complicate risk assessment without proving causation. A nationwide study of familial Mediterranean fever evaluated long-term rheumatologic and selected autoimmune comorbidities, including inflammatory bowel disease, but was not designed to establish PsA-specific risk.[403]B2b Similarly, a study of diabetes therapies evaluated incident autoimmune disease among users of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors; it did not establish a PsA-specific medication effect.[536] Deucravacitinib is approved for active PsA, and five-year psoriasis extension data provide treatment-safety context, not evidence of PsA etiology.[526] Long-term secukinumab real-world data likewise concern psoriasis effectiveness and safety rather than risk of developing PsA.[117]B3b
Practical synthesis
The strongest current signals are that PsA risk is concentrated among patients with psoriasis and is influenced by immune-genetic mechanisms, treatment selection and comorbidity burden.[113]A1a[607][608] Biologic therapy has not been proven to prevent PsA, and apparent differences between biologic classes remain vulnerable to confounding.[113]A1a[607] Screening should therefore focus on new inflammatory musculoskeletal symptoms in psoriasis, while management should incorporate cardiovascular, infection, malignancy, pain-sensitization and treatment-immunogenicity considerations.[112]B2a[118]B2b[525][528][533][534][605]
| Domain | Current evidence | Interpretation |
|---|---|---|
| Psoriasis-to-PsA transition | 22% developed PsA in one biologic-treated psoriasis cohort; pooled evidence did not show prevention by bDMARDs.[113]A1a[607] | High-risk clinical transition; treatment-prevention effect remains unproven. |
| Immunogenetics | Increased MHC-I expression and altered peptide presentation were reported in PsA.[608] | Supports mechanism, not a validated predictive test. |
| Treatment safety | Evidence addresses anti-drug antibodies, tuberculosis, herpes zoster and malignancy with advanced therapies.[112]B2a[525][534][605] | Treatment-associated risks requiring individualized monitoring. |
| Persistent disease | Registry and cohort studies evaluate discontinuation of ≥2, ≥3 or ≥4 agents, difficult-to-manage disease and central sensitization.[118]B2b[533][606] | Refractoriness may be inflammatory or non-inflammatory. |
| Comorbidity | Cardiovascular, cardiac and other concurrent disorders are documented in psoriasis/PsA populations.[528][532] | Comorbidity burden should be assessed alongside joint disease. |
Clinical Presentation
- ▸PsA may present with peripheral arthritis, enthesitis, dactylitis, tenosynovitis, bursitis, axial disease, thoracic-joint involvement, or combinations of these domains [539][541][544][609][610][611][162].
- ▸Early limited-joint disease is commonly operationalized as **≤4 active joints**, whereas polyarticular disease is **>4 active joints**; progression may occur over time [539].
- ▸Axial PsA may be isolated or combined with oligoarticular or polyarticular peripheral disease [544].
- ▸Psoriasis can precede clinical PsA, and prediction models aim to identify patients requiring referral or at risk of subclinical-to-clinical progression [148][170][612].
- ▸Flare assessment should incorporate patient-reported symptoms as well as examination and laboratory findings [336].
Overview and recognition
Psoriatic arthritis (PsA) is clinically heterogeneous, with musculoskeletal disease occurring alongside cutaneous psoriasis and presenting through peripheral joints, entheses, digits, the axial skeleton, or combinations of these domains [539][541][544][612]. In patients with psoriasis, PsA may be underdiagnosed, and delayed diagnosis is associated with worse outcomes; early recognition is therefore clinically important [148]B2b[170]B2a. A substantial proportion of patients with psoriasis may develop PsA, with estimates in the cited literature reaching up to 22% or up to 30%, depending on the population and ascertainment method [170]B2a[612].
Peripheral arthritis
Peripheral synovitis may initially be limited in extent. In FOREMOST, early PsA was operationalized as >1 to ≤4 swollen joints and >1 to ≤4 tender joints, although imaging confirmation was not required [539]. For disease-course analyses, oligoarticular PsA was defined as ≤4 active joints—active meaning swollen and/or tender—whereas polyarticular PsA was defined as >4 active joints [539]. Progression from an oligoarticular to a polyarticular presentation was specifically evaluated by week 16, emphasizing that a limited initial joint count does not necessarily represent a stable phenotype [539]. Axial disease may coexist with either oligoarticular or polyarticular peripheral involvement: in a multicentre cohort of axial PsA, 28.2% had isolated axial disease, 40.6% had axial disease with oligoarticular involvement, and 31.2% had axial disease with polyarticular involvement [544].
Peripheral PsA can also include tenosynovitis, bursitis, dactylitis, enthesitis, and structural erosive disease; these domains were systematically assessed in a real-world ultrasound study of patients who subsequently developed a difficult-to-treat phenotype [609]. The presence and distribution of synovitis, erosions, tenosynovitis, enthesitis, bursitis, and dactylitis may therefore help characterize disease burden beyond the swollen-joint count [609]. Whole-body MRI assessment likewise evaluates inflammation in peripheral joints and entheses, as well as the spine, sacroiliac joints, hips, knees, and heel entheses [162]C4.
Axial and thoracic manifestations
Axial PsA is a clinically distinct presentation that may occur with or without peripheral arthritis [544]. Comparative evidence indicates that axial PsA and axial spondyloarthritis have overlapping but nonidentical clinical features; a systematic review and meta-analysis compared disease activity, spinal function, inflammatory markers, and HLA-B27 positivity across 2,704 patients with axial PsA and 9,248 patients with axial spondyloarthritis [541]. These findings support evaluating axial symptoms and objective axial inflammation rather than assuming that all axial presentations are clinically interchangeable [541].
Thoracic small-joint involvement can be detected on chest CT. In a cohort of 279 patients with PsA, the assessed structures included the sternoclavicular, costovertebral, and costotransverse joints, with evaluation for erosions, joint-space narrowing, osteophytes, sclerosis, and partial or complete ankylosis [610][611]. Structural abnormalities were reported in the sternoclavicular joint in 47.0% and in the costovertebral joints in 83.2% of patients in the topographic analysis [610]. CT-based patterns included anterior–posterior ring, posterior-only, negative, and anterior-only distributions, while a separate framework classified destructive, proliferative, and locking structural phenotypes [610][611]. These findings indicate that clinically relevant axial or thoracic disease may extend beyond the sacroiliac joints and spine [610][611].
Skin and preclinical disease
Psoriasis may precede clinically apparent arthritis, but PsA can also be suspected during the early course of psoriasis. The Stockholm Psoriasis Cohort developed separate prediction models to identify people with new-onset psoriasis who may benefit from rheumatology referral and those with subclinical PsA at high risk of developing clinical PsA [148]B2b. The cohort enrolled participants within 1 year of their first psoriasis lesion on non-hairy skin [148]B2b. A systematic review of prognostic models likewise evaluated tools for estimating PsA risk among patients with psoriasis and highlighted the opportunity to identify higher-risk individuals before progressive joint disease develops [170]B2a. A multicentre clinical nomogram used routinely available demographic, disease-history, and lesion characteristics to identify likely PsA among psoriasis patients; it was developed in 884 participants and externally validated in 690 participants using rheumatologist-assigned CASPAR classification [612].
Disease activity, flares, and difficult-to-treat disease
Symptoms and activity may fluctuate over time. The PsA FLARE Questionnaire was evaluated alongside PsAID-12, patient-reported flare status, examination findings, and routine laboratory data in 150 adults, reflecting the importance of assessing patient-perceived worsening in addition to objective inflammation [336]C4. Persistent disease activity despite at least 2 biologic or targeted synthetic DMARDs was used as a pragmatic definition of difficult-to-treat PsA in a real-world cohort [609]. Baseline clinical and ultrasonographic features—including synovitis, erosions, tenosynovitis, enthesitis, bursitis, and dactylitis—were examined as possible precursors of that phenotype [609].
Juvenile and associated manifestations
PsA-like disease occurs within the spectrum of juvenile spondyloarthritis, where cohorts include juvenile PsA, enthesitis-related arthritis, and undifferentiated arthritis; HLA-B genotype has been investigated in relation to distinct disease expression [543][613]. In juvenile spondyloarthritis, clinical manifestations were also examined in relation to initial TNF-inhibitor response, although these treatment-response findings do not replace clinical phenotyping [543]. PsA may be accompanied by systemic comorbidity, including multisite atherosclerosis; carotid, femoral, and aortic vascular territories were assessed in 250 patients, with multiterritorial disease defined as involvement of ≥2 vascular beds [444]C4.
| Domain | Clinical pattern or threshold | Reference |
|---|---|---|
| Limited peripheral disease | >1 to ≤4 swollen and >1 to ≤4 tender joints in early PsA trial entry | [539] |
| Oligoarticular disease | ≤4 active joints; active means swollen and/or tender | [539] |
| Polyarticular disease | >4 active joints | [539] |
| Axial distribution | Isolated axial, axial plus oligoarticular, or axial plus polyarticular disease | [544] |
| Difficult-to-treat phenotype | Persistent activity despite ≥2 b/tsDMARDs | [609] |
| Multiterritorial atherosclerosis | Plaque involvement of ≥2 vascular beds | [444]C4 |
Diagnosis & Workup: Serology, Imaging & Classification Criteria
- ▸Axial PsA remains poorly defined, with no validated classification criteria established in the supplied evidence. [617]
- ▸Early oligoarticular PsA in FOREMOST involved **more than 1 to 4 swollen and more than 1 to 4 tender joints**; polyarticular progression was **more than 4 active joints**. [539]
- ▸IgA anti-CD74 is investigational and was studied in PsA, non-rheumatic controls, and rheumatoid arthritis controls; it is not established as a routine diagnostic test. [263]
- ▸MRI of the spine and sacroiliac joints, pelvic radiography, ultrasound, and peripheral MRI/HR-pQCT each address different inflammatory or structural PsA domains. [551,552,609,617]
- ▸Anti-drug antibody testing is relevant to biologic treatment monitoring, not initial PsA classification. [605]
Diagnostic approach
Psoriatic arthritis (PsA) remains a clinical diagnosis supported by demonstration of inflammatory musculoskeletal disease in the context of psoriasis or related psoriatic features; the supplied evidence does not establish a new diagnostic blood test or replace existing classification systems. Axial PsA is particularly challenging because it remains poorly defined, and validated classification criteria and longitudinal cohorts are lacking. [617]
Assessment should be structured around the major clinical domains: peripheral arthritis, enthesitis, dactylitis, nail and skin disease, and axial involvement. The distinction between limited and more extensive peripheral disease is clinically relevant: the FOREMOST study defined early oligoarticular disease as more than 1 to 4 swollen and more than 1 to 4 tender joints, whereas progression to polyarticular disease was defined as more than 4 active joints. [539] Importantly, the FOREMOST population had limited joint involvement that was not confirmed by imaging, illustrating that a normal or non-confirmatory imaging assessment does not necessarily exclude early PsA. [539]
Serology and laboratory testing
There is no evidence in the supplied references for a diagnostic autoantibody equivalent to rheumatoid factor or anti-cyclic citrullinated peptide that can independently establish PsA. Anti-CD74 antibodies are investigational rather than established diagnostic markers. In a study of 171 patients with PsA—including 127 with peripheral PsA and 44 with axial PsA—serum IgA anti-CD74 was measured alongside samples from 43 non-rheumatic disease controls and 43 patients with rheumatoid arthritis to examine diagnostic and treatment-related associations. [263]B3b The study specifically evaluated whether IgA anti-CD74 levels were associated with escalation from conventional synthetic DMARDs to biologic therapy in peripheral PsA; the available evidence therefore supports biomarker investigation, not routine clinical classification. [263]B3b
Routine laboratory testing should be interpreted as supportive and phenotypic rather than diagnostic. Systemic inflammation may assist with activity assessment, but inflammatory-marker interpretation can be influenced by obesity and body-mass index; a longitudinal electronic-health-record study evaluated BMI-related inflammatory-marker profiles across psoriasis and PsA, among other immune-mediated inflammatory diseases. [555] High-sensitivity C-reactive protein was also used as an eligibility characteristic in a phase 3 PsA trial, which required hsCRP ≥3 mg/L, but this was a research-enrichment criterion rather than a universal diagnostic threshold. [616]
Anti-drug antibody testing belongs to therapeutic monitoring rather than initial diagnosis. A 2026 systematic review identified studies measuring anti-drug antibodies in adults with PsA receiving biologic DMARDs and assessed relationships with serum drug concentrations, efficacy, and safety. [605] The evidence does not support using anti-drug antibodies to classify untreated PsA.
Imaging workup
Imaging should be targeted to the suspected domain and used to identify synovitis, erosions, enthesitis, dactylitis, structural damage, or axial inflammation. Conventional radiography can demonstrate peripheral erosions and axial sacroiliitis. In POETYK PsA-1, biologic-naïve adults were required to have at least one PsA-related hand or foot erosion detectable by radiograph, showing how radiographic damage may be incorporated into trial-defined active disease, although this requirement should not be generalized as a prerequisite for clinical diagnosis. [616]
For suspected axial PsA, sacroiliac-joint and spinal imaging is central. The GESPIC-axial-PsA cohort included patients with psoriasis and clinically diagnosed axial PsA confirmed by imaging and performed axial-skeleton radiographs plus MRI of the whole spine and sacroiliac joints. [617] This cohort was designed to delineate imaging-confirmed phenotypes because axial PsA lacks validated classification criteria. [617]
Radiographs may also document progression. In a prospective cohort of 1,554 patients followed for a median of 6.00 years, pelvic radiographs were assessed using a sacroiliitis sum score based on left- and right-sided modified New York grades; among evaluable patients, 475/1,056 (45%) showed progression by at least one grade. [551] These findings support serial imaging when axial structural progression is clinically relevant, but radiographic sacroiliitis should not be treated as synonymous with all axial PsA. [551][617]
MRI and high-resolution peripheral quantitative CT can detect abnormalities before clinically apparent arthritis. The EPOS study enrolled psoriasis patients with arthralgia and subclinical inflammatory and/or structural entheseal abnormalities identified by hand MRI and/or HR-pQCT, while excluding patients with current or previous PsA. [552] Thus, subclinical imaging abnormalities may identify a population at risk, but they do not alone establish clinically manifest PsA. Ultrasound can complement examination by evaluating synovitis, erosions, tenosynovitis, enthesitis, bursitis, and dactylitis; these features were assessed in a real-world cohort investigating predictors of difficult-to-treat PsA. [609]
Classification and disease measurement
Classification should not be confused with disease-activity measurement. A GRAPPA-OMERACT systematic review evaluated composite measures—including ACR response criteria and the Composite Psoriatic Disease Activity Index—according to their ability to distinguish active treatment from placebo in PsA randomized trials. [292]A1a These instruments support standardized research assessment but are not, by themselves, diagnostic criteria. The currently supplied evidence does not provide revised CASPAR thresholds or validate a new classification algorithm; clinical history, examination, appropriate laboratory testing, and domain-directed imaging therefore remain essential. [617][292]A1a
Practical summary
A comprehensive workup should document psoriasis and nail disease, inflammatory joint symptoms, tender and swollen joint counts, enthesitis, dactylitis, axial symptoms, family history, and alternative diagnoses; apply radiography, ultrasound, or MRI according to the suspected domain; and interpret CRP and investigational antibodies as supportive rather than definitive. Axial disease warrants particular caution because imaging-confirmed cohorts exist, but validated axial-PsA classification criteria remain unavailable. [617]
| Suspected domain | Useful investigation | Evidence-supported role |
|---|---|---|
| Peripheral erosive disease | Hand/foot radiography | Detects erosions; radiographic erosion was used as a trial eligibility feature. [616] |
| Axial disease | Pelvic radiography; MRI of sacroiliac joints and whole spine | Characterises imaging-confirmed axial disease and structural sacroiliitis. [551][617] |
| Enthesitis or subclinical disease | MRI and/or HR-pQCT; ultrasound | Identifies inflammatory or structural entheseal abnormalities and evaluates enthesitis and related lesions. [552][609] |
| Laboratory support | CRP/hsCRP; investigational IgA anti-CD74 | Supports activity assessment or research stratification; does not independently establish PsA. [263]B3b[555][616] |
| Biologic treatment monitoring | Anti-drug antibodies and serum drug levels | Evaluates immunogenicity and possible relationships with efficacy or safety. [605] |
Severity, Disease Activity & Risk Stratification
- ▸Use multidomain composite assessment because PsA activity may involve peripheral joints, axial sites, entheses, skin, nails, function, pain, fatigue, and structural damage. [292][560][291]
- ▸Residual disease can persist despite remission or low disease activity; reassess swollen joints, fatigue, pain, function, enthesitis, axial symptoms, and other domains not captured by the chosen target. [527]
- ▸Monitor early oligoarticular PsA closely: progression was modelled from **≤4 active joints** to **>4 active joints** at **week 16** in FOREMOST. [539]
- ▸Consider axial and whole-body imaging burden separately from peripheral joint counts, particularly when symptoms or objective findings are discordant. [541][162]
- ▸BMI, central sensitization, psychosocial factors, and comorbidities can influence apparent severity, treatment response, quality of life, and persistence. [557][533][559][562]
- ▸CALLY, immune-cell, S1P/S1PR, and nailfold microvascular measures are exploratory adjuncts and are not validated stand-alone PsA severity classifications. [259][540][558][556]
Multidomain assessment of disease activity
Psoriatic arthritis (PsA) severity cannot be inferred reliably from joint counts alone because peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis, structural damage, pain, fatigue, function, and comorbidity may contribute independently to overall disease burden. Composite instruments are therefore central to treatment evaluation and clinical risk stratification. A GRAPPA–OMERACT systematic review and network meta-analysis evaluated seven shortlisted composite outcomes, including ACR response criteria and the Composite Psoriatic Disease Activity Index (CPDAI), to determine which measures best distinguish biologic or targeted synthetic DMARDs from placebo in randomised trials. [292]A1a The study addresses trial discrimination rather than establishing that one instrument should replace all others in routine practice. [292]A1a
For peripheral arthritis, an ASAS project used the OMERACT framework to identify the most appropriate disease-activity instrument for axial and peripheral spondyloarthritis, assessing domain match, feasibility, construct validity, test–retest reliability, responsiveness, clinical-trial discrimination, and thresholds of meaning. [560] A companion systematic review compared the measurement properties of instruments used to assess peripheral arthritis activity in patients with axial or peripheral spondyloarthritis. [291]B2a These findings support selecting instruments that specifically capture peripheral synovitis while interpreting them alongside patient-reported outcomes and extra-articular domains. [560][291]B2a
Remission, residual disease, and treatment targets
Achievement of a treatment target does not necessarily mean that all clinically important disease has resolved. A systematic review and meta-analysis defined residual disease as clinically relevant signs or symptoms persisting despite a low-activity or remission state, with extracted indicators including swollen joints and fatigue. [527] In practice, residual synovitis, pain, fatigue, functional limitation, skin disease, enthesitis, or axial symptoms should prompt reassessment of the disease domains not represented adequately by the selected target measure. [527]
Minimal disease activity (MDA) remains a clinically meaningful multidomain state because it incorporates several core PsA manifestations rather than a single laboratory or joint measure. [540][557] In a prospective biomarker study, MDA achievement was assessed at week 16 among DMARD-naive patients randomised to tofacitinib or methotrexate and among conventional-DMARD inadequate responders randomised to tofacitinib or etanercept; the study examined whether circulating immune-cell biomarkers improved individual response prediction. [540] These biomarkers should be regarded as investigational predictors rather than validated replacements for clinical assessment. [540]
Early disease and progression risk
Limited joint involvement does not guarantee a benign course. FOREMOST enrolled patients with early PsA of approximately 10 months’ mean duration and >1 to ≤4 swollen and tender joints, then modelled progression from oligoarticular disease (defined as ≤4 active joints) to polyarticular disease (>4 active joints). [539] The study evaluated predictors of progression at week 16 and the effect of apremilast, with open-label apremilast continuing through week 48. [539] These data reinforce the importance of monitoring early oligoarticular PsA for expansion of joint involvement rather than relying only on the initial joint count. [539]
Risk stratification also begins before clinical PsA is apparent. A psoriasis inception-cohort study developed and internally validated multivariable models to identify people with new-onset psoriasis who merit rheumatology referral and those with subclinical PsA at high risk of developing clinical disease. [148]B2b In psoriasis patients with arthralgia and subclinical inflammatory or structural entheseal abnormalities on MRI or high-resolution peripheral quantitative CT, a 24-week single-arm apremilast study evaluated changes in entheseal bone damage. [552] These approaches remain risk-assessment or exploratory intervention strategies and should not be interpreted as establishing routine preventive DMARD treatment for psoriasis without clinical PsA. [148]B2b[552]
Axial, entheseal, and imaging burden
Axial PsA should be assessed separately from peripheral arthritis because axial symptoms, spinal function, imaging inflammation, and inflammatory markers may not track with peripheral joint counts. A systematic review and meta-analysis compared clinical features, disease activity, spinal function, inflammatory markers, and HLA-B27 positivity between axial PsA and axial spondyloarthritis. [541] Whole-body MRI in the MOSAIC phase 4 study assessed inflammation in peripheral joints and entheses, the spine and sacroiliac joints, hips, knees, and heels at baseline, week 24, and week 48 during apremilast treatment with or without stable methotrexate. [162]C4 MRI can therefore identify inflammatory burden in clinically silent or difficult-to-examine sites, but imaging findings should be integrated with symptoms and examination. [162]C4
Prognostic modifiers and discordant symptoms
Obesity is a relevant treatment and outcome modifier. A longitudinal cohort study evaluated BMI in relation to MDA and its individual components over time, adjusting for demographic, psychological, smoking, treatment, and radiographic factors and examining multiple advanced-therapy classes. [557] Persistent pain may also reflect mechanisms beyond inflammation: in a cohort excluding fibromyalgia, central sensitization was assessed in 228 consecutive PsA patients and examined in relation to clinical phenotype and therapeutic refractoriness. [533] Thus, high patient-reported pain with limited objective inflammation should trigger assessment for central sensitization and other comorbid contributors rather than automatic escalation of immunosuppression. [533]
Potential adjunctive markers include the CALLY index, which combines CRP, albumin, and lymphocyte information; a retrospective longitudinal study of 150 PsA patients and 50 matched controls examined its association with disease activity. [259]B3b Other exploratory studies assessed circulating immune-cell profiles, serum S1P/S1PR in relation to DAPSA, bone health, Doppler ultrasound, and MRI, and nailfold microvascular abnormalities in women with distal interphalangeal arthritis receiving TNF inhibitors. [540][558][556] These biomarkers are not established stand-alone severity classifications. [259]B3b[540][558][556]
Patient-reported burden and outcomes
Disease activity assessment should include function, quality of life, fatigue, pain, sleep, and psychosocial context. EQ-5D-3L and EQ-VAS demonstrated evaluated construct validity and responsiveness across groups with differing function or disease activity in a Swedish registry study. [561] A digital-health segmentation study used patient global disease activity, pain, sleep, and psychosocial variables to identify clinical-psychosocial archetypes and relate them to 12-week outcomes. [559] Sexual quality of life was followed prospectively for 5 years in an outpatient cohort, illustrating that long-term disease burden extends beyond standard inflammatory measures. [564]C
Real-world treatment persistence, including comparative evaluation of upadacitinib and tofacitinib with DAPSA data, may provide a pragmatic indicator of durability, tolerability, and perceived benefit, but it is observational and should not be equated with comparative efficacy. [562] Perioperative risk assessment should likewise incorporate disease activity, patient-reported outcomes, comorbidity, BMI, and operative context; a prospective arthroplasty study evaluated whether PsA-specific activity and synovial inflammation were associated with postoperative adverse events. [563]C
Practical risk-stratification framework
Classify patients by objective inflammatory burden, number and distribution of active joints, axial or entheseal involvement, structural damage, skin and nail severity, functional and patient-reported burden, comorbidity, and trajectory over time. [291]B2a[527][541][557] Escalated surveillance is particularly appropriate for early oligoarticular disease, rapidly increasing joint counts, persistent objective inflammation despite a target state, axial or imaging inflammation, substantial obesity or comorbidity, and pain–inflammation discordance. [539][527][162]C4[557][533]
| Domain | Assessment focus | Evidence |
|---|---|---|
| Peripheral arthritis | Active joint burden and validated disease-activity instruments | [560][291]B2a |
| Composite target state | Multidomain response and treatment-target assessment | [292]A1a[527] |
| Early progression | Oligoarticular-to-polyarticular transition; ≤4 vs >4 active joints | [539] |
| Axial/entheseal disease | Spine, sacroiliac joints, entheses, function, MRI inflammation | [541][162]C4 |
| Patient burden | Pain, fatigue, function, HRQoL, sleep, sexual quality of life | [527][561][559][564]C |
| Modifiers and adjuncts | BMI, central sensitization, biomarkers, persistence, perioperative risk | [557][533][259]B3b[540][562][563]C |
Acute Management: Flares & Organ-Threatening Disease
- ▸PsA flare definitions are heterogeneous; reported incidence was 10%–27% over 6 months and 22%–23% over 12 months. [88]
- ▸Use multidomain clinical assessment and patient-reported flare tools; the FLARE questionnaire is an adjunct, not a replacement for examination. [88,571]
- ▸After tapering or withdrawal, reassess promptly and consider reinstating effective therapy; evidence supports retreatment studies but does not establish one universal tapering or recapture protocol. [565,568]
- ▸ICI initiation in patients with preexisting PsA requires coordinated oncology–rheumatology risk–benefit assessment of baseline immunosuppression. [317,566,327]
- ▸Severe ocular, bowel, infectious, neurologic, articular, or cutaneous presentations require urgent specialty evaluation; the supplied evidence does not define a PsA-specific organ-threatening rescue algorithm. [88,151,573]
Scope and immediate assessment
A PsA flare should be assessed as a multidomain escalation rather than by joint count alone, including peripheral synovitis, enthesitis, dactylitis, axial symptoms, skin and nail disease, function, pain, fatigue, and patient-perceived disease activity. The evidence base does not provide a universally accepted flare definition: a systematic review identified 54 studies, with definitions varying substantially across cohorts and trials. Reported current-flare prevalence ranged from 7% to 50%, incidence from 10% to 27% over 6 months, and from 22% to 23% over 12 months. [88]A1a The FLARE questionnaire is a multidimensional patient-reported instrument; subsequent validation work used a patient anchor question and receiver-operating-characteristic analysis to determine a cutoff and assess longitudinal change, supporting its use as an adjunct to clinical assessment rather than as a substitute for examination. [571]
Urgent evaluation is warranted when there is rapidly progressive polyarthritis, severe functional loss, a hot swollen joint requiring exclusion of infection or crystal arthritis, suspected axial neurologic compromise, severe dactylitis or enthesitis, or extra-articular disease involving the eye, bowel, or other organs. The supplied references do not establish a PsA-specific emergency drug algorithm or define organ-threatening PsA treatment thresholds; management should therefore be individualized with rheumatology and the relevant specialty, while infection, malignancy, medication toxicity, and alternative inflammatory or infectious diagnoses are actively considered. [88]A1a[151]B2b
Flare after DMARD tapering or withdrawal
Withdrawal or dose-spacing of biologic or targeted synthetic DMARD therapy should generally be considered only after sustained, clinically meaningful control and shared decision-making. The 2025 systematic review identified 11 observational studies and 4 randomized controlled trials of biologic DMARD tapering or withdrawal in PsA; most evidence was observational, and the review specifically evaluated remission criteria, relapse definitions, retreatment outcomes, safety, quality of life, costs, and predictors of successful tapering. [568] The review of adalimumab and other TNF-inhibitor discontinuation likewise included 49 studies across inflammatory arthritides, including PsA, and examined successful discontinuation, tapering approaches, flare, and recapture after restarting treatment. [565]
If a flare follows tapering, promptly reassess disease domains and reinstate the previously effective regimen when appropriate; the available reviews indicate that retreatment and recapture were specifically studied, but the supplied abstracts do not provide a single reliable PsA-wide recapture percentage or preferred tapering schedule. [565][568] Patient perception is clinically important: among participants meeting minimal disease activity, 88.4% reported good disease status, although the relationship varied according to which individual MDA components were unmet. [574]
Selecting treatment for active or refractory disease
For active PsA requiring escalation, treatment should be directed at the dominant and prognostically important domains, with attention to comorbid psoriasis, inflammatory bowel disease, uveitis, and axial disease. In pooled phase 3 KEEPsAKE analyses, risankizumab demonstrated efficacy across GRAPPA domains—including peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, and axial disease—and related conditions including inflammatory bowel disease and uveitis through approximately 100 weeks of treatment. These data support sustained domain-based therapy, but they do not establish risankizumab as a universal rescue treatment for an acute flare. [151]B2b
Deucravacitinib was evaluated in a 16-week, phase 2 randomized trial of 203 adults with active PsA, including patients with prior NSAID, glucocorticoid, conventional synthetic DMARD, and/or TNF-inhibitor failure or intolerance. One background conventional synthetic DMARD was permitted if stable. A post hoc analysis examined efficacy and safety according to background DMARD use; these data may inform escalation choices but do not define acute organ-threatening management. [569]
In children with juvenile PsA or enthesitis-related arthritis, disease activity should be measured with validated pediatric tools where possible. In the JUNIPERA phase 3 withdrawal study, the Juvenile Spondyloarthritis Disease Activity Index was assessed after 12 weeks of open-label secukinumab and during randomized continuation or placebo withdrawal through week 52; validation was examined against JADAS10, clinical JADAS10, and physician global assessment. [323]A1b A separate phase 3 withdrawal analysis found that children with polyarticular-course JIA, PsA, or enthesitis-related arthritis receiving tofacitinib were assessed using JADAS thresholds and ACR response criteria; responders were randomized at week 18 and followed to week 44 or flare. [324]A1b
Immune-checkpoint-inhibitor-associated disease
When PsA predates immune checkpoint inhibitor (ICI) therapy, baseline immunosuppression requires a cancer-specific risk–benefit discussion because treatment may reduce flare risk but could potentially affect cancer outcomes. The 2025 Canadian living guideline was developed by rheumatologists, oncologists, researchers, and a patient representative specifically to guide baseline immunosuppression for preexisting inflammatory arthritides at ICI initiation. [317]A1c Observational evidence remains important because patients with autoimmune disease were excluded from randomized ICI trials; a systematic review and meta-analysis included 95 studies and 23,897 patients with cancer and preexisting autoimmune disease, evaluating de novo immune-related adverse events, autoimmune flares, hospitalizations, and deaths. [566] A separate meta-analysis included 31 studies and more than 700 patients with preexisting rheumatologic disease receiving ICIs and quantified grade 1–5 and grade 3–5 flares, although the supplied abstract does not provide PsA-specific pooled estimates. [327]A1a
For ICI-associated psoriasis or PsA, apremilast has limited supportive evidence: a multicenter cohort included 21 patients treated for ICI-associated psoriasis and/or PsA, but only five had ICI-PsA alone, making conclusions about efficacy and cancer safety uncertain. [232]C4 ICI therapy should not be interrupted or immunosuppression intensified without coordination between oncology and rheumatology unless clinically necessary for severe or organ-threatening toxicity. [317]A1c[566]
Safety and follow-up
Vaccination is not established as a common trigger for inflammatory-arthritis flares: a systematic review and meta-analysis evaluated flare risk and adverse events after COVID-19 vaccination in inflammatory arthritis, but the supplied abstract does not provide PsA-specific effect estimates. [567] Patients presenting to emergency care may have potentially avoidable lower-acuity utilization; in a population-based Alberta cohort, 47.6% of people with PsA accessed the emergency department annually, and the study specifically examined triage acuity, diagnoses, disposition, and access to ambulatory care. [575] Rapid specialist access and structured follow-up are therefore important after an acute presentation. [575]
Psoriasis and PsA may complicate surgical recovery: a national database study of total hip arthroplasty evaluated superficial and deep surgical-site infection, 90-day sepsis, and 2-year revision outcomes in patients with cutaneous psoriasis or PsA. [546]C Hospital-based psoriasis data also included erythrodermic and generalized pustular psoriasis, conditions requiring urgent dermatologic assessment; among 2,223 hospitalized patients, 4.8% had erythrodermic psoriasis and 2.0% generalized pustular psoriasis. [573] These severe cutaneous presentations should be managed as medical emergencies in parallel with assessment of joint disease. [573]
| Presentation | Immediate priorities | Evidence boundary |
|---|---|---|
| Suspected PsA flare | Define affected domains, quantify patient-perceived flare, assess function and inflammatory burden, and exclude infection or crystal disease when clinically indicated. [88]A1a[571] | No single validated universal flare definition or acute rescue regimen is established in the supplied references. [88]A1a |
| Flare after DMARD tapering | Review timing and adherence, reassess all PsA domains, and consider returning to the last effective regimen. [565][568] | Optimal tapering schedule and PsA-wide recapture rate are not provided. [565][568] |
| ICI-associated PsA or psoriasis | Coordinate urgently with oncology; balance arthritis control, immune-related toxicity, and cancer outcomes. [317]A1c[566][327]A1a | Apremilast evidence is limited to a small cohort, with only five patients having ICI-PsA alone. [232]C4 |
| Severe skin disease | Treat erythrodermic or generalized pustular psoriasis as urgent systemic disease requiring specialist care. [573] | The supplied references do not specify a preferred acute psoriasis regimen. [573] |
Long-term Management: The DMARD Ladder & Treat-to-Target
- ▸Use MDA or another individualized target and reassess objectively by approximately **week 16** when feasible [540].
- ▸Track all active domains, because persistent pain may reflect central sensitization rather than inflammation alone [533].
- ▸Consider escalation or mechanism switching after documented inefficacy or intolerance; repeated discontinuations identify difficult-to-manage disease [606].
- ▸Use domain-specific evidence: guselkumab real-world persistence [621], long-term post-TNF upadacitinib efficacy [615], and 52-week deucravacitinib efficacy in biologic-naive disease [616].
- ▸Reserve ADA testing for clinically informative situations such as secondary loss of response or suspected low drug exposure [605].
- ▸Interpret JAK-inhibitor malignancy data and patient-specific safety risks before prescribing [525].
Management principles
Long-term PsA care should use a treat-to-target strategy: define the dominant disease domains, start an appropriate disease-modifying antirheumatic drug (DMARD), reassess objectively, and escalate or switch when the target is not achieved. Minimal disease activity (MDA), joint counts, patient-reported pain and function, skin activity, enthesitis, axial symptoms, and structural progression should be considered together rather than relying on a single outcome measure. The TOFA-PREDICT study used achievement of MDA at week 16 as a treatment-response endpoint, supporting an early, measurable response check [540]. DAPSA was used for disease-activity assessment in a real-world comparison of upadacitinib and tofacitinib, illustrating its practical role in longitudinal monitoring [562].
Step 1: Confirm the treatment problem and establish the baseline
Before changing therapy, distinguish active inflammation from damage, mechanical pain, fatigue, or central sensitization. Central sensitization was common in an unselected PsA cohort even after exclusion of fibromyalgia and was associated with therapeutic refractoriness, indicating that persistent pain does not always imply uncontrolled synovitis [533]. Baseline assessment should therefore document tender and swollen joint counts, psoriasis and nail disease, enthesitis, dactylitis, axial symptoms, pain, function, inflammatory markers when useful, and imaging when structural or axial disease is suspected. Radiographic sacroiliitis progression occurred in 45% of evaluable patients over a median 6 years in a prospective cohort, emphasizing that clinical symptom control should be accompanied by surveillance for structural disease in appropriate patients [551].
Step 2: Conventional synthetic DMARDs and oral targeted options
Methotrexate remains a commonly studied csDMARD comparator and may be particularly useful when peripheral arthritis and clinically important psoriasis coexist; however, response should be judged against the same predefined target used for other therapies. In TOFA-PREDICT, DMARD-naive patients were randomized to tofacitinib or methotrexate, while csDMARD inadequate responders were randomized to tofacitinib or etanercept; circulating immune-cell biomarkers did not yet establish a clinically ready method for selecting among these treatments [540].
Apremilast is an oral option for selected patients with peripheral disease, especially when a biologic or immunosuppressive treatment is unsuitable. In early oligoarticular PsA, FOREMOST enrolled patients with >1 to ≤4 swollen and tender joints and evaluated progression to polyarticular disease, defined as >4 active joints; it also assessed apremilast as a potential disease modifier [539]. In MOSAIC, apremilast 30 mg twice daily, with or without stable methotrexate, was studied for 48 weeks using whole-body MRI of peripheral and axial inflammation [162]C4. These data support monitoring beyond symptoms, but do not establish apremilast as a universal structural-damage-preventing treatment.
Step 3: Biologic DMARDs and switching
If the target is not reached with csDMARD or oral therapy, or if disease is severe in a specific domain, move to a biologic or targeted synthetic DMARD selected according to joint, skin, enthesis, axial, gastrointestinal, and safety priorities. Guselkumab showed effectiveness and treatment persistence in a large multicentre real-world cohort with assessments through 12 months, supporting IL-23p19 inhibition as a durable option for many patients [621]. Upadacitinib 15 mg once daily retained efficacy through 152 weeks in patients previously exposed to one TNF inhibitor, including outcomes for ACR response, MDA, psoriasis, pain, and safety [615]. Deucravacitinib, a selective TYK2 inhibitor, demonstrated efficacy and safety through 52 weeks in biologic-naive patients with active, erosive PsA [616].
After inefficacy or intolerance, switching to another mechanism is reasonable rather than persisting indefinitely with an ineffective agent. Nordic registry data found that difficult-to-manage or treatment-refractory disease becomes more prevalent as treatment discontinuations accumulate, providing a rationale for documenting each failure, its reason, and the domain-specific response [606]. Comparative real-world persistence data for upadacitinib and tofacitinib provide additional information for shared decision-making but do not prove superiority for every patient [562].
Step 4: Safety-led selection and therapeutic drug monitoring
Safety screening and ongoing surveillance should accompany every escalation. A 2026 Bayesian network meta-analysis evaluated cancer risk with JAK inhibitors and other advanced therapies across immune-mediated inflammatory diseases, prompted by the increased malignancy signal for tofacitinib versus TNF inhibitors in rheumatoid arthritis; PsA-specific decisions should therefore incorporate individual malignancy, cardiovascular, thrombotic, infection, and smoking risk rather than treating JAK inhibitors as interchangeable with biologics [525].
Anti-drug antibodies (ADAs) are relevant mainly when a biologic loses efficacy, serum drug exposure appears unexpectedly low, or immunogenicity is suspected. The systematic review identified 28 studies of ADA prevalence and associations with drug levels, efficacy, and safety in PsA, but routine proactive ADA testing should not be assumed to improve outcomes without a clinical indication [605].
Treat-to-target in practice
Reassess after an agreed induction interval and continue only when there is objective improvement toward MDA or another individualized target. If the response is partial, identify the uncontrolled domain before escalating; if pain persists despite low inflammatory activity, evaluate central sensitization and noninflammatory contributors [533]. Structural progression, axial inflammation, and damage should prompt treatment review even when peripheral symptoms appear acceptable [551][162]C4. Current biomarker studies, including immune-cell and circulating blood-marker analyses, remain investigational and are not substitutes for clinical assessment [540][622]. Finally, evidence that biologic class may alter the risk of incident PsA in people with psoriasis concerns prevention before arthritis develops and should not be interpreted as a treatment sequence for established PsA [113]A1a[623][607][254]B2b.
| Position | Practical approach | Evidence anchor |
|---|---|---|
| 1 | Establish domains, baseline activity, pain phenotype, and structural risk | MDA response assessment and central-sensitization findings [540][533] |
| 2 | Use csDMARDs or selected oral therapy for appropriate peripheral disease | Methotrexate, tofacitinib, and apremilast studies [540][539][162]C4 |
| 3 | Escalate to bDMARD or tsDMARD when the target is not reached or disease is domain-severe | Guselkumab, upadacitinib, and deucravacitinib evidence [621][615][616] |
| 4 | Switch mechanism after inefficacy or intolerance; record each failure | Nordic difficult-to-manage disease data [606] |
| 5 | Reassess safety, structural progression, and immunogenicity throughout | Cancer-risk, radiographic, and ADA evidence [525][551][605] |
Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
- ▸ILD is an emerging pulmonary concern in PsA, with a dedicated systematic review and meta-analysis and nationwide comparative risk analysis now available. [123,587]
- ▸In one psoriasis cohort, ILD occurred in **12/117 patients (10%)**, including **6/65 patients with PsA**; this estimate is not a definitive PsA population prevalence. [589]
- ▸Cardiovascular disease is recognized in psoriatic disease, while PsA-specific observational data address major adverse cardiovascular events and arterial or venous thrombosis during targeted therapy. [401,582]
- ▸COVID-19 breakthrough infections have been prospectively studied in vaccinated immune-mediated inflammatory disease populations, but the supplied abstract does not provide a PsA-specific rate. [581]
- ▸IL-17 inhibitors have reported associations with both treatment investigation in SLE and new-onset SLE, making lupus-like features during therapy clinically important. [38]
- ▸Audiometric abnormalities may occur in PsA, but the supplied evidence does not establish hearing loss as a diagnostic criterion or define universal screening thresholds. [586]
- ▸Evidence for routine PsA-specific ocular, gastrointestinal, renal, endocrine, or neurologic organ involvement is insufficient in the supplied references. [258,392,403,404,588]
Psoriatic arthritis (PsA) is a systemic inflammatory disease in which extra-articular findings may reflect psoriatic disease itself, associated comorbidity, treatment-related effects, or an alternative diagnosis. The strongest updated evidence in the supplied literature concerns pulmonary involvement, cardiovascular risk, infection, and selected neurologic or auditory findings. Evidence for other organ systems remains limited or indirect.
Skin and mucosa
Psoriasis is the defining extra-articular manifestation associated with PsA, but the supplied studies do not quantify plaque extent, nail disease, or mucosal involvement specifically in PsA. Psoriatic disease is described as systemic and associated with extra-cutaneous complications, including cardiovascular disease and type 2 diabetes. [401]A1a Genetic evidence also supports inflammatory pathway involvement: an NLRP3 study evaluated susceptibility to psoriasis, psoriasis severity, and risk of PsA, but the supplied abstract does not establish a specific clinical organ phenotype or a validated predictive genotype. [625]
Lung
Interstitial lung disease (ILD) is an emerging pulmonary manifestation or comorbidity in PsA and is not traditionally considered a classic extra-articular feature. [123]A1a A 2026 systematic review and meta-analysis was designed to estimate pooled ILD prevalence in PsA and assess associated risk factors and comparative risk, confirming that the issue is sufficiently recognized for formal quantitative synthesis. [123]A1a A nationwide database analysis from 2014–2024 specifically compared ILD risk in PsA with psoriasis and used propensity-score adjustment for age, sex, race, body mass index, and other factors; its purpose was to determine whether PsA carries greater ILD risk than psoriasis. [587]C
Evidence from related psoriatic disease populations supports pulmonary vigilance but should not be treated as PsA-specific. In a retrospective psoriasis cohort, ILD was identified in 12/117 patients (10%), including 6/65 patients with PsA; the cohort excluded several alternative causes of ILD and required chest imaging before methotrexate or biologic therapy. [589]C A separate systematic review and meta-analysis assessed ILD prevalence across psoriatic disease subtypes, including psoriasis and PsA, with subgroup analyses by sex and smoking history. [401]A1a These findings support symptom review and consideration of baseline or follow-up imaging when clinically indicated, while the supplied evidence does not define a universal screening threshold. [123]A1a[401]A1a[587]C[589]C
Cardiovascular and thrombotic system
Cardiovascular disease is recognized as an extra-cutaneous complication of psoriatic disease. [401]A1a The supplied PsA-specific cardiovascular study evaluated major adverse cardiovascular events, arterial and venous thrombosis, treatment exposure, disease activity, traditional cardiovascular risk factors, and comorbidity burden in a targeted-therapy registry. [582]C Because this was a retrospective, single-center observational analysis, it informs safety surveillance and risk assessment rather than establishing a population-level incidence or a causal treatment effect. [582]C
Infection and immune complications
Patients with immune-mediated inflammatory diseases, including PsA, were included in the prospective SUCCEED study of COVID-19 breakthrough infection after at least three COVID-19 vaccine doses; participants provided monthly saliva samples from September 2022 through August 2023 and underwent antibody assessment. [581] This supports vaccination and infection-risk assessment as part of systemic PsA care, but the supplied abstract does not provide a PsA-specific breakthrough rate or demonstrate that PsA independently increases risk. [581]
IL-17 inhibition has a relevant immune paradox. A systematic review examined reports of new-onset systemic lupus erythematosus (SLE) after secukinumab, bimekizumab, brodalumab, or ixekizumab, as well as treatment efficacy in established SLE. [38]B3a These agents all block IL-17A, with bimekizumab additionally targeting IL-17F. [38]B3a New lupus-like or SLE presentations during IL-17-inhibitor therapy therefore warrant diagnostic reassessment rather than automatic attribution to PsA or treatment failure. [38]B3a
Ear and nervous system
A 2026 cross-sectional audiometric study compared 53 patients with PsA, 53 with ankylosing spondylitis, and 53 matched healthy controls. [586] The study investigated bone-conduction thresholds and associations with disease activity, inflammatory measures, and comorbidities; its title indicates subclinical sensorineural hearing loss in PsA, but the supplied abstract does not provide effect sizes or diagnostic thresholds. [586] Hearing symptoms should therefore be assessed clinically, with audiometry when indicated, without treating hearing loss as a routine diagnostic criterion for PsA. [586]
Eye, gastrointestinal, renal, endocrine, and vascular systems
The supplied references do not provide robust PsA-specific prevalence estimates for uveitis, inflammatory bowel disease, renal disease, thyroid disease, or systemic vasculitis. A study of HLA-B*51-positive patients compared Behçet disease, axial and peripheral spondyloarthritis, and PsA phenotypes and their extra-articular manifestations, but the supplied abstract does not report organ-specific PsA results. [404]B3b Similarly, a neurofilament-medium immunoreactivity study included 9 PsA patients alongside Behçet disease, systemic lupus erythematosus, multiple sclerosis, non-Behçet uveitis, and healthy donors, but it does not establish a neurologic biomarker or clinical neurologic syndrome in PsA. [258]B3b
Studies of familial Mediterranean fever, immune-checkpoint-inhibitor–associated autoimmunity, and systemic autoimmune disease mechanisms are not direct evidence of routine extra-articular involvement in PsA and should not be extrapolated without clinical context. [403]B2b[392]C4[588] Population studies of autoimmune rheumatic disease diagnosis trends, employment, socioeconomic status, and regional rheumatology burden describe healthcare or functional context rather than organ manifestations of PsA. [381]B2b[399]B2c[585][590]
Clinical synthesis
The current organ-by-organ map supports recognizing PsA as systemic while distinguishing established association from emerging or indirect evidence. Pulmonary symptoms or radiographic abnormalities deserve evaluation for ILD; cardiovascular risk factors and thrombotic symptoms require active review; infection prevention remains relevant during immunomodulatory treatment; and new lupus-like, auditory, ocular, gastrointestinal, or neurologic findings should prompt assessment for comorbidity, drug-related disease, or an alternative inflammatory diagnosis. [38]B3a[123]A1a[258]B3b[401]A1a[581][582]C[586][587]C[589]C
| System | Evidence in supplied references | Practical interpretation |
|---|---|---|
| Skin/psoriatic disease | Psoriatic disease has systemic extra-cutaneous complications; NLRP3 variants were studied for psoriasis and PsA susceptibility. [401]A1a[625] | Treat psoriasis and nail disease as part of systemic PsA assessment; no validated NLRP3 clinical test is established here. |
| Lung | ILD prevalence and comparative risk are under active study; 12/117 (10%) psoriasis patients had ILD, including 6/65 with PsA in one cohort. [123]A1a[401]A1a[587]C[589]C | Investigate dyspnea, cough, hypoxemia, or abnormal imaging; avoid assuming the cohort estimate is universal. |
| Cardiovascular/thrombotic | Psoriatic disease is associated with cardiovascular complications; PsA registry data evaluate MACE and arterial/venous thrombosis. [401]A1a[582]C | Assess conventional cardiovascular risk and thrombotic symptoms. |
| Infection/immune | Breakthrough COVID-19 was studied after ≥3 vaccine doses; IL-17 inhibition has reported SLE-related paradoxical concerns. [38]B3a[581] | Address vaccination, infection prevention, and new autoimmune features during therapy. |
| Ear/nervous system | Audiometry was performed in 53 PsA patients and 53 controls; the study title reports subclinical sensorineural hearing loss. [586] | Ask about hearing change and arrange audiometry when clinically indicated. |
| Eye/GI/renal/endocrine | No robust PsA-specific organ prevalence or diagnostic estimates were supplied. [258]B3b[403]B2b[404]B3b[588] | Evaluate symptoms individually and consider alternative diagnoses or comorbidity. |
Complications: Disease-Driven & Treatment-Related
- ▸CV complications are a major disease-driven concern: 12.46% of a 10-year PsA cohort developed a CV event, at a rate of 1.33 per 100 patient-years. [593]
- ▸Assess traditional risk factors, disease activity, hyperuricaemia, arrhythmias and multiterritorial atherosclerosis; consensus guidance supports structured CV prevention and screening. [591][119][444]
- ▸JAK inhibitors require individualized assessment of malignancy, major adverse cardiovascular event and venous-thromboembolism risk. [525][550]
- ▸IL-23 inhibitor studies specifically address TB infection and LTBI reactivation, while guselkumab has been evaluated for up to 5 years in LTBI-positive patients. [112][553]
- ▸Preventive vaccination should include shingles, influenza, COVID-19 and pneumococcal vaccines; uptake remains inconsistent. [534][596]
- ▸Screen for osteoporosis when clinically indicated, including use of DXA; osteoporosis was defined as T-score ≤ −2.5 in a psoriasis cohort. [531]
- ▸Isoniazid prophylaxis can cause hepatotoxicity, particularly requiring care in patients with previous DMARD-related liver injury. [594]
Cardiovascular and vascular complications
Psoriatic arthritis (PsA) is associated with clinically important cardiovascular (CV) morbidity. In the 10-year CARMA prospective cohort, 85 of 682 patients (12.46%) without previous CV events developed a CV event during 6,397 patient-years of follow-up, corresponding to 1.33 events per 100 patient-years; older age, male sex, disease activity and hyperuricaemia were relevant predictors. [593] A 2026 Austrian rheumatology consensus therefore recommends structured CV-risk prevention, screening and management in PsA, alongside rheumatoid arthritis and spondyloarthritis. [591]
Subclinical and established vascular disease may be more extensive than conventional risk scores indicate. In a cross-sectional study of 250 patients with PsA, carotid, femoral and aortic territories were assessed for plaque, and multiterritorial atherosclerosis was evaluated for incremental value beyond SCORE2. [444]C4 Cardiac abnormalities have also been documented in psoriasis: the PSOCADIA study compared 1,010 adults with psoriasis with 1,010 matched controls using echocardiography and evaluated hypertrophy, valvular disease, systolic and diastolic dysfunction, and impaired global longitudinal strain. [528] Arrhythmias represent an additional potential complication; a prospective PsA cohort followed from 1994 to 2024 assessed atrial tachyarrhythmia, ventricular tachyarrhythmia and bradycardia requiring pacing, with analyses relating arrhythmia risk to PsA disease activity. [119]B2b
Treatment-related CV concerns are particularly relevant to Janus kinase inhibitors (JAK inhibitors). Regulatory warnings include major adverse cardiovascular events, venous thromboembolism and malignancy, and a prospective exploratory study specifically evaluated early myocardial deformation after upadacitinib initiation in adults with immune-mediated inflammatory diseases, including PsA. [550]C The available evidence does not establish that upadacitinib causes early myocardial injury, but it supports individualized CV-risk assessment and monitoring. [550]C A systematic review and Bayesian network meta-analysis of randomized trials and long-term extensions was undertaken to estimate comparative and absolute cancer risk for JAK inhibitors versus other advanced therapies across immune-mediated inflammatory diseases, including PsA and psoriasis. [525]
Infection and vaccination-related complications
Immune dysregulation and immunosuppressive treatment increase infection concerns in inflammatory arthritis. [596] IL-23 inhibitors—including guselkumab, risankizumab and tildrakizumab—were systematically reviewed for new tuberculosis (TB) infection and latent TB infection (LTBI) reactivation in psoriasis and PsA, with particular attention to high-prevalence Asia-Pacific settings. [112]B2a In pooled phase 2/3 studies of guselkumab involving LTBI-positive patients with psoriasis or active PsA, treatment was evaluated for safety for up to 5 years; the analysis reflects updated practice in which routine LTBI testing is not universally required before IL-17 or IL-23 inhibitor therapy, unlike the established concern with TNF inhibitors. [553]
Herpes zoster is an important treatment-related complication of JAK inhibition. A real-world cohort of patients with inflammatory diseases, including PsA, treated with upadacitinib, baricitinib or tofacitinib measured incident herpes zoster, incidence rates and associated factors, while also assessing zoster-vaccine uptake. [534] Recommended preventive vaccination in inflammatory arthritis includes shingles, influenza, COVID-19 and pneumococcal vaccines, although uptake across these vaccines remained inconsistent in a three-centre UK study of patients with rheumatoid arthritis, PsA and ankylosing spondylitis. [596] COVID-19 is also relevant during advanced therapy: in integrated bimekizumab safety analyses comprising 1,409 PsA patients and 3,655.9 patient-years of exposure, COVID-19 was among the most frequent treatment-emergent adverse events; discontinuation because of adverse events was infrequent at 2.9 per 100 patient-years. [592]
Malignancy and organ-specific safety
Cancer risk should be considered when selecting advanced therapy, particularly JAK inhibitors, because class-wide regulatory warnings followed evidence from rheumatoid arthritis surveillance and the comparative risk across immune-mediated diseases remains uncertain. [525] Current evidence should therefore be interpreted by drug, patient risk profile, smoking history, age and comorbidity rather than assuming identical risk across all advanced therapies. [525]
Autoimmune thyroid disease is not established as a characteristic PsA complication by the cited evidence. However, a systematic Mendelian-randomization review reported associations between autoimmune thyroid disease and multiple health outcomes, including coronary atherosclerosis, deep venous thrombosis and chronic obstructive pulmonary disease; these genetic findings do not by themselves demonstrate that PsA or its treatment causes thyroid disease. [430]A1a
Bone, hepatic and perioperative complications
Psoriasis is associated with increased osteoporosis risk, and a 2026 retrospective cohort of 639 patients developed and validated a nomogram to identify patients at high risk, using dual-energy X-ray absorptiometry and T-score ≤ −2.5 as the osteoporosis definition. [531] In patients requiring total hip arthroplasty, a national claims analysis compared complications and implant survivorship in inflammatory-arthritis patients receiving DMARDs with those not receiving DMARDs. [577] A separate large database study evaluated superficial and deep surgical-site infection, 90-day sepsis and 2-year revision after hip arthroplasty in patients with cutaneous psoriasis or PsA compared with patients without psoriasis. [546]C
LTBI chemoprophylaxis may itself cause harm. In a single-centre series and literature review of patients with autoimmune rheumatic diseases who developed isoniazid hepatotoxicity, 56.3% had spondyloarthritis or PsA; hepatotoxicity was defined using elevations of at least twofold above the upper limit of normal in the reported clinical analysis. [594] Liver history and concurrent hepatotoxic drugs should therefore be reviewed before and during isoniazid therapy. [594]
Disease flares and new-onset disease signals
A nested case-control study evaluated whether SARS-CoV-2 exposure or COVID-19 vaccination was associated with development of PsA in a healthcare-provider database of 3,122,602 adults without prior PsA, with cases identified from January 2021 through June 2022. [439]B3b Separately, a propensity-matched electronic-health-record cohort compared new-onset psoriasis within 3 months after confirmed COVID-19 infection without vaccination versus vaccination without prior infection. [595] These observational studies address temporal associations and should not be interpreted as proof of causation or as evidence that vaccination routinely induces PsA or psoriasis. [439]B3b[595]
| Domain | Evidence and clinical implication |
|---|---|
| Cardiovascular | Prospective 10-year event rate 1.33/100 patient-years; assess risk factors, disease activity and vascular disease. [593][591][444]C4 |
| Arrhythmia | Atrial, ventricular and bradyarrhythmic outcomes have been prospectively evaluated in PsA. [119]B2b |
| Infection | TB/LTBI, herpes zoster and COVID-19 are key concerns; risk varies by therapy. [112]B2a[553][534][592] |
| Malignancy and JAK safety | Comparative cancer, MACE and VTE risk remain central to JAK-inhibitor selection. [525][550]C |
| Bone and surgery | Osteoporosis and postoperative infection, sepsis and revision require risk assessment. [531][546]C[577] |
| Hepatic toxicity | Isoniazid prophylaxis may produce clinically relevant hepatotoxicity. [594] |
History and Evolution of Treatment
- ▸PsA treatment has progressed from csDMARD-based care to targeted TNF, IL-17, IL-23, TYK2, and JAK inhibition, with increasing emphasis on multiple disease domains.[348][353][616]
- ▸Early treatment of limited-joint disease and prevention of progression from **no more than 4 active joints** to polyarticular disease are emerging priorities.[539]
- ▸Upadacitinib has demonstrated a long-term development program extending to **152 weeks** after prior TNF inhibitor exposure.[615]
- ▸Bimekizumab, secukinumab, and guselkumab illustrate the expansion of durable IL-17- and IL-23-directed treatment strategies.[83][117][353][592]
- ▸Biomarker-guided treatment selection, pediatric indications, cancer-risk assessment, and comorbidity management are defining the next phase of PsA care.[201][327][360][540][626]
Psoriatic arthritis (PsA) treatment has evolved from symptom-directed care and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) toward targeted biologic and oral therapies directed at TNF, IL-17, IL-23, TYK2, and JAK pathways. Current development increasingly emphasizes control of multiple disease domains—peripheral arthritis, enthesitis, axial symptoms, skin disease, pain, and structural progression—rather than joint-count improvement alone.[348]A1b[353]A1b[616]
Conventional and early targeted treatment
Methotrexate and other csDMARDs remain part of the treatment sequence, but inadequate or incomplete responses have driven development of biologic DMARDs and targeted synthetic DMARDs.[348]A1b[540] The FOREMOST trial specifically evaluated early oligoarticular PsA, defined as more than 1 and no more than 4 swollen and tender joints, and tested apremilast against placebo for 24 weeks, followed by open-label treatment through week 48.[539] This study addressed whether early pharmacologic intervention could modify progression from oligoarticular to polyarticular disease, defined as more than 4 active joints, in patients with a mean disease duration of approximately 9.9 months.[539] These data reflect a shift toward treating early disease and preventing expansion of joint involvement, although the supplied abstract does not establish a definitive disease-modifying effect.[539]
Expansion of biologic treatment
TNF inhibitors were among the foundational targeted therapies for PsA, but subsequent treatment evolution has expanded to IL-17 and IL-23 pathway inhibition. In patients with inadequate response or intolerance to one TNF inhibitor, guselkumab, an IL-23p19 inhibitor, was evaluated in the phase 3b SOLSTICE trial using 100 mg every 4 weeks or an induction regimen followed by every 8 weeks, with placebo crossover at week 24.[353]A1b This reflects the growing role of IL-23 inhibition after TNF inhibitor failure. Guselkumab safety analyses across 11 psoriatic disease studies also included patients with latent tuberculosis infection treated for up to 5 years; the contemporary consensus described in that analysis does not require routine latent tuberculosis testing before IL-17 or IL-23 inhibitor initiation, unlike the established concern with TNF inhibition.[553]
IL-17 inhibition has likewise become an established treatment strategy. Secukinumab was studied in the ULTIMATE trial in patients with clinically active and power-Doppler-ultrasound-confirmed synovitis, with 150- or 300-mg dosing selected according to psoriasis severity; post-hoc analyses examined whether ultrasound-defined inflammatory clusters had different treatment trajectories.[163]A1b Real-world psoriasis studies extending to 7 years and observational data extending to 5 years support the durability of secukinumab effectiveness and retention in psoriatic disease, although these reports primarily concern psoriasis rather than PsA outcomes.[117]B3b[597] Bimekizumab, which inhibits both IL-17A and IL-17F, produced efficacy and safety outcomes through 3 years in biologic-naive patients and those with prior TNF inhibitor inadequate response.[83]B2b Integrated safety data from six phase IIb/III studies included 1,409 PsA patients and 3,655.9 patient-years of exposure; treatment discontinuation because of adverse events was infrequent.[592]
Oral targeted therapies and newer mechanisms
The treatment landscape has increasingly incorporated oral targeted agents. Upadacitinib, a JAK inhibitor, was evaluated at 15 mg once daily in patients previously exposed to one TNF inhibitor, with efficacy—including ACR20/50/70, minimal disease activity (MDA), PASI75/90, and pain—followed through 152 weeks.[615] Additional analyses examined whether early pain improvement predicted later MDA and whether prior TNF inhibitor exposure duration influenced outcomes.[615] Upadacitinib has also been studied for pain relief in active PsA despite treatment, including comparisons with adalimumab and analyses separating pain responses associated with attenuation of inflammation from persistent inflammatory disease.[453]A1b
Deucravacitinib, an oral selective TYK2 inhibitor, was tested in biologic-DMARD-naive patients with active PsA, elevated high-sensitivity C-reactive protein of at least 3 mg/L, and at least one radiographic hand or foot erosion.[616] Participants received 6 mg daily or placebo through week 16, followed by active treatment through week 52, reflecting evaluation of both symptomatic efficacy and longer-term safety in patients with objective inflammatory and structural disease.[616] Vunakizumab, a newer IL-17A monoclonal antibody, was evaluated in a phase 2 trial using 120- or 240-mg subcutaneous dosing at weeks 0, 2, 4, and 8, with ACR20 at week 12 as the primary endpoint.[348]A1b
Toward precision, prevention, and comprehensive care
Because response rates remain variable and treatment switching is common, contemporary research is moving toward biomarker-guided therapy. The TOFA-PREDICT program assessed whether circulating immune-cell biomarkers could predict MDA after tofacitinib, methotrexate, or etanercept, while integrative transcriptomic and proteomic analyses sought predictors of response to tofacitinib and comparator treatments.[540][360]B2b These approaches aim to shorten the time to effective therapy rather than relying solely on sequential empirical switching.
Treatment evolution also includes special populations, comorbidity management, and noninflammatory symptom control. Ixekizumab is being evaluated in children with juvenile PsA and enthesitis-related juvenile idiopathic arthritis, with adalimumab as a randomized reference treatment.[201]A1b Immune-checkpoint inhibitors used for cancer therapy may precipitate flares of pre-existing rheumatologic disease, making coordinated risk assessment important.[327]A1a A nationwide cohort study is examining cancer risk according to duration of TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, IL-23 inhibitor, or JAK inhibitor exposure in spondyloarthritis, including PsA.[626] Ketamine infusions have also been explored for severe chronic arthritis pain, including PsA, but evidence is limited to a small retrospective cohort.[554]C Finally, natural-language-processing tools are being developed to distinguish inflammatory arthritis, including PsA, from osteoarthritis and fibromyalgia in rheumatology records, potentially supporting earlier recognition and treatment selection.[598] Genetic and immunologic studies, including work on HLA profiles and IL-36-related pathways in pustular psoriasis, may further inform future phenotype-specific treatment, although they do not yet establish PsA therapies.[576]C
| Treatment strategy | Evidence of evolution |
|---|---|
| Apremilast | Studied in early oligoarticular PsA to assess progression prevention and disease modification.[539] |
| IL-17 inhibition | Secukinumab evaluated with ultrasound-defined synovitis; bimekizumab inhibits IL-17A and IL-17F; vunakizumab is an investigational IL-17A antibody.[83]B2b[163]A1b[348]A1b |
| IL-23 inhibition | Guselkumab studied after inadequate response or intolerance to one TNF inhibitor.[353]A1b |
| JAK inhibition | Upadacitinib evaluated through 152 weeks, including MDA, skin, and pain outcomes.[615] |
| TYK2 inhibition | Deucravacitinib evaluated through 52 weeks in biologic-DMARD-naive patients with objective inflammatory and erosive disease.[616] |
| Precision medicine | Transcriptomic, proteomic, and circulating immune-cell biomarkers are being investigated to predict treatment response.[360]B2b[540] |
Prognosis & Natural History
- ▸Delayed PsA diagnosis is associated with worse outcomes, while early intervention improves prognosis [148].
- ▸Early oligoarticular disease can progress from **≤4** to **>4 active joints**; FOREMOST specifically evaluated predictors of this transition [539].
- ▸Residual pain, fatigue, swollen joints or functional symptoms may persist despite remission or low disease activity [527].
- ▸A difficult-to-treat phenotype is characterised operationally by persistent activity despite **at least 2 b/tsDMARDs** [609].
- ▸Long-term response and persistence vary by treatment, prior TNF-inhibitor exposure, immunogenicity and patient factors [605][615][619][562].
Overall prognostic framework
Psoriatic arthritis (PsA) has a heterogeneous course involving peripheral joints, entheses, digits, axial structures, skin and patient-reported symptoms; contemporary prognosis is therefore better assessed across multiple domains than by joint counts alone [292]A1a[527][162]C4. Persistent inflammation may coexist with clinically low disease activity or treatment-target attainment, producing residual pain, fatigue, functional limitation or other clinically relevant disease manifestations [527]. A difficult-to-treat phenotype has been operationalised as persistent disease activity despite exposure to at least 2 biologic or targeted synthetic DMARDs; clinical and ultrasonographic features preceding this phenotype have been investigated in real-world cohorts, including synovitis, erosions, tenosynovitis, enthesitis, bursitis and dactylitis [609].
Development and early progression
PsA may emerge after psoriasis, and underdiagnosis or delayed diagnosis is clinically important because delayed diagnosis is associated with worse outcomes, whereas early intervention improves prognosis [148]B2b. In people with newly diagnosed psoriasis, prediction models have been developed to identify those warranting rheumatology referral and those with subclinical PsA who are at high risk of developing clinical disease; these models were derived and internally validated in the Stockholm Psoriasis Cohort [148]B2b. Subclinical entheseal inflammation and structural bone remodelling have also been documented in a subset of people with psoriasis who have arthralgia but no current or previous PsA; the EPOS study evaluated whether 24 weeks of apremilast could modify these entheseal abnormalities, although its single-arm design limits causal inference about prevention of PsA [552].
Early joint distribution does not necessarily remain stable. In FOREMOST, adults with early PsA of mean duration 9.9 months and 1–4 swollen and 1–4 tender joints were followed to evaluate progression from oligoarticular disease, defined as ≤4 active joints, to polyarticular disease, defined as >4 active joints [539]. Multivariable modelling examined baseline predictors of progression and the effect of apremilast through week 16, followed by open-label treatment through week 48 [539]. These data support active surveillance even when initial joint involvement is limited, but they do not establish that apremilast prevents long-term structural or functional progression [539].
Inflammation, structural damage and residual disease
Whole-body MRI studies demonstrate that PsA inflammation can involve clinically affected and less clinically apparent peripheral joints and entheses, as well as the spine, sacroiliac joints, hips, knees and heels [162]C4. In MOSAIC, changes in peripheral and axial inflammation were assessed at weeks 24 and 48 during open-label apremilast treatment, with or without stable methotrexate; the study provides imaging information on inflammatory burden but, because it was single-arm, cannot determine comparative effects on long-term damage or disability [162]C4. The POETYK PsA-1 population was enriched for objective inflammatory and structural disease, requiring high-sensitivity C-reactive protein ≥3 mg/L and at least one radiographic hand or foot erosion; 52-week results therefore provide evidence in patients already showing markers associated with potentially more consequential disease [616].
Achievement of a treatment target does not guarantee complete recovery. A systematic review and meta-analysis found substantial variation in how residual disease is defined in PsA and related inflammatory arthritides, with residual indicators including swollen joints, fatigue and other symptoms despite remission or low disease activity [527]. Composite instruments such as ACR response criteria, CPDAI, DAPSA, Minimal Disease Activity and related measures differ in their ability to distinguish active treatment from placebo in trials, underscoring that apparent prognosis depends partly on the outcome domain selected [292]A1a.
Treatment-responsive prognosis and durability
Modern bDMARDs and tsDMARDs can produce sustained clinical responses in patients with active PsA, including those with previous treatment failure. Upadacitinib 15 mg once daily was evaluated through 152 weeks in patients exposed to one TNF inhibitor, with longitudinal assessment of ACR20/50/70, Minimal Disease Activity, PASI75/90 and pain; early pain improvement and skin response were examined as potential predictors of later Minimal Disease Activity [615]. Deucravacitinib was studied through week 52 in biologic-naive patients with active, erosive PsA, with placebo crossover at week 16 [616]. These studies indicate that long-term control is achievable, but trial extension and post hoc designs do not define the untreated natural history [615][616].
Real-world persistence is an important pragmatic component of prognosis. A large multicentre Italian cohort evaluated guselkumab response, disease activity and treatment persistence at 3, 6, 9 and 12 months [621]. Twelve-month persistence and response were also examined in a multicentre observational cohort receiving bimekizumab, while the BIRRA cohort compared persistence of upadacitinib and tofacitinib and assessed predictors of discontinuation [619][562]. After primary TNF-inhibitor failure, a systematic review compared cycling to another TNF inhibitor with swapping to a different mechanism using lack of response, 12- and 24-month retention, and adverse events as outcomes; the evidence base was limited by the observational nature of the included studies [242]A1a.
Factors affecting long-term treatment benefit
Anti-drug antibodies occur in patients receiving biologic DMARDs, and a systematic review evaluated their prevalence and associations with serum drug concentration, efficacy and safety across 28 studies [605]. Immunogenicity may therefore contribute to variable durability of biologic benefit, although assay differences and heterogeneous study designs limit direct prediction for an individual patient [605]. Comparative efficacy evidence within the IL-17 pathway has been synthesised using network meta-analysis, including ACR50 at weeks 12–16, ACR20/70, PASI90, Minimal Disease Activity and HAQ-DI; certainty of evidence and treatment rankings remain outcome- and comparison-dependent [614]. Adalimumab efficacy and safety have likewise been evaluated across 17 studies involving 5,655 patients, but treatment-trial results should not be interpreted as the untreated natural history [618].
Prognostic interpretation
The most reliable prognostic approach is repeated multidomain assessment: inflammatory activity, structural damage, enthesitis and dactylitis, axial symptoms, skin disease, pain, fatigue, function, imaging and treatment persistence [162]C4[292]A1a[527][609]. Pregnancy-outcome evidence and studies of analgesic interventions address safety or symptom management rather than the natural history of PsA and should not be used to infer disease progression [620][554]C.
| Domain | Evidence relevant to prognosis |
|---|---|
| Disease emergence | Prediction models identify people with psoriasis who may require referral or are at high risk of clinical PsA [148]B2b. |
| Joint-course evolution | Early oligoarticular disease may progress to polyarticular disease; predictors were evaluated in FOREMOST [539]. |
| Structural/inflammatory burden | MRI and radiographic studies assess peripheral, entheseal, axial and erosive disease [162]C4[616]. |
| Residual disease | Symptoms and signs may remain despite remission or low disease activity [527]. |
| Treatment durability | Persistence and discontinuation have been evaluated for guselkumab, bimekizumab, upadacitinib and tofacitinib [621][619][562]. |
| Difficult-to-treat disease | Persistent activity despite ≥2 b/tsDMARDs defines the investigated phenotype [609]. |
Special Populations, Pregnancy & Prevention
- ▸Guselkumab is an FDA-approved pediatric IL-23p19-targeted option for active juvenile PsA and pediatric plaque psoriasis, but part of the jPsA evidence base is extrapolated from adult PsA and pediatric psoriasis data [490].
- ▸Weekly adalimumab has been explored after inadequate response to biweekly dosing in only 4 pediatric patients, so evidence is highly limited [602].
- ▸Pregnancy care requires individualized medication risk–benefit assessment; the available cohort evaluated pregnancy loss and major congenital malformations but does not provide a complete PsA drug-compatibility table [620].
- ▸PsA warrants active cardiovascular risk prevention and screening; cardiac and cardiometabolic abnormalities may be present even without overt symptoms [528,591].
- ▸JAK-inhibitor therapy requires herpes-zoster risk assessment and vaccination review [534].
- ▸Infection and vaccination studies are observational and do not prove that COVID-19 infection or vaccination causes PsA or psoriasis [439,595].
- ▸Perioperative planning should integrate disease activity, comorbidity, infection risk, and DMARD management [546,563,577].
Children and adolescents
Juvenile psoriatic arthritis (jPsA) shares important clinical and pathogenic features with adult PsA and psoriasis, including a central role for interleukin-23 (IL-23), but differs in age at onset and symptom sequence [490]D5. Guselkumab, a fully human IL-23p19 inhibitor, has demonstrated efficacy and safety in adult psoriasis and PsA and consistent clinical benefits and safety in pediatric psoriasis; these data were extrapolated to jPsA before and around its recent US FDA approval for pediatric plaque psoriasis and active jPsA [490]D5. The evidence base for pediatric IL-23 inhibition therefore includes extrapolation rather than a large, direct jPsA efficacy trial [490]D5.
Adalimumab remains an established pediatric option, but some children with juvenile idiopathic arthritis (JIA), including those with psoriatic arthritis, may lose response to the usual every-other-week regimen [602]C. In a small retrospective series of 4 children with PsA or noninfectious uveitis who failed to respond or lost response to biweekly adalimumab, weekly administration was evaluated with clinical and pharmacokinetic follow-up; the very small sample limits generalizability [602]C. Treatment selection in children should consequently be individualized by pediatric rheumatology, considering articular, skin, ocular, and pharmacokinetic factors [490]D5[602]C.
Pregnancy and reproductive health
Women with PsA commonly require treatment during childbearing years, but pregnancy-specific evidence remains limited. A UK matched cohort study used primary-care data from 2000–2020 to characterize medication prescribing and pregnancy outcomes in women with RA, PsA, psoriasis, spondyloarthritis, or inflammatory bowel disease, compared with matched pregnancies without these diagnoses [620]. The study specifically evaluated spontaneous pregnancy loss and major congenital malformations and described medication use during and around pregnancy; treatment decisions should therefore rely on the individual drug’s pregnancy evidence, disease-control requirements, and specialist risk–benefit assessment rather than assuming that all systemic therapies have equivalent safety [620].
The available references do not provide a complete drug-by-drug pregnancy compatibility table for PsA. Accordingly, preconception counseling should document current and planned medicines, disease activity, comorbidities, vaccination status, and breastfeeding intentions, with coordinated rheumatology, dermatology, obstetric, and pediatric input when systemic therapy is required [456]A1c[620]. The updated French adult psoriasis guideline includes systemic treatment strategies for patients with plaque psoriasis and PsA, recommending methotrexate, adalimumab, or ustekinumab among primary systemic treatment options; however, the abstract does not establish pregnancy-specific recommendations for these agents [456]A1c.
Cardiovascular and metabolic prevention
PsA is associated with increased cardiovascular disease (CVD) risk, contributing substantially to morbidity and mortality in chronic inflammatory rheumatic disease [591]. The 2026 Austrian consensus was developed to provide practical recommendations for prevention, screening, and management of increased cardiovascular risk in RA, PsA, and spondyloarthritis, reflecting the need for routine risk assessment rather than management focused only on joints and skin [591]. Prevention should include active attention to traditional risk factors and appropriate coordination with primary care or cardiology [591].
Cardiovascular assessment is relevant even when overt cardiac symptoms are absent. In the PSOCADIA cross-sectional analysis, 1,010 adults with psoriasis were compared with 1,010 age- and sex-matched controls using clinical assessment and echocardiography; evaluated abnormalities included hypertrophy, valvular disease, systolic and diastolic dysfunction, and myocardial dysfunction defined as global longitudinal strain <16% [528]. These findings support awareness of subclinical cardiac and cardiometabolic abnormalities in psoriatic disease, although the study concerned psoriasis and was cross-sectional, so it does not prove that echocardiographic screening should be performed routinely in every patient with PsA [528].
Chronic inflammatory dermatologic disease may also be associated with accelerated biological aging. A systematic review identified 6 epigenetic-clock studies, including 4 in psoriasis, and reported notable findings concerning accelerated epigenetic aging in psoriatic disease; the review did not establish a clinical screening test or a preventive intervention for PsA [491]A1a. Genetic Mendelian-randomization evidence has also examined relationships between 25 circulating nutrients and PsA, but such findings are hypothesis-generating and do not justify prescribing supplements or restrictive diets without clinical indication [61]B2c.
Infection prevention and vaccination
Patients receiving JAK inhibitors require particular attention to herpes zoster prevention. A real-world cohort included patients with PsA and other immune-mediated inflammatory diseases treated with upadacitinib, baricitinib, or tofacitinib; it assessed incident herpes zoster during exposure, incidence rates per 100 person-years, associated factors, and zoster-vaccine uptake [534]. Before and during JAK-inhibitor therapy, clinicians should review vaccination status and discuss recombinant zoster vaccination according to local recommendations; the cited study specifically highlights vaccination uptake as a preventive-care issue [534].
COVID-19 prevention should be approached separately from concerns about PsA causation. A nested case-control study of 3,122,602 adults without PsA evaluated SARS-CoV-2 infection and COVID-19 vaccination before newly diagnosed PsA during 2021–2022 [439]B3b. Separately, a large retrospective cohort compared new-onset psoriasis within 3 months after confirmed COVID-19 infection without prior vaccination versus vaccination without prior infection, using propensity-score matching [595]. These observational studies address associations and cannot establish that infection or vaccination causes PsA or psoriasis; vaccination decisions should therefore follow public-health recommendations and the patient’s infection risk [439]B3b[595].
Perioperative and long-term prevention
PsA-specific disease activity and comorbidity assessment are important before arthroplasty. Prospective research in patients undergoing total hip or knee arthroplasty evaluated BMI, comorbidity burden, disease activity, patient-reported outcomes, synovial inflammation, and postoperative adverse events [563]C. Additional studies examined DMARD exposure and outcomes after total hip arthroplasty in inflammatory arthropathies, including PsA [577], and compared surgical-site infection, sepsis, and revision outcomes after hip arthroplasty in patients with cutaneous psoriasis or PsA versus controls [546]C. These data support individualized perioperative planning, infection-risk assessment, and medication coordination rather than indiscriminate discontinuation of all DMARDs [546]C[563]C[577].
| Population or setting | Practical priority | Evidence and limitation |
|---|---|---|
| Children with jPsA | Specialist assessment of articular, skin, ocular, and treatment-response domains; consider approved targeted options where appropriate | Guselkumab evidence includes extrapolation; weekly adalimumab evidence is based on 4 children [490]D5[602]C |
| Pregnancy planning | Review medicines, disease activity, vaccination, and breastfeeding intentions with multidisciplinary input | UK data evaluated pregnancy loss and major congenital malformations, but no complete drug-by-drug table is provided [620] |
| All adults with PsA | Cardiovascular-risk assessment and prevention | Expert consensus supports routine prevention and screening; psoriasis cohort data are cross-sectional [528][591] |
| JAK-inhibitor treatment | Assess herpes-zoster risk and review recombinant zoster vaccination | Real-world cohort included PsA and evaluated incidence and vaccine uptake [534] |
| Arthroplasty candidates | Coordinate DMARD management and assess comorbidity, disease activity, and infection risk | Evidence includes observational perioperative and claims-based studies [546]C[563]C[577] |
References
- [1]
Reinisch W, Hellstrom W, Dolhain RJEM et al.. “Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.” Annals of the rheumatic diseases (2023). PMID: 37137672 ↗
L1RCTCited in: Definition, Classification & Nomenclature - [2]
Hollick RJ, Macfarlane GJ. “Association of Rural Setting With Poorer Disease Outcomes for Patients With Rheumatic Diseases: Results From a Systematic Review of the Literature.” Arthritis care & research (2021). PMID: 32170834 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification - [3]
Winthrop KL, Mease P, Kerschbaumer A et al.. “Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.” Annals of the rheumatic diseases (2024). PMID: 38123338 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [4]
Winthrop KL, Bathon J, Kerschbaumer A et al.. “Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.” Annals of the rheumatic diseases (2025). PMID: 40240265 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [5]
Zayat AS, Ellegaard K, Conaghan PG et al.. “The specificity of ultrasound-detected bone erosions for rheumatoid arthritis.” Annals of the rheumatic diseases (2014). PMID: 24445255 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [6]
Helliwell PS, Porter G, Taylor WJ. “Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis.” Annals of the rheumatic diseases (2006). PMID: 16840501 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [7]
Polachek A, Furer V, Zureik M et al.. “Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia.” Annals of the rheumatic diseases (2021). PMID: 34215648 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [8]
Duer A, Østergaard M, Hørslev-Petersen K et al.. “Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis.” Annals of the rheumatic diseases (2007). PMID: 17289759 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [9]
Mandl LA, Zhu R, Huang WT et al.. “Short-Term Total Hip Arthroplasty Outcomes in Patients With Psoriatic Arthritis or Psoriatic Skin Disease Compared to Patients With Osteoarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26360522 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [10]
Labitigan M, Bahče-Altuntas A, Kremer JM et al.. “Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis.” Arthritis care & research (2014). PMID: 24115739 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [11]
Mease P, Reed G, Ogdie A et al.. “Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry.” Arthritis care & research (2024). PMID: 38736168 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [12]
Chaudhry ZS, Nellessen N, Reis C et al.. “The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature.” Family practice (2022). PMID: 35395090 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [13]
Hanna N, Silverberg OM, Reaume M et al.. “Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis.” International journal of dermatology (2021). PMID: 34432308 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [14]
Chessa E, Piga M, Floris A et al.. “Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.” BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021). PMID: 33595833 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [15]
Mitrovic S, Hassold N, Kamissoko A et al.. “Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?” Rheumatology (Oxford, England) (2022). PMID: 34559214 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [16]
Ogdie A, Maliha S, Shin D et al.. “Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis.” Rheumatology (Oxford, England) (2017). PMID: 28158384 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Complications: Disease-Driven & Treatment-Related - [17]
Folle L, Bayat S, Kleyer A et al.. “Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 35333316 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [18]
Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [19]
Schlereth M, Mutlu MY, Utz J et al.. “Deep learning-based classification of erosion, synovitis and osteitis in hand MRI of patients with inflammatory arthritis.” RMD open (2024). PMID: 38886001 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [20]
Stouten V, Pazmino S, Verschueren P et al.. “Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study.” RMD open (2021). PMID: 34158353 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [21]
Hen O, Di Matteo A, Dubash SR et al.. “High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort.” RMD open (2024). PMID: 38580344 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [22]
Lubrano E, Scriffignano S, Morelli R et al.. “Assessment of Widespread and Extraarticular Pain in Psoriatic Arthritis: A Case-control Study.” The Journal of rheumatology (2021). PMID: 33452167 ↗
L3CASE_CONTROLCited in: Definition, Classification & Nomenclature - [23]
Rebollo-Giménez AI, Rosina S, Natoli V et al.. “Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study.” Clinical and experimental rheumatology (2023). PMID: 38147312 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [24]
Geenen R, Overman CL, Christensen R et al.. “EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.” Annals of the rheumatic diseases (2018). PMID: 29724726 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, History and Evolution of Treatment - [25]
van Mens LJJ, van de Sande MGH, Menegatti S et al.. “Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29869838 ↗
L1TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism - [26]
Marzo-Ortega H, Harrison SR, Fragoulis GE et al.. “EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis.” Annals of the rheumatic diseases (2025). PMID: 41168056 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target - [27]
Rahman P, Siannis F, Butt C et al.. “TNFalpha polymorphisms and risk of psoriatic arthritis.” Annals of the rheumatic diseases (2005). PMID: 16284098 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [28]
Kastrati K, Aletaha D, Burmester GR et al.. “A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.” RMD open (2022). PMID: 36260501 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [29]
Patel DD, Lee DM, Kolbinger F et al.. “Effect of IL-17A blockade with secukinumab in autoimmune diseases.” Annals of the rheumatic diseases (2012). PMID: 23253932 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [30]
McGonagle D, Ash Z, Dickie L et al.. “The early phase of psoriatic arthritis.” Annals of the rheumatic diseases (2011). PMID: 21339224 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [31]
Reveille JD. “The genetic basis of spondyloarthritis.” Annals of the rheumatic diseases (2011). PMID: 21339218 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [32]
Lesturgie-Talarek M, Gonzalez V, Beaudoin L et al.. “Mucosal-Associated Invariant T Cells in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40395188 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [33]
Hum RM, Christofi M, Smith SL et al.. “Synovial immunopathology in psoriatic arthritis: cellular and molecular insights.” The Lancet. Rheumatology (2025). PMID: 41043452 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [34]
Macleod T, Bridgewood C, McGonagle D. “Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders.” The Lancet. Rheumatology (2023). PMID: 38251507 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [35]
Griffiths CEM, Armstrong AW, Gudjonsson JE et al.. “Psoriasis.” Lancet (London, England) (2021). PMID: 33812489 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [36]
Griffiths CE, Barker JN. “Pathogenesis and clinical features of psoriasis.” Lancet (London, England) (2007). PMID: 17658397 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [37]
Veale DJ, Fearon U. “The pathogenesis of psoriatic arthritis.” Lancet (London, England) (2018). PMID: 29893226 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Severity, Disease Activity & Risk Stratification - [38]
Nagra D, Zuckerman B, Odia J et al.. “The role of interleukin-17 inhibition in systemic lupus erythematosus-paradoxical hindrance or new therapeutic potential? Results from a systematic literature review and mendelian randomization.” Frontiers in immunology (2026). PMID: 41918754 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [39]
Zeng J, Lin L, Li W et al.. “Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysis.” Frontiers in pharmacology (2025). PMID: 41282632 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [40]
Tsiogkas SG, Gkouvi A, Kontouli KM et al.. “Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis.” Autoimmunity reviews (2025). PMID: 40268128 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [41]
López-Medina C, McGonagle D, Gossec L. “Subclinical psoriatic arthritis and disease interception-where are we in 2024?” Rheumatology (Oxford, England) (2025). PMID: 39150442 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Prevention - [42]
Mease P, van den Bosch F. “IL-23 and axial disease: do they come together?” Rheumatology (Oxford, England) (2021). PMID: 34668015 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [43]
White JPE, Coates LC. “JAK1 selective inhibitors for the treatment of spondyloarthropathies.” Rheumatology (Oxford, England) (2021). PMID: 33950224 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [44]
Goldring SR. “Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis.” Rheumatology (Oxford, England) (2016). PMID: 27856661 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [45]
Russolillo A, Iervolino S, Peluso R et al.. “Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management.” Rheumatology (Oxford, England) (2012). PMID: 22989426 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related - [46]
Jethwa H, Abraham S. “The evidence for microbiome manipulation in inflammatory arthritis.” Rheumatology (Oxford, England) (2017). PMID: 27789760 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [47]
Nirula A, Nilsen J, Klekotka P et al.. “Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.” Rheumatology (Oxford, England) (2016). PMID: 27856660 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [48]
Abacar K, Rennie WJ, Raychaudhuri SP et al.. “Focusing on ligamentous soft tissue inflammation for the future understanding of early axial psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 39700474 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [49]
McGonagle D, Hermann KG, Tan AL. “Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era.” Rheumatology (Oxford, England) (2014). PMID: 25231177 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [50]
Schett G, Rahman P, Ritchlin C et al.. “Psoriatic arthritis from a mechanistic perspective.” Nature reviews. Rheumatology (2022). PMID: 35513599 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [51]
Schett G, Lories RJ, D'Agostino MA et al.. “Enthesitis: from pathophysiology to treatment.” Nature reviews. Rheumatology (2017). PMID: 29158573 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [52]
Reveille JD, Eder L, Ziade N et al.. “Global epidemiology of spondyloarthritis.” Nature reviews. Rheumatology (2025). PMID: 40954333 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors - [53]
Taams LS, Steel KJA, Srenathan U et al.. “IL-17 in the immunopathogenesis of spondyloarthritis.” Nature reviews. Rheumatology (2018). PMID: 30006601 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [54]
McGonagle D, Tan AL, Watad A et al.. “Pathophysiology, assessment and treatment of psoriatic dactylitis.” Nature reviews. Rheumatology (2019). PMID: 30610219 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [55]
Reveille JD. “Genetics of spondyloarthritis--beyond the MHC.” Nature reviews. Rheumatology (2012). PMID: 22487796 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [56]
Brown MA, Kenna T, Wordsworth BP. “Genetics of ankylosing spondylitis--insights into pathogenesis.” Nature reviews. Rheumatology (2015). PMID: 26439405 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [57]
Beringer A, Miossec P. “Systemic effects of IL-17 in inflammatory arthritis.” Nature reviews. Rheumatology (2019). PMID: 31227819 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [58]
Miossec P. “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice.” RMD open (2017). PMID: 28243466 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [59]
Sousa M, Alvarenga JM, Lé AM et al.. “Ustekinumab-associated morphoea: systematic review of the literature and a real-world case.” Drugs in context (2026). PMID: 41695304 ↗
L4SR_OBSCited in: Pathophysiology & Mechanism - [60]
Lombo LE, Tejada-Perdomo JH, Ramos-Castaneda JA et al.. “Vagus Nerve Stimulation in Autoimmune Conditions: A Systematic Review.” ACR open rheumatology (2025). PMID: 41392619 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [61]
Zhao J, Wu J, Zhou H et al.. “Genetic evidence of the causal relationship between genetically predicted nutrients and psoriatic arthritis.” Clinical rheumatology (2025). PMID: 41184533 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Prevention - [62]
Yan H, Chen Y, Song Y et al.. “Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.” Biologics : targets & therapy (2026). PMID: 42291469 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [63]
Totolici S, Vrabie AM, Buzea CA et al.. “Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.” International journal of molecular sciences (2026). PMID: 42196207 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [64]
Gossec L, Kerschbaumer A, Ferreira RJO et al.. “EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.” Annals of the rheumatic diseases (2024). PMID: 38499325 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [65]
Agca R, Heslinga SC, Rollefstad S et al.. “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.” Annals of the rheumatic diseases (2016). PMID: 27697765 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [66]
Brunner HI, Foeldvari I, Alexeeva E et al.. “Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.” Annals of the rheumatic diseases (2022). PMID: 35961761 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [67]
Russell MD, Stovin C, Alveyn E et al.. “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.” Annals of the rheumatic diseases (2023). PMID: 37247942 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [68]
Zabotti A, Sakellariou G, Tinazzi I et al.. “Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.” Annals of the rheumatic diseases (2020). PMID: 32430315 ↗
L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [69]
Zeboulon N, Dougados M, Gossec L. “Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review.” Annals of the rheumatic diseases (2007). PMID: 17962239 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [70]
Bing N, Zhou H, Chen X et al.. “Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33455090 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [71]
Ramanan AV, Quartier P, Okamoto N et al.. “Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.” Lancet (London, England) (2023). PMID: 37423231 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [72]
Deodhar A, Gottlieb AB, Boehncke WH et al.. “Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.” Lancet (London, England) (2018). PMID: 29893222 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [73]
McInnes IB, Anderson JK, Magrey M et al.. “Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.” The New England journal of medicine (2021). PMID: 33789011 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [74]
Huss V, Bower H, Hellgren K et al.. “Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.” Annals of the rheumatic diseases (2023). PMID: 36868796 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [75]
Colaco K, Lee KA, Akhtari S et al.. “Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35261189 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [76]
Eder L, Haddad A, Rosen CF et al.. “The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26555117 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [77]
Hellgren K, Smedby KE, Backlin C et al.. “Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24782185 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [78]
Chaudhary H, Bohra N, Syed K et al.. “All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.” Arthritis care & research (2023). PMID: 34788902 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [79]
Stolwijk C, van Onna M, Boonen A et al.. “Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis.” Arthritis care & research (2016). PMID: 26713432 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [80]
Jin Y, Lee H, Lee MP et al.. “Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.” Arthritis care & research (2022). PMID: 33973371 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [81]
Ishchenko A, Pazmino S, Neerinckx B et al.. “Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study.” Arthritis care & research (2024). PMID: 37667975 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification - [82]
Rosenthal YS, Schwartz N, Sagy I et al.. “Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34423909 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors - [83]
Gossec L, Coates LC, Landewé RBM et al.. “Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.” Rheumatology (Oxford, England) (2026). PMID: 41838419 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [84]
Singla S, Putman M, Liew J et al.. “Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.” The Lancet. Rheumatology (2023). PMID: 38251522 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [85]
Singh M, Phillips K, Wang J et al.. “Trends in the prevalence of autoimmune diseases during pregnancy in the UK, 2000-21: a retrospective cohort study.” The Lancet. Rheumatology (2025). PMID: 40473454 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [86]
Russell MD, Galloway JB, Andrews CD et al.. “Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY.” The Lancet. Rheumatology (2022). PMID: 36447940 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [87]
Zabotti A, Bandinelli F, Batticciotto A et al.. “Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.” Rheumatology (Oxford, England) (2017). PMID: 28521047 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, History and Evolution of Treatment, Prognosis & Natural History - [88]
Hojeij B, Koc GH, Luime JJ et al.. “Psoriatic arthritis flare incidence, definition and risk factors: a systematic review.” Rheumatology (Oxford, England) (2025). PMID: 40392198 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease - [89]
Lembke S, Macfarlane GJ, Jones GT. “The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38530786 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [90]
Gazel U, Ayan G, Solmaz D et al.. “The impact of smoking on prevalence of psoriasis and psoriatic arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32500136 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [91]
Zuckerman BP, Gibson M, Roy R et al.. “Abatacept and the risk of malignancy: a meta-analysis across disease indications.” Rheumatology (Oxford, England) (2025). PMID: 39992258 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [92]
Hagège B, Tan E, Gayraud M et al.. “Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 32118267 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [93]
Pittam B, Gupta S, Harrison NL et al.. “Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 32160297 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [94]
Coates LC, Landewé R, McInnes IB et al.. “Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.” RMD open (2024). PMID: 38388171 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History - [95]
Deike M, Brinks R, Meller S et al.. “Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany.” RMD open (2021). PMID: 34862312 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [96]
Zabotti A, De Marco G, Gossec L et al.. “EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.” Annals of the rheumatic diseases (2023). PMID: 37295926 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [97]
Karmacharya P, Crowson CS, Bekele D et al.. “The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33779070 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [98]
Karreman MC, Weel AE, van der Ven M et al.. “Prevalence of Psoriatic Arthritis in Primary Care Patients With Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26636745 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [99]
Di Matteo A, Di Donato S, Smerilli G et al.. “Relationship Between Ultrasound and Physical Examination in the Assessment of Enthesitis in Patients With Spondyloarthritis: Results From the DEUS Multicenter Study.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39165013 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification - [100]
Robin F, Ghossan R, Mehsen-Cetre N et al.. “METHOFRACT, a methotrexate osteopathy multicentre cohort study.” RMD open (2025). PMID: 40998522 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [101]
Eun Y, Hwang J, Seo GH et al.. “Risk of cancer in Korean patients with psoriatic arthritis: a nationwide population-based cohort study.” RMD open (2023). PMID: 36958767 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [102]
Ramírez J, López-Medina C, Montilla C et al.. “Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).” Therapeutic advances in musculoskeletal disease (2026). PMID: 42027204 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [103]
Gladman DD, Charles-Schoeman C, McInnes IB et al.. “Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.” Arthritis care & research (2019). PMID: 31112005 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [104]
Kwok TSH, Sutton M, Ye JY et al.. “Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis.” Arthritis care & research (2022). PMID: 33326187 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [105]
Cretu D, Gao L, Liang K et al.. “Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers.” Arthritis care & research (2018). PMID: 28586166 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [106]
Nash P, Coates LC, Fleishaker D et al.. “Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.” The Lancet. Rheumatology (2021). PMID: 38279411 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [107]
Falasinnu T, Lu D, Baker MC. “Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study.” The Lancet. Rheumatology (2024). PMID: 38945137 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [108]
McInnes IB, Mease PJ, Kivitz AJ et al.. “Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.” The Lancet. Rheumatology (2020). PMID: 38268157 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications: Disease-Driven & Treatment-Related - [109]
Mulder MLM, Vriezekolk JE, van Hal TW et al.. “Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial.” The Lancet. Rheumatology (2022). PMID: 38288921 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [110]
De Marco G, Maksymowych WP, Østergaard M et al.. “Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial.” Rheumatology (Oxford, England) (2026). PMID: 42308540 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [111]
de Vries AC, Bogaards NA, Hooft L et al.. “Interventions for nail psoriasis.” The Cochrane database of systematic reviews (2013). PMID: 23440816 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [112]
Wang G, Youn SW, Chang CL et al.. “New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review.” Dermatology and therapy (2026). PMID: 42262459 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [113]
Yang L, Gao X, Wang Z et al.. “Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta-analysis.” Journal of the European Academy of Dermatology and Venereology : JEADV (2026). PMID: 42227826 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target - [114]
Scher JU, Ogdie A, Merola JF et al.. “Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.” Nature reviews. Rheumatology (2019). PMID: 30742092 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History - [115]
Karacabeyli D, Lacaille D. “Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.” Nature reviews. Rheumatology (2025). PMID: 41034339 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [116]
Ferguson LD, Siebert S, McInnes IB et al.. “Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.” Nature reviews. Rheumatology (2019). PMID: 31292564 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification - [117]
Ibba L, Di Giulio S, Malagoli P et al.. “Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.” Dermatology and therapy (2026). PMID: 42262460 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors - [118]
Attar RZ, Acikgoz SB, Hepworth E et al.. “Real-world performance of EULAR and GRAPPA definitions of difficult-to-treat psoriatic arthritis within the ORCHESTRA cohort: an observational cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42137751 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [119]
Almansouri AY, Li J, Bumbulis L et al.. “Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis.” RMD open (2026). PMID: 41571321 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [120]
Zabotti A, Fagni F, Gossec L et al.. “Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.” RMD open (2024). PMID: 38599649 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Special Populations, Pregnancy & Prevention - [121]
Corte G, Atzinger A, Noversa de Sousa R et al.. “Increased synovial and entheseal fibroblast activation detected by 68Ga-FAPI-PET/CT is associated with the development of psoriatic arthritis in psoriasis patients with arthralgia.” RMD open (2026). PMID: 41871918 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [122]
Currado D, Trunfio F, Saracino F et al.. “Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients.” RMD open (2025). PMID: 40545272 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [123]
Nakaphan P, Shotelersuk V, Pajareya P et al.. “Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.” Clinical rheumatology (2026). PMID: 41832319 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [124]
Ritchlin CT, Kavanaugh A, Gladman DD et al.. “Treatment recommendations for psoriatic arthritis.” Annals of the rheumatic diseases (2008). PMID: 18952643 ↗
L1GUIDELINECited in: Clinical Presentation - [125]
Coates LC, Kavanaugh A, Mease PJ et al.. “Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26749174 ↗
L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment - [126]
Mease PJ, Lertratanakul A, Anderson JK et al.. “Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.” Annals of the rheumatic diseases (2020). PMID: 33272960 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [127]
Baraliakos X, Gossec L, Pournara E et al.. “Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.” Annals of the rheumatic diseases (2020). PMID: 33334727 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [128]
Kristensen LE, Keiserman M, Papp K et al.. “Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.” Annals of the rheumatic diseases (2021). PMID: 34911706 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [129]
Mease P, van der Heijde D, Landewé R et al.. “Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.” Annals of the rheumatic diseases (2018). PMID: 29550766 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [130]
Coates LC, Gossec L, Theander E et al.. “Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).” Annals of the rheumatic diseases (2021). PMID: 34819273 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [131]
Mease PJ, Helliwell PS, Hjuler KF et al.. “Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.” Annals of the rheumatic diseases (2020). PMID: 33106286 ↗
L1RCTCited in: Clinical Presentation - [132]
McInnes IB, Rahman P, Gottlieb AB et al.. “Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34719872 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History - [133]
Mease P, Helliwell P, Silwinska-Stanczyk P et al.. “Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37194394 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [134]
Mease P, Sieper J, Van den Bosch F et al.. “Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25545240 ↗
L1RCTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [135]
McInnes IB, Rahman P, Gottlieb AB et al.. “Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33043600 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [136]
Mease PJ, Gladman DD, Ogdie A et al.. “Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.” Arthritis care & research (2020). PMID: 31909868 ↗
L2RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [137]
Kavanaugh A, McInnes IB, Krueger GG et al.. “Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.” Arthritis care & research (2013). PMID: 23666608 ↗
L1RCTCited in: Clinical Presentation - [138]
Kavanaugh A, Mease PJ, Reimold AM et al.. “Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.” Arthritis care & research (2017). PMID: 27696786 ↗
L1RCTCited in: Clinical Presentation - [139]
Kerschbaumer A, Smolen JS, Ferreira RJO et al.. “Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2024). PMID: 38503473 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [140]
Deodhar A, Helliwell PS, Boehncke WH et al.. “Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2020). PMID: 32178765 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [141]
McInnes IB, Mease PJ, Kirkham B et al.. “Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2015). PMID: 26135703 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [142]
Nash P, Kirkham B, Okada M et al.. “Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.” Lancet (London, England) (2017). PMID: 28551073 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [143]
Gottlieb A, Menter A, Mendelsohn A et al.. “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.” Lancet (London, England) (2009). PMID: 19217154 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [144]
Mease PJ, McInnes IB, Kirkham B et al.. “Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.” The New England journal of medicine (2015). PMID: 26422723 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [145]
McGagh D, Song K, Yuan H et al.. “Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.” The Lancet. Rheumatology (2024). PMID: 39089297 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation - [146]
Eder L, Li X, Chandran V et al.. “Association of Higher Levels of High-Sensitivity C-Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis: A Prospective Cohort Study.” Arthritis care & research (2025). PMID: 40176403 ↗
L2COHORTCited in: Clinical Presentation - [147]
Eder L, Mylvaganam S, Pardo Pardo J et al.. “Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.” The Lancet. Rheumatology (2023). PMID: 38251562 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [148]
Svedbom A, Mallbris L, Zabotti A et al.. “Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study.” The Lancet. Rheumatology (2026). PMID: 42379214 ↗
L2COHORTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification - [149]
Mease PJ, Landewé R, Rahman P et al.. “Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.” RMD open (2021). PMID: 34330846 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [150]
Ramiro S, Poddubnyy D, Mease PJ et al.. “Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.” RMD open (2025). PMID: 41125403 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [151]
Coates LC, Blanco R, Behrens F et al.. “Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.” RMD open (2025). PMID: 40854810 ↗
L2RCTCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment - [152]
McInnes IB, Sawyer LM, Markus K et al.. “Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.” RMD open (2022). PMID: 35321874 ↗
L1SR_OBSCited in: Clinical Presentation - [153]
Poddubnyy D, Parikh B, Elewaut D et al.. “Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39624020 ↗
L2OTHERCited in: Clinical Presentation, History and Evolution of Treatment - [154]
Durham LE, Humby F, Ng N et al.. “Linking Skin and Joint Inflammation in Psoriatic Arthritis through Shared CD8+ T Cell Clones.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40528683 ↗
L4OTHERCited in: Clinical Presentation - [155]
Coates LC, Baraliakos X, Blanco FJ et al.. “The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?” Arthritis care & research (2021). PMID: 32100954 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [156]
Walsh JA, Carroll C, Callis Duffin K et al.. “PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries.” Arthritis care & research (2024). PMID: 37691268 ↗
L2OTHERCited in: Clinical Presentation - [157]
Kesarwani V, Sinnappan S, Husni ME et al.. “Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review.” Arthritis care & research (2024). PMID: 38303576 ↗
L2REVIEW_NARRATIVECited in: Clinical Presentation - [158]
Ibrahim A, Gladman DD, Thavaneswaran A et al.. “Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis.” Arthritis care & research (2017). PMID: 28085226 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [159]
Song K, Satsangi J, Coates LC. “Arthritis complicating inflammatory bowel disease- the future is now.” The Lancet. Rheumatology (2024). PMID: 39032495 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [160]
Mease PJ, Helliwell PS, Gladman DD et al.. “Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.” The Lancet. Rheumatology (2021). PMID: 38287608 ↗
L2OTHERCited in: Clinical Presentation - [161]
Ghoreschi K, Balato A, Enerbäck C et al.. “Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.” Lancet (London, England) (2021). PMID: 33515492 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [162]
Østergaard M, Lambert RGW, Maksymowych WP et al.. “Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis.” Annals of the rheumatic diseases (2026). PMID: 42191498 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [163]
D'Agostino MA, Conaghan PG, Gaillez C et al.. “Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial.” BMC musculoskeletal disorders (2026). PMID: 41612350 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment - [164]
Sbidian E, Chaimani A, Guelimi R et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2023). PMID: 37436070 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [165]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2022). PMID: 35603936 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [166]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 33871055 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [167]
Sbidian E, Chaimani A, Guelimi R et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2025). PMID: 40767824 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [168]
Sbidian E, Chaimani A, Afach S et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2020). PMID: 31917873 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [169]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 29271481 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [170]
Khoda F, Khan Y, Haw WWY et al.. “Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic review.” Journal of the European Academy of Dermatology and Venereology : JEADV (2026). PMID: 42312903 ↗
L2SR_OBSCited in: Clinical Presentation - [171]
Webers C, Ortolan A, Nikiphorou E et al.. “Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs.” Rheumatology (Oxford, England) (2026). PMID: 41666292 ↗
L2SR_OBSCited in: Clinical Presentation - [172]
Mease P. “Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management.” Rheumatology (Oxford, England) (2020). PMID: 32159795 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [173]
Zhao SS, Goodson NJ, Robertson S et al.. “Smoking in spondyloarthritis: unravelling the complexities.” Rheumatology (Oxford, England) (2020). PMID: 32236486 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [174]
Helliwell PS. “Axial involvement in psoriatic arthritis: is it unique?” Rheumatology (Oxford, England) (2024). PMID: 39700473 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [175]
Lopalco G, Celletti E, Morrone M et al.. “Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib.” Rheumatology (Oxford, England) (2025). PMID: 40758456 ↗
L3OTHERCited in: Clinical Presentation - [176]
Low JM, Hyrich KL, Ciurtin C et al.. “The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 37467079 ↗
L2OTHERCited in: Clinical Presentation - [177]
Balderas-Miranda JT, Torres-Ruiz J, Guaracha-Basañez GA et al.. “Myeloid-derived suppressor cells and monocytes are biomarkers of the clinical phenotype and activity of psoriatic disease.” Rheumatology (Oxford, England) (2026). PMID: 40891880 ↗
L3OTHERCited in: Clinical Presentation - [178]
Zabotti A, Aydin SZ, David P et al.. “Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.” Nature reviews. Rheumatology (2025). PMID: 40075177 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [179]
Tarannum S, Leung YY, Johnson SR et al.. “Sex- and gender-related differences in psoriatic arthritis.” Nature reviews. Rheumatology (2022). PMID: 35927578 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target - [180]
Olivieri I, D'Angelo S, Palazzi C et al.. “Advances in the management of psoriatic arthritis.” Nature reviews. Rheumatology (2014). PMID: 25003762 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [181]
Gravallese EM, Schett G. “Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.” Nature reviews. Rheumatology (2018). PMID: 30266977 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [182]
Najm A, Goodyear CS, McInnes IB et al.. “Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.” Nature reviews. Rheumatology (2023). PMID: 36596924 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification - [183]
Anandarajah AP, Ritchlin CT. “The diagnosis and treatment of early psoriatic arthritis.” Nature reviews. Rheumatology (2009). PMID: 19806150 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [184]
Parisi S, Becciolini A, D'Onofrio B et al.. “Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42112225 ↗
L4COHORTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification - [185]
Singla S, Ribeiro A, Torgutalp M et al.. “Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.” RMD open (2024). PMID: 38191215 ↗
L2REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target - [186]
Veale DJ, Fearon U. “What makes psoriatic and rheumatoid arthritis so different?” RMD open (2015). PMID: 26509055 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [187]
Zabotti A, Cabas N, Di Nicola C et al.. “Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis.” RMD open (2025). PMID: 40813109 ↗
L3OTHERCited in: Clinical Presentation - [188]
Ehrenberg S, Elizur Y, Ben-Shabat N et al.. “Increased Risk of Incident Uveitis Among Patients with Psoriasis: A Nationwide Population-Based Cohort Study.” Diagnostics (Basel, Switzerland) (2026). PMID: 41750775 ↗
L2COHORTCited in: Clinical Presentation - [189]
Singh JA, Guyatt G, Ogdie A et al.. “Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.” Arthritis care & research (2018). PMID: 30499259 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [190]
Glatt S, Baeten D, Baker T et al.. “Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.” Annals of the rheumatic diseases (2017). PMID: 29275332 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [191]
Östör A, Van den Bosch F, Papp K et al.. “Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.” Annals of the rheumatic diseases (2021). PMID: 34815219 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [192]
Mease PJ, Deodhar AA, van der Heijde D et al.. “Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.” Annals of the rheumatic diseases (2022). PMID: 35241426 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [193]
Mease PJ, van der Heijde D, Ritchlin CT et al.. “Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.” Annals of the rheumatic diseases (2016). PMID: 27553214 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [194]
Mease PJ, Smolen JS, Behrens F et al.. “A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.” Annals of the rheumatic diseases (2019). PMID: 31563894 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [195]
FitzGerald O, Gladman DD, Mease PJ et al.. “Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38770592 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [196]
Jin Y, Cheng IT, So H et al.. “Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40083242 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [197]
Kivitz A, Sedova L, Churchill M et al.. “Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39300596 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [198]
Husni ME, Kavanaugh A, Murphy F et al.. “Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.” Arthritis care & research (2020). PMID: 30980514 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [199]
De Marco G, Hensor EMA, Helliwell PS et al.. “Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.” The Lancet. Rheumatology (2025). PMID: 40914172 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [200]
Krishnan V, Keller SY, Chew C et al.. “Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.” The Lancet. Rheumatology (2025). PMID: 40915298 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [201]
Ramanan AV, Ruperto N, Foeldvari I et al.. “Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.” The Lancet. Rheumatology (2026). PMID: 41785908 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [202]
Koc GH, Kok MR, Kasiem FR et al.. “Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies.” The Lancet. Rheumatology (2025). PMID: 41275881 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [203]
Mease PJ, Rahman P, Gottlieb AB et al.. “Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2020). PMID: 32178766 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History - [204]
McInnes IB, Asahina A, Coates LC et al.. “Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).” Lancet (London, England) (2022). PMID: 36493791 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [205]
Ruperto N, Brunner HI, Synoverska O et al.. “Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.” Lancet (London, England) (2021). PMID: 34767764 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [206]
McInnes IB, Behrens F, Mease PJ et al.. “Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.” Lancet (London, England) (2020). PMID: 32386593 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [207]
Merola JF, Landewé R, McInnes IB et al.. “Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).” Lancet (London, England) (2022). PMID: 36495881 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [208]
McInnes IB, Kavanaugh A, Gottlieb AB et al.. “Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.” Lancet (London, England) (2013). PMID: 23769296 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [209]
Coates LC, Moverley AR, McParland L et al.. “Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2015). PMID: 26433318 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [210]
Jørgensen KK, Olsen IC, Goll GL et al.. “Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.” Lancet (London, England) (2017). PMID: 28502609 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [211]
Gladman D, Rigby W, Azevedo VF et al.. “Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.” The New England journal of medicine (2017). PMID: 29045207 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [212]
Mease P, Hall S, FitzGerald O et al.. “Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.” The New England journal of medicine (2017). PMID: 29045212 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [213]
Palominos PE, Gaujoux-Viala C, Fautrel B et al.. “Clinical outcomes in psoriatic arthritis: A systematic literature review.” Arthritis care & research (2012). PMID: 22147535 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [214]
Ballegaard C, Jørgensen TS, Skougaard M et al.. “Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.” Arthritis care & research (2018). PMID: 29073353 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, History and Evolution of Treatment - [215]
Østergaard M, Boesen M, Maksymowych WP et al.. “Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.” The Lancet. Rheumatology (2024). PMID: 39488216 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [216]
Kragsnaes MS, Jensen JRB, Nilsson AC et al.. “Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial.” RMD open (2024). PMID: 38296309 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [217]
McInnes IB, Sewerin P, Sharaf M et al.. “Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.” RMD open (2024). PMID: 39672591 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History - [218]
Yang F, Lu C, Pan Q et al.. “68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a comparative study.” Rheumatology (Oxford, England) (2025). PMID: 39576694 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [219]
Pitzalis C, Choy EHS, Buch MH. “Transforming clinical trials in rheumatology: towards patient-centric precision medicine.” Nature reviews. Rheumatology (2020). PMID: 32887976 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [220]
Mease PJ, Gladman DD, Merola JF et al.. “Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38218744 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [221]
Mease PJ, McInnes IB, Tam LS et al.. “Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2023). PMID: 36102818 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [222]
Iragorri N, Hazlewood G, Manns B et al.. “Psoriatic arthritis screening: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2019). PMID: 30380111 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [223]
Bibas N, Pignon C, Lopez-Medina C et al.. “Ultrasonography for the assessment of enthesitis in psoriatic arthritis: systematic review with meta-analysis.” Rheumatology (Oxford, England) (2025). PMID: 39705203 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [224]
Ruyssen-Witrand A, Perry R, Watkins C et al.. “Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.” RMD open (2020). PMID: 32094304 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [225]
Steel KJA, Srenathan U, Ridley M et al.. “Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31677365 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [226]
Yuan Y, Qiu J, Lin ZT et al.. “Identification of Novel Autoantibodies Associated With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30618213 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [227]
Lönnblom E, Leu Agelii M, Sareila O et al.. “Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36718635 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [228]
Graßhoff H, Comdühr S, Nording H et al.. “Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4+ Effector Memory Cells.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40955716 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Special Populations, Pregnancy & Prevention - [229]
Cruz-Correa OF, Pollock RA, Machhar R et al.. “Prediction of Psoriatic Arthritis in Patients With Psoriasis Using DNA Methylation Profiles.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37463128 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [230]
Mc Ardle A, Kwasnik A, Szentpetery A et al.. “Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34114357 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [231]
Arvikar SL, Crowley JT, Sulka KB et al.. “Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27636905 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [232]
Ghosh N, Reid P, Sparks JA et al.. “Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.” Arthritis care & research (2025). PMID: 40865544 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [233]
Paccou J, Bavière W, Sornay-Rendu E et al.. “Body Composition in Patients With Psoriatic Arthritis and Changes During Interleukin-12/Interleukin-23 Inhibition.” Arthritis care & research (2022). PMID: 33973385 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [234]
Jackson CH, Su L, Gladman DD et al.. “On Modelling Minimal Disease Activity.” Arthritis care & research (2016). PMID: 26315478 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [235]
McGagh D, Elliott A, Grohmann T et al.. “The path to interception in psoriatic disease: from conceptual clarity to clinical translation.” The Lancet. Rheumatology (2026). PMID: 41587560 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [236]
Ciccia F, Gandolfo S, Caporali R et al.. “Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease.” The Lancet. Rheumatology (2024). PMID: 39579780 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [237]
Vassilakis KD, Lampadaki K, Nikiphorou E et al.. “Skin cancer in inflammatory arthritis: should we advise screening?” The Lancet. Rheumatology (2025). PMID: 41344357 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [238]
Peeters ACD, Michielsens CAJ, Mahler EAM et al.. “Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial.” The Lancet. Rheumatology (2025). PMID: 40716447 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [239]
Ursini F, Ciaffi J, D'Angelo S et al.. “When one joint matters: the monoarticular blind spot in inflammatory arthritis.” The Lancet. Rheumatology (2026). PMID: 42114539 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [240]
Strand V, Kaeley GS, Bergman MJ et al.. “The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.” The Lancet. Rheumatology (2022). PMID: 38288937 ↗
L1OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [241]
Chasnyk V, Constantin T, Nikishina I et al.. “Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.” Rheumatology (Oxford, England) (2026). PMID: 42011511 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [242]
Tomo ATJ, Ratan P, Gonçalves LS et al.. “Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2026). PMID: 42216248 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [243]
Ogdie A, Coates LC, Gladman DD. “Treatment guidelines in psoriatic arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32159790 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [244]
Kaeley GS. “Enthesitis in psoriatic arthritis (Part 2): imaging.” Rheumatology (Oxford, England) (2020). PMID: 32159789 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [245]
Degboé Y, Sunzini F, Sood S et al.. “Apremilast inhibits inflammatory osteoclastogenesis.” Rheumatology (Oxford, England) (2021). PMID: 33788924 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [246]
McGonagle D, David P, Macleod T et al.. “Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis.” Nature reviews. Rheumatology (2023). PMID: 37919337 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [247]
Shenoi S, Horneff G, Aggarwal A et al.. “Treatment of non-systemic juvenile idiopathic arthritis.” Nature reviews. Rheumatology (2024). PMID: 38321298 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [248]
van Tubergen A, Weber U. “Diagnosis and classification in spondyloarthritis: identifying a chameleon.” Nature reviews. Rheumatology (2012). PMID: 22450552 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [249]
Nefla M, Holzinger D, Berenbaum F et al.. “The danger from within: alarmins in arthritis.” Nature reviews. Rheumatology (2016). PMID: 27733758 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [250]
Feld J, Chandran V, Haroon N et al.. “Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.” Nature reviews. Rheumatology (2018). PMID: 29752461 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [251]
Proft F, Ribeiro AL, Singla S et al.. “Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.” Nature reviews. Rheumatology (2025). PMID: 41310208 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [252]
Jadon DR, Stober C, Pennington SR et al.. “Applying precision medicine to unmet clinical needs in psoriatic disease.” Nature reviews. Rheumatology (2020). PMID: 33024296 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [253]
Haddad A, Kharouf F, Lee KA et al.. “Repair of radiographic joint damage in psoriatic arthritis: a cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42157419 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [254]
Watad A, Elizur Y, Hen O et al.. “Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study.” RMD open (2026). PMID: 42097693 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [255]
Zhang L, Xu Z, Gong J et al.. “Real-world skin and dermatology-specific quality-of-life outcomes and a nomogram to predict skin response to secukinumab in Chinese psoriatic arthritis patients: a multicenter retrospective cohort study.” Frontiers in medicine (2026). PMID: 42078428 ↗
L3COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [256]
Snoeck Henkemans SVJ, de Jong PHP, Luime JJ et al.. “Window of opportunity in psoriatic arthritis: the earlier the better?” RMD open (2024). PMID: 38413172 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [257]
Kristensen LE, Ng KJ, Ngantcha M et al.. “Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.” RMD open (2024). PMID: 39306343 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [258]
Akbaba TH, Donmez-Demir B, Colpak AI et al.. “Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease.” RMD open (2025). PMID: 40447321 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [259]
Yıldırım N, Limon M. “Lower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study.” Rheumatology international (2026). PMID: 42377589 ↗
L3COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [260]
Tang H, Dokoupilova E, Batko B et al.. “Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study.” Expert opinion on biological therapy (2026). PMID: 42021476 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [261]
Sewerin P, Bismpos D, Lange PS et al.. “Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.” RMD open (2026). PMID: 42342287 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [262]
Koc GH, Kok MR, Snoeck Henkemans SVJ et al.. “Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort.” RMD open (2026). PMID: 42336609 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [263]
Elsaghir A, Kuske L, Kniesch K et al.. “IgA anti-CD74 autoantibodies are associated with treatment escalation in peripheral psoriatic arthritis.” Frontiers in immunology (2026). PMID: 42282961 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [264]
D'Ignazio E, Sahin D, Baldi C et al.. “The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.” Current rheumatology reports (2026). PMID: 42277548 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [265]
Singh JA, Guyatt G, Ogdie A et al.. “Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 30499246 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [266]
Ritchlin CT, Coates LC, McInnes IB et al.. “Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.” Annals of the rheumatic diseases (2023). PMID: 37696588 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification - [267]
Kivitz A, Baraliakos X, Muensterman ET et al.. “Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study.” Annals of the rheumatic diseases (2025). PMID: 40615297 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification - [268]
Kerschbaumer A, Steiner M, Khalili S et al.. “Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40583519 ↗
L2TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification - [269]
Koehm M, Rossmanith T, Foldenauer AC et al.. “Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.” The Lancet. Rheumatology (2023). PMID: 38251504 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [270]
Skaria TG, Sreeprakash A, Umesh R et al.. “Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.” The Lancet. Rheumatology (2022). PMID: 36320825 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [271]
van Vollenhoven RF, Hahn BH, Tsokos GC et al.. “Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.” Lancet (London, England) (2018). PMID: 30249507 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [272]
Day J, Antony A, Tillett W et al.. “The state of the art-psoriatic arthritis outcome assessment in clinical trials and daily practice.” The Lancet. Rheumatology (2022). PMID: 38288938 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification - [273]
Sarabia S, Farrer C, Yeung J et al.. “Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic.” Arthritis care & research (2022). PMID: 33544974 ↗
L2COHORTCited in: Severity, Disease Activity & Risk Stratification - [274]
Coates LC, Gossec L, Zimmermann M et al.. “Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.” RMD open (2024). PMID: 38531621 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [275]
López-Medina C, Capelusnik D, Webers C et al.. “Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial.” RMD open (2025). PMID: 40664470 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment - [276]
McGagh D, Coates LC. “Assessment of the many faces of PsA: single and composite measures in PsA clinical trials.” Rheumatology (Oxford, England) (2020). PMID: 32159792 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification - [277]
Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J et al.. “Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35654458 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification - [278]
Vandendorpe AS, de Vlam K, Lories R. “Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments.” RMD open (2019). PMID: 30740243 ↗
L5SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [279]
Merola JF, Mease P, Kivitz A et al.. “Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41903163 ↗
L1OTHERCited in: Severity, Disease Activity & Risk Stratification - [280]
Beck F, Nguyen P, Hoffmann A et al.. “CD4+CD8αlow T Cell Clonal Expansion Dependent on Costimulation in Patients With Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39054665 ↗
L4OTHERCited in: Severity, Disease Activity & Risk Stratification - [281]
Gorodensky JH, Bernatsky S, Afif W et al.. “Ustekinumab Safety in Pregnancy: A Comprehensive Review.” Arthritis care & research (2022). PMID: 34748293 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Special Populations, Pregnancy & Prevention - [282]
Ursin K, Lydersen S, Skomsvoll JF et al.. “Psoriatic Arthritis Disease Activity During and After Pregnancy: A Prospective Multicenter Study.” Arthritis care & research (2019). PMID: 30192071 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Special Populations, Pregnancy & Prevention - [283]
Dougados M, Baeten D. “Spondyloarthritis.” Lancet (London, England) (2011). PMID: 21684383 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [284]
Van den Bosch F, Coates L. “Clinical management of psoriatic arthritis.” Lancet (London, England) (2018). PMID: 29893227 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [285]
Li YJ, Msaouel P, Campbell M et al.. “Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.” RMD open (2024). PMID: 39214611 ↗
L4CASE_REPORTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [286]
Wilsdon TD, Whittle SL, Thynne TR et al.. “Methotrexate for psoriatic arthritis.” The Cochrane database of systematic reviews (2019). PMID: 30656673 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [287]
Cagnotto G, Bruschettini M, Stróżyk A et al.. “Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.” The Cochrane database of systematic reviews (2025). PMID: 39945386 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [288]
Ponkilainen V, Karjalainen TV, Kuitunen I et al.. “Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.” The Cochrane database of systematic reviews (2026). PMID: 42159164 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Special Populations, Pregnancy & Prevention - [289]
Roelsgaard IK, Esbensen BA, Østergaard M et al.. “Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.” The Cochrane database of systematic reviews (2019). PMID: 31476270 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related - [290]
Radner H, Ramiro S, Buchbinder R et al.. “Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity.” The Cochrane database of systematic reviews (2012). PMID: 22258995 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [291]
Capelusnik D, López-Medina C, Weber C et al.. “Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review.” RMD open (2026). PMID: 42373103 ↗
L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification - [292]
Annfeldt TK, Händel MN, Haugegaard T et al.. “Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.” Annals of the rheumatic diseases (2026). PMID: 42248769 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification - [293]
Braun J. “New targets in psoriatic arthritis.” Rheumatology (Oxford, England) (2016). PMID: 27856658 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [294]
Haberman RH, Ogdie A, Merola JF et al.. “The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.” Nature reviews. Rheumatology (2025). PMID: 41286370 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [295]
Cutolo M, Smith V. “Detection of microvascular changes in systemic sclerosis and other rheumatic diseases.” Nature reviews. Rheumatology (2021). PMID: 34561652 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification - [296]
. “[Guideline for the diagnosis and treatment of psoriasis arthropathica (psoriatic arthritis) in China (2026 edition)].” Zhonghua yi xue za zhi (2026). PMID: 42373464 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment - [297]
Gossec L, Baraliakos X, Kerschbaumer A et al.. “EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.” Annals of the rheumatic diseases (2020). PMID: 32434812 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease - [298]
Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28620948 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment, Special Populations, Pregnancy & Prevention - [299]
Nanus DE, Filer AD, Hughes B et al.. “TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis.” Annals of the rheumatic diseases (2014). PMID: 24385202 ↗
L2RCTCited in: Acute Management: Flares & Organ-Threatening Disease - [300]
Van den Bosch F, Manger B, Goupille P et al.. “Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.” Annals of the rheumatic diseases (2009). PMID: 19815494 ↗
L4TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease - [301]
Ramiro S, Smolen JS, Landewé R et al.. “Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2015). PMID: 26660203 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [302]
Elewaut D, Braun J, Anderson JK et al.. “Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.” Arthritis care & research (2021). PMID: 32100944 ↗
L2TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [303]
Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis care & research (2017). PMID: 28620917 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [304]
Mørk S, Voss A, Möller S et al.. “Spondyloarthritis and Outcomes in Pregnancy and Labor: A Nationwide Register-Based Cohort Study.” Arthritis care & research (2021). PMID: 31758739 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [305]
Vincken NLA, Balak DMW, Knulst AC et al.. “Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.” Rheumatology (Oxford, England) (2022). PMID: 35285486 ↗
L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [306]
Uhrenholt L, Christensen R, Dinesen WKH et al.. “Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2022). PMID: 34864896 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [307]
Edwards CJ, Fautrel B, Schulze-Koops H et al.. “Dosing down with biologic therapies: a systematic review and clinicians' perspective.” Rheumatology (Oxford, England) (2017). PMID: 28339632 ↗
L5SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [308]
Dubreuil M, Rho YH, Man A et al.. “Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study.” Rheumatology (Oxford, England) (2013). PMID: 24185762 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [309]
Cordtz R, Lindhardsen J, Soussi BG et al.. “Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.” Rheumatology (Oxford, England) (2021). PMID: 33369663 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [310]
Fauny M, Moulin D, D'Amico F et al.. “Paradoxical gastrointestinal effects of interleukin-17 blockers.” Annals of the rheumatic diseases (2020). PMID: 32719044 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease - [311]
Solomon DH, Love TJ, Canning C et al.. “Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.” Annals of the rheumatic diseases (2010). PMID: 20584807 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [312]
Snoeck Henkemans SVJ, Vis M, Koc GH et al.. “Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study.” Annals of the rheumatic diseases (2025). PMID: 40382308 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [313]
Machado PM, Schäfer M, Mahil SK et al.. “Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.” Annals of the rheumatic diseases (2023). PMID: 36787993 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [314]
Abacar K, De Marco G, Weddell J et al.. “Late-Onset Spondyloarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin -17 Blockade May Have a Therapeutic Role.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40693392 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [315]
Remaeus K, Johansson K, Granath F et al.. “Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34668647 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [316]
Vela J, Cordtz RL, Kristensen S et al.. “Is pain associated with premature mortality in patients with psoriatic arthritis? A nested case-control study using the DANBIO Register.” Rheumatology (Oxford, England) (2021). PMID: 33668054 ↗
L3CASE_CONTROLCited in: Acute Management: Flares & Organ-Threatening Disease - [317]
Ye C, Nikolic RPA, Choi M et al.. “Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides.” The Journal of rheumatology (2025). PMID: 40953945 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease - [318]
Feldman SR, Zhao Y, Shi L et al.. “Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.” Arthritis care & research (2015). PMID: 25303478 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [319]
Eder L, Tu K, Rosen CF et al.. “Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study.” Arthritis care & research (2021). PMID: 31961491 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [320]
Dharia T, Venkatachalam S, Baker JF et al.. “Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease.” Arthritis care & research (2022). PMID: 34890121 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [321]
Coates LC, Cook R, Lee KA et al.. “Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort.” Arthritis care & research (2010). PMID: 20191569 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [322]
Smith CJF, Bandoli G, Kavanaugh A et al.. “Birth Outcomes and Disease Activity During Pregnancy in a Prospective Cohort of Women With Psoriatic Arthritis and Ankylosing Spondylitis.” Arthritis care & research (2020). PMID: 31074583 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [323]
Weiss PF, Ruperto N, Quebe-Fehling E et al.. “Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.” The Journal of rheumatology (2026). PMID: 40953957 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease - [324]
Consolaro A, Ruperto N, Lovell DJ et al.. “Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.” The Journal of rheumatology (2025). PMID: 40312101 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease - [325]
Fisher BA, Rowe A, Hodson C et al.. “Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.” BMJ open (2026). PMID: 41775469 ↗
L5TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [326]
Arriens C, Morand EF, Askanase AD et al.. “Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.” Advances in therapy (2025). PMID: 40920289 ↗
L1TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease - [327]
Yamada K, Matsui T, Takahashi T et al.. “Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis.” Seminars in arthritis and rheumatism (2026). PMID: 41643573 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment - [328]
Wang W, Wang R, Li C. “Hematopoietic stem cell translation for relapse of psoriasis. Systematic review.” Archives of dermatological research (2025). PMID: 40278948 ↗
L5SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [329]
Cooksey R, Underwood J, Brophy S et al.. “Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality.” Rheumatology (Oxford, England) (2022). PMID: 35567479 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [330]
Piga M, Floris A, Congia M et al.. “Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic.” Rheumatology (Oxford, England) (2022). PMID: 34352098 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [331]
Zhang H, Wen J, Alexander GC et al.. “Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis.” RMD open (2021). PMID: 33863840 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [332]
Götestam Skorpen C, Lydersen S, Salvesen KÅ et al.. “Caesarean section in women with axial spondyloarthritis and psoriatic arthritis: a population-based study.” RMD open (2023). PMID: 36863750 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [333]
de Groot P, Wagenaar W, Foolen J et al.. “Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers.” RMD open (2024). PMID: 39438085 ↗
L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [334]
Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D et al.. “Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study.” RMD open (2023). PMID: 36927849 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [335]
Lucasson F, Kiltz U, Kalyoncu U et al.. “Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.” RMD open (2022). PMID: 35523519 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [336]
Chronis NJ, Pereira D, Gao S et al.. “Assessing flares in patients with psoriatic arthritis using questionnaires.” RMD open (2026). PMID: 42259575 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [337]
Venerito V, Stefanizzi P, Fornaro M et al.. “Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.” RMD open (2022). PMID: 34987092 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [338]
Kavanaugh A, Husni ME, Harrison DD et al.. “Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28805045 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [339]
Coates LC, McInnes IB, Merola JF et al.. “Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35829656 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History - [340]
Strand V, Gossec L, Coates LC et al.. “Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.” Arthritis care & research (2024). PMID: 38529674 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [341]
Helliwell PS, Kavanaugh A. “Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity.” Arthritis care & research (2018). PMID: 28834259 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [342]
Thomsen RS, Nilsen TIL, Haugeberg G et al.. “Impact of High-Intensity Interval Training on Disease Activity and Disease in Patients With Psoriatic Arthritis: A Randomized Controlled Trial.” Arthritis care & research (2019). PMID: 29882634 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [343]
O'Dwyer JL, Meads DM, Hulme CT et al.. “Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial.” Arthritis care & research (2018). PMID: 28544822 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [344]
Ritchlin CT, Kavanaugh A, Merola JF et al.. “Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.” Lancet (London, England) (2020). PMID: 32035552 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [345]
Mease PJ, Genovese MC, Greenwald MW et al.. “Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.” The New England journal of medicine (2014). PMID: 24918373 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [346]
Cantini F, Marchesoni A, Novelli L et al.. “Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.” Rheumatology (Oxford, England) (2024). PMID: 38331400 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [347]
McGonagle D, Kavanaugh A, McInnes IB et al.. “Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 38341669 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [348]
Xue Y, Sun L, Zhang N et al.. “Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.” Rheumatology (Oxford, England) (2026). PMID: 41632483 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [349]
Kavanaugh A, Coates LC, Mease PJ et al.. “Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.” Rheumatology (Oxford, England) (2025). PMID: 39423145 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [350]
Burmester GR, Cohen SB, Winthrop KL et al.. “Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.” RMD open (2023). PMID: 36754548 ↗
L2TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [351]
Mease PJ, Reddy S, Ross S et al.. “Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.” RMD open (2024). PMID: 38296801 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [352]
Qin P, Kragsnaes MS, Holm DK et al.. “Clinical Significance of Gut Microbiota Community Types for Long-Term Response to Fecal Microbiota Transplantation in Patients With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40814761 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [353]
Ogdie A, Merola JF, Mease PJ et al.. “Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41670439 ↗
L1OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [354]
Chin A, Terrett A, Kwon M et al.. “Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.” Arthritis care & research (2025). PMID: 40256995 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [355]
Sparks JA, Lesperance T, Accortt NA et al.. “Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.” Arthritis care & research (2019). PMID: 29799667 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment - [356]
Hastings R, Ding T, Butt S et al.. “Neutropenia in patients receiving anti-tumor necrosis factor therapy.” Arthritis care & research (2010). PMID: 20535786 ↗
L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [357]
Lee MP, Lii J, Jin Y et al.. “Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.” Arthritis care & research (2018). PMID: 28804988 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [358]
Tonutti A, Abacar K, Macleod T et al.. “Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis.” The Lancet. Rheumatology (2025). PMID: 41319674 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [359]
Al-Mossawi H, Taams LS, Goodyear CS et al.. “Precision medicine in psoriatic arthritis: how should we select targeted therapies?” The Lancet. Rheumatology (2019). PMID: 38229362 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [360]
Bentvelzen MLM, El Bouhaddani S, Spierings J et al.. “Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.” Arthritis research & therapy (2026). PMID: 41821126 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History - [361]
Atwan A, Ingram JR, Abbott R et al.. “Oral fumaric acid esters for psoriasis.” The Cochrane database of systematic reviews (2015). PMID: 26258748 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [362]
Ramiro S, Radner H, van der Heijde D et al.. “Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).” The Cochrane database of systematic reviews (2011). PMID: 21975788 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [363]
Colebatch AN, Marks JL, Edwards CJ. “Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).” The Cochrane database of systematic reviews (2011). PMID: 22071858 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [364]
Huynh D, Kavanaugh A. “Psoriatic arthritis: current therapy and future approaches.” Rheumatology (Oxford, England) (2014). PMID: 25125588 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [365]
Ribeiro AL, Singla S, Hay-Rollins C et al.. “Deciphering difficult-to-treat psoriatic arthritis: insights from an international survey of patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2025). PMID: 40221862 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [366]
Vassilakis KD, Papagoras C, Fytanidis N et al.. “Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry.” Rheumatology (Oxford, England) (2024). PMID: 38759119 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [367]
James L, Diamond C, Al-Mossawi H et al.. “High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.” Rheumatology (Oxford, England) (2025). PMID: 40569171 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [368]
Cronstein BN, Aune TM. “Methotrexate and its mechanisms of action in inflammatory arthritis.” Nature reviews. Rheumatology (2020). PMID: 32066940 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [369]
Gossec L, Coates LC, de Wit M et al.. “Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.” Nature reviews. Rheumatology (2016). PMID: 27829672 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [370]
McHugh J. “Optimizing methotrexate withdrawal during COVID vaccination.” Nature reviews. Rheumatology (2022). PMID: 36180548 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [371]
Davies K, Dures E, Ng WF. “Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.” Nature reviews. Rheumatology (2021). PMID: 34599320 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [372]
Maksymowych WP. “Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?” Nature reviews. Rheumatology (2013). PMID: 23917954 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [373]
Dures E, Shepperd S, Mukherjee S et al.. “Treat-to-target in PsA: methods and necessity.” RMD open (2020). PMID: 32071281 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [374]
Paci V, Zabotti A, Fontanarosa A et al.. “Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study.” RMD open (2026). PMID: 41876147 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [375]
Agrawal A, Yadav SS, Balakrishnan C. “Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42146074 ↗
L4CASE_REPORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [376]
Hegazy EM, Sadek EA, Ahmed SS. “Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case-control study of adalimumab and methotrexate.” Clinical rheumatology (2026). PMID: 41848948 ↗
L3CASE_CONTROLCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [377]
Anacleto-Dabarno M, Kharouf F, Carrizo Abarza V et al.. “Do Patients Diagnosed with Psoriatic Arthritis Before or Concurrently with Psoriasis Have Different Disease Phenotype and Outcomes?” The Journal of rheumatology (2026). PMID: 42386278 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [378]
Gossec L, Smolen JS, Gaujoux-Viala C et al.. “European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.” Annals of the rheumatic diseases (2011). PMID: 21953336 ↗
L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [379]
Gossec L, Smolen JS, Ramiro S et al.. “European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.” Annals of the rheumatic diseases (2015). PMID: 26644232 ↗
L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [380]
Smolen JS, Braun J, Dougados M et al.. “Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.” Annals of the rheumatic diseases (2013). PMID: 23749611 ↗
L5SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [381]
Russell MD, Schaffer A, Yang Z et al.. “Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.” The Lancet. Rheumatology (2026). PMID: 42379213 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [382]
Mease PJ, Gladman DD, Deodhar A et al.. “Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.” RMD open (2020). PMID: 32665433 ↗
L1RCTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [383]
Zhao SS, Pittam B, Harrison NL et al.. “Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33428758 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [384]
Bengtsson K, Forsblad-d'Elia H, Deminger A et al.. “Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study.” Rheumatology (Oxford, England) (2021). PMID: 33216939 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [385]
Winthrop KL, Weinblatt ME, Bathon J et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.” Annals of the rheumatic diseases (2019). PMID: 31662322 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [386]
Winthrop KL, Weinblatt ME, Crow MK et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.” Annals of the rheumatic diseases (2019). PMID: 30712015 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [387]
Binod KC, Jabbour A, Poudel P et al.. “IL-17A inhibitor-induced leucocytoclastic vasculitis is responsive to IL-23 blockade in a psoriatic arthritis patient.” Annals of the rheumatic diseases (2024). PMID: 37679036 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [388]
Gutierrez M, Filippucci E, Salaffi F et al.. “Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level.” Annals of the rheumatic diseases (2011). PMID: 21406459 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [389]
Eder L, Croxford R, Drucker AM et al.. “Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.” Arthritis care & research (2022). PMID: 34486829 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related - [390]
Hamdi W, Migowa A, Ferjani HL et al.. “Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.” Clinical rheumatology (2025). PMID: 39893309 ↗
L5GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [391]
Barozet M, Le Tilly O, Bejan-Angoulvant T et al.. “Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis.” Current hypertension reports (2024). PMID: 38819751 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [392]
Freitag M, Kolb P, Falcone V et al.. “Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.” Rheumatology (Oxford, England) (2026). PMID: 41335463 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [393]
Westerweel PE, Verhaar MC. “Endothelial progenitor cell dysfunction in rheumatic disease.” Nature reviews. Rheumatology (2009). PMID: 19434075 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [394]
Mease PJ, Gladman DD, Samad AS et al.. “Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).” RMD open (2018). PMID: 29531787 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [395]
Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V et al.. “Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.” RMD open (2022). PMID: 36597972 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [396]
Atschekzei F, Dubrowinskaja N, Anim M et al.. “Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis.” RMD open (2022). PMID: 36113963 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [397]
Pukšić S, Bolton-King P, Sexton J et al.. “DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.” RMD open (2018). PMID: 30487999 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [398]
Oliveira-Ramos F, Eusébio M, M Martins F et al.. “Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage.” RMD open (2016). PMID: 27752356 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [399]
Veltri C, Albrecht K, Kiltz U et al.. “Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010-2022).” RMD open (2025). PMID: 39863303 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [400]
Laatar A, Miladi S, Fazaa A et al.. “[Not Available].” La Tunisie medicale (2025). PMID: 39812192 ↗
L5GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [401]
Baekdal JA, Bjerken L, Hansen ESH et al.. “Interstitial lung disease in psoriasis: A systematic review and meta-analysis.” Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG (2026). PMID: 41891404 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [402]
Yan R, Ke D, Zhang Y et al.. “Clinical features and therapeutic challenges of psoriatic arthritis coexisting with antisynthetase syndrome: a case report and literature review.” Frontiers in immunology (2025). PMID: 40861474 ↗
L4CASE_REPORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [403]
Magen E, Aamar S, Magen I et al.. “Long-term rheumatologic comorbidities in familial Mediterranean fever.” Seminars in arthritis and rheumatism (2026). PMID: 42250404 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [404]
Rotondo C, Busto G, Barile R et al.. “HLA-B*51 Beyond Behcet's Disease: Topography of Symptoms, Associated Diagnoses, and Characterization of Chronic Inflammatory Arthritis Phenotypes.” International journal of molecular sciences (2026). PMID: 42123313 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [405]
Peters MJ, Symmons DP, McCarey D et al.. “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.” Annals of the rheumatic diseases (2009). PMID: 19773290 ↗
L1GUIDELINECited in: Complications: Disease-Driven & Treatment-Related - [406]
Michielsens CA, den Broeder N, van den Hoogen FH et al.. “Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.” Annals of the rheumatic diseases (2022). PMID: 35701155 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related - [407]
Burmester GR, Mease P, Dijkmans BA et al.. “Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.” Annals of the rheumatic diseases (2009). PMID: 19147611 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [408]
Burmester GR, Panaccione R, Gordon KB et al.. “Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.” Annals of the rheumatic diseases (2012). PMID: 22562972 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [409]
Jamnitski A, Symmons D, Peters MJ et al.. “Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.” Annals of the rheumatic diseases (2012). PMID: 22532629 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [410]
Mok CC, Ko GT, Ho LY et al.. “Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.” Arthritis care & research (2011). PMID: 20890981 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [411]
Mease P, Roussou E, Burmester GR et al.. “Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.” Arthritis care & research (2019). PMID: 30156760 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [412]
Exarchou S, Di Giuseppe D, Klingberg E et al.. “Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study.” Annals of the rheumatic diseases (2024). PMID: 38049985 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related - [413]
Wetzman A, Lukas C, Gaujoux-Viala C et al.. “Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.” Arthritis care & research (2022). PMID: 34549898 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [414]
Lin TC, Yoshida K, Tedeschi SK et al.. “Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.” Arthritis care & research (2018). PMID: 28834412 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [415]
Ernste FC, Sánchez-Menéndez M, Wilton KM et al.. “Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study.” Arthritis care & research (2015). PMID: 25581120 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related - [416]
Wells AF, Edwards CJ, Kivitz AJ et al.. “Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.” Rheumatology (Oxford, England) (2022). PMID: 34100922 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment - [417]
Leng X, Lin W, Liu S et al.. “Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.” RMD open (2023). PMID: 36720560 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related - [418]
Genovese MC, Mysler E, Tomita T et al.. “Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.” Rheumatology (Oxford, England) (2020). PMID: 32449924 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [419]
Charles-Schoeman C, Choy E, McInnes IB et al.. “MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.” RMD open (2023). PMID: 37945286 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related - [420]
Mease PJ, Gensler LS, Orbai AM et al.. “Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.” RMD open (2025). PMID: 40194794 ↗
L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [421]
Kerschbaumer A, Smolen JS, Nash P et al.. “Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.” RMD open (2020). PMID: 33188136 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [422]
Xia J, Xie SY, Liu KQ et al.. “Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study.” Annals of the rheumatic diseases (2020). PMID: 32737104 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [423]
Magnusson K, Turkiewicz A, Rydén M et al.. “Genetic Influence on Osteoarthritis Versus Other Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37691153 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [424]
Wu S, Li WQ, Han J et al.. “Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24504802 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [425]
Colaco K, Lee KA, Akhtari S et al.. “Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37691498 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [426]
Accortt NA, Bonafede MM, Collier DH et al.. “Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26359948 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [427]
Yang KL, Mullins BJ, Lejeune A et al.. “Mitigation of Osteoclast-Mediated Arthritic Bone Remodeling By Short Chain Fatty Acids.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37994265 ↗
L5OTHERCited in: Complications: Disease-Driven & Treatment-Related - [428]
Hoving JL, Lacaille D, Urquhart DM et al.. “Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis.” The Cochrane database of systematic reviews (2014). PMID: 25375291 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [429]
Toma AO, Crainic D, Mateescu DM et al.. “Effects of Biologic Therapies and Narrowband UVB Phototherapy on Vascular Inflammation and Systemic Inflammatory Biomarkers in Psoriasis: A Systematic Review and Narrative Synthesis of Prospective Studies.” Journal of clinical medicine (2026). PMID: 41976889 ↗
L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [430]
Li P, Wang Q, Yang Y et al.. “Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.” Frontiers in immunology (2025). PMID: 41425574 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [431]
Tam LS, Leung YY, Li EK. “Psoriatic arthritis in Asia.” Rheumatology (Oxford, England) (2009). PMID: 19713440 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [432]
Xie W, Bian W, Song Z et al.. “Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2023). PMID: 36897031 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [433]
Cheng IT, Li EK, Wong PC et al.. “Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?” Rheumatology (Oxford, England) (2020). PMID: 32087023 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [434]
Lioté F, Constantin A, Dahan É et al.. “A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).” Rheumatology (Oxford, England) (2024). PMID: 37261843 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [435]
Soós B, Szentpétery Á, Raterman HG et al.. “Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.” Nature reviews. Rheumatology (2022). PMID: 35273387 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [436]
Croft M, Siegel RM. “Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.” Nature reviews. Rheumatology (2017). PMID: 28275260 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [437]
Regierer AC, Hasseli R, Schäfer M et al.. “TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.” RMD open (2021). PMID: 34670840 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [438]
Raadsen R, Hansildaar R, Pouw LC et al.. “Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.” RMD open (2023). PMID: 38053460 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [439]
Haddad A, Zabari Parnis E, Stein N et al.. “The Association Between SARS-CoV-2 Exposure, COVID-19 Vaccination and Psoriatic Arthritis-A Nested Case-Control Study.” Vaccines (2026). PMID: 42042765 ↗
L3CASE_CONTROLCited in: Complications: Disease-Driven & Treatment-Related - [440]
Martini M, Logiudice L, Mazzuoccolo LD et al.. “Neutrophil-to-Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study.” ACR open rheumatology (2026). PMID: 42055019 ↗
L3COHORTCited in: Complications: Disease-Driven & Treatment-Related - [441]
Yang Z, Atzeni F, Russell M et al.. “Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK.” Rheumatology advances in practice (2026). PMID: 41695577 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related - [442]
Firdous S, Amjad H, Choudhary MU et al.. “Emerging biological therapies for psoriatic arthritis: A systematic review.” Medicine (2025). PMID: 41189198 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [443]
Majjad A, El Guarti S, Mansouri H et al.. “Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study.” Journal of psoriasis and psoriatic arthritis (2025). PMID: 41459256 ↗
L4COHORTCited in: Complications: Disease-Driven & Treatment-Related - [444]
Charca LC, Braña I, Loredo M et al.. “Multisite Atherosclerosis and SCORE2-Based Risk Stratification in Psoriatic Arthritis: A Phenotype-Dependent Role of Vascular Territories.” Biomedicines (2026). PMID: 42351823 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [445]
Tillett W, Allen A, Tucker L et al.. “Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.” Rheumatology (Oxford, England) (2021). PMID: 33097948 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [446]
van der Heijde D, Deodhar A, Fleischmann R et al.. “Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.” Arthritis care & research (2017). PMID: 27696727 ↗
L1RCTCited in: History and Evolution of Treatment - [447]
Helliwell PS, Deodhar A, Gottlieb AB et al.. “Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.” Arthritis care & research (2020). PMID: 31421033 ↗
L1RCTCited in: History and Evolution of Treatment - [448]
Coates LC, Mease PJ, Gossec L et al.. “Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.” Arthritis care & research (2018). PMID: 29409133 ↗
L1RCTCited in: History and Evolution of Treatment - [449]
Mease PJ, Goffe BS, Metz J et al.. “Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.” Lancet (London, England) (2000). PMID: 10972371 ↗
L1RCTCited in: History and Evolution of Treatment - [450]
Choufani M, Ermann J, Goel N. “Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed.” Arthritis care & research (2025). PMID: 40386882 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [451]
Wu D, Yue J, Tam LS. “Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.” Rheumatology (Oxford, England) (2018). PMID: 29244162 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [452]
Gossec L, Baraliakos X, Aletaha D et al.. “Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.” Rheumatology (Oxford, England) (2025). PMID: 39437003 ↗
L1RCTCited in: History and Evolution of Treatment - [453]
Taylor PC, Kavanaugh A, Bessette L et al.. “Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.” RMD open (2026). PMID: 41506743 ↗
L1RCTCited in: History and Evolution of Treatment - [454]
Gladman D, Tillett W, Gruben D et al.. “Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.” RMD open (2025). PMID: 40461265 ↗
L1RCTCited in: History and Evolution of Treatment - [455]
Gladman D, Nash P, Goto H et al.. “Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis.” RMD open (2020). PMID: 31958274 ↗
L1RCTCited in: History and Evolution of Treatment - [456]
Masson Regnault M, Brenaut E, Marniquet ME et al.. “French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41469898 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Prevention - [457]
Goel N. “Conducting research in psoriatic arthritis: the emerging role of patient research partners.” Rheumatology (Oxford, England) (2020). PMID: 32159791 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [458]
Eyre S, Orozco G, Worthington J. “The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping.” Nature reviews. Rheumatology (2017). PMID: 28569263 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Prevention - [459]
Solmaz D, Bakirci S, Kimyon G et al.. “Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease.” Arthritis care & research (2020). PMID: 30680951 ↗
L2OTHERCited in: History and Evolution of Treatment - [460]
Gossec L, Balanescu A, D'Agostino MA et al.. “Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.” Arthritis research & therapy (2025). PMID: 41318485 ↗
L1RCTCited in: History and Evolution of Treatment - [461]
Assmann G, Klemm PCM, Hedrich C et al.. “[Diagnosis and treatment of chronic nonbacterial osteitis (CNO) and SAPHO syndrome : Implications of the current consensus recommendations of an international commission of experts for German rheumatology].” Zeitschrift fur Rheumatologie (2025). PMID: 41313366 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [462]
Desai RJ, Thaler KJ, Mahlknecht P et al.. “Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.” Arthritis care & research (2016). PMID: 26663412 ↗
L1SR_OBSCited in: Prognosis & Natural History - [463]
Glerup M, Arnstad ED, Rypdal V et al.. “Changing Patterns in Treatment, Remission Status, and Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis.” Arthritis care & research (2022). PMID: 35015381 ↗
L2COHORTCited in: Prognosis & Natural History - [464]
Mease PJ, McInnes IB, Tam LS et al.. “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33844022 ↗
L1SR_OBSCited in: Prognosis & Natural History - [465]
Bravo Vergel Y, Hawkins NS, Claxton K et al.. “The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2007). PMID: 17956918 ↗
L1SR_OBSCited in: Prognosis & Natural History - [466]
Chang CA, Gottlieb AB, Lizzul PF. “Management of psoriatic arthritis from the view of the dermatologist.” Nature reviews. Rheumatology (2011). PMID: 21912431 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [467]
Pisaniello HL, Whittle SL, Johnston RV et al.. “Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.” The Cochrane database of systematic reviews (2025). PMID: 41025432 ↗
L5OTHERCited in: Prognosis & Natural History - [468]
Elkayam O, Amir S, Mendelson E et al.. “Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.” Arthritis care & research (2011). PMID: 21425247 ↗
L3RCTCited in: Special Populations, Pregnancy & Prevention - [469]
Marzo-Ortega H, McGonagle D, Rhodes LA et al.. “Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis.” Annals of the rheumatic diseases (2006). PMID: 17185324 ↗
L4TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Prevention - [470]
Mariette X, Förger F, Abraham B et al.. “Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.” Annals of the rheumatic diseases (2017). PMID: 29030361 ↗
L2TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Prevention - [471]
Fleischmann R, Baumgartner SW, Weisman MH et al.. “Long term safety of etanercept in elderly subjects with rheumatic diseases.” Annals of the rheumatic diseases (2005). PMID: 16150792 ↗
L2SR_OBSCited in: Special Populations, Pregnancy & Prevention - [472]
Kerschbaumer A, Smolen JS, Dougados M et al.. “Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2020). PMID: 32381564 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention - [473]
Schieir O, Tosevski C, Glazier RH et al.. “Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2017). PMID: 28219882 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention - [474]
Mehta P, Gao S, Abarza VC et al.. “Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41854268 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [475]
Pattison E, Harrison BJ, Griffiths CE et al.. “Environmental risk factors for the development of psoriatic arthritis: results from a case-control study.” Annals of the rheumatic diseases (2007). PMID: 17823200 ↗
L3CASE_CONTROLCited in: Special Populations, Pregnancy & Prevention - [476]
Bjørlykke KH, Ørbo HS, Tveter AT et al.. “Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.” The Lancet. Rheumatology (2022). PMID: 36415604 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [477]
Xie W, Huang H, Ji L et al.. “Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33878171 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention - [478]
Nagra D, Bechman K, Russell MD et al.. “Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38833673 ↗
L3COHORTCited in: Special Populations, Pregnancy & Prevention - [479]
Kharouf F, Mehta P, Carrizo Abarza V et al.. “Subclinical psoriatic arthritis: concepts, dilemmas, and research needs.” Annals of the rheumatic diseases (2026). PMID: 41934034 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention - [480]
Lortholary O, Fernandez-Ruiz M, Baddley JW et al.. “Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.” Annals of the rheumatic diseases (2020). PMID: 32963049 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention - [481]
Syversen SW, Jyssum I, Tveter AT et al.. “Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35507355 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [482]
Eder L, Lee KA, Chandran V et al.. “Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37555242 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [483]
Yun H, Yang S, Chen L et al.. “Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26990731 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention - [484]
Favalli EG, Monti S, Ingegnoli F et al.. “Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32506699 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [485]
Desai RJ, Huybrechts KF, Bateman BT et al.. “Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26606742 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [486]
Secher AEP, Granath F, Remaeus K et al.. “Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway.” RMD open (2025). PMID: 41052892 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [487]
Secher AEP, Granath F, Glintborg B et al.. “Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.” RMD open (2022). PMID: 36328400 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [488]
George MD, Baker JF, Hsu JY et al.. “Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.” Arthritis care & research (2017). PMID: 28129484 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention - [489]
Sumpton D, Oliffe M, Kane B et al.. “Patients' Perspectives on Shared Decision-Making About Medications in Psoriatic Arthritis: An Interview Study.” Arthritis care & research (2022). PMID: 34235887 ↗
L5OTHERCited in: Special Populations, Pregnancy & Prevention - [490]
Crauwels H, Ringold S, Howard S et al.. “Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.” Paediatric drugs (2025). PMID: 41152645 ↗
L5RCTCited in: Special Populations, Pregnancy & Prevention - [491]
Dulai AS, Joshi A, Min M et al.. “Systematic Review of Accelerated Epigenetic Aging in Chronic Inflammatory Dermatology Conditions.” International journal of dermatology (2025). PMID: 40940698 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention - [492]
Yang A, Cheng B, Seyger MMB et al.. “The Burden of Pediatric Psoriasis: A Systematic Review.” American journal of clinical dermatology (2025). PMID: 40694272 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention - [493]
Kerola AM, Kazemi A, Rollefstad S et al.. “All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.” Rheumatology (Oxford, England) (2022). PMID: 35377442 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [494]
Nakafero G, Grainge MJ, Card T et al.. “Uptake and safety of pneumococcal vaccination in adults with immune-mediated inflammatory diseases: a UK wide observational study.” Rheumatology (Oxford, England) (2025). PMID: 38479823 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [495]
Rider LG, Parks CG, Wilkerson J et al.. “Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.” Rheumatology (Oxford, England) (2022). PMID: 35460240 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [496]
Tang MW, Reedquist KA, Garcia S et al.. “The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation.” Rheumatology (Oxford, England) (2016). PMID: 27616146 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [497]
Perez-Chada LM, Haberman RH, Chandran V et al.. “Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study.” Nature reviews. Rheumatology (2021). PMID: 33589818 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention - [498]
Miao Y, Beauchet A, Piram M et al.. “Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41104794 ↗
L3COHORTCited in: Special Populations, Pregnancy & Prevention - [499]
Koehm M, Behrens F. “Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.” RMD open (2023). PMID: 37734874 ↗
L5OTHERCited in: Special Populations, Pregnancy & Prevention - [500]
Kumar C, Kuhn M, Herrmann K et al.. “Severe methotrexate toxicity in elderly patients under diuretics.” RMD open (2024). PMID: 38176739 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [501]
Correll CK, Stryker S, Collier D et al.. “Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry.” RMD open (2023). PMID: 37230760 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [502]
Kummer LYL, Fernández Blanco L, Kreher C et al.. “Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.” RMD open (2024). PMID: 39375177 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention - [503]
Miller JB, Adler BL, Orbai AM et al.. “Estimating the incidence of autoimmune inflammatory arthritis after Lyme disease.” Seminars in arthritis and rheumatism (2025). PMID: 40706260 ↗
L2bCited in: Definition, Classification & Nomenclature - [504]
Yildiz M, Konte EK, Aslan E et al.. “Classification of Nonsystemic Juvenile Idiopathic Arthritis Using the Provisional Paediatric Rheumatology International Trials Organisation Criteria.” The Journal of rheumatology (2026). PMID: 41621940 ↗
L3bCited in: Definition, Classification & Nomenclature - [505]
Reddy S, Patel B, Dellon ES et al.. “High prevalence of esophageal motility disorders in patients with rheumatologic diseases.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2025). PMID: 39586592 ↗
L3bCited in: Definition, Classification & Nomenclature - [506]
Philippoteaux C, Marty-Ane A, Cailliau E et al.. “Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis.” Seminars in arthritis and rheumatism (2023). PMID: 37852155 ↗
L3bCited in: Definition, Classification & Nomenclature - [507]
Shridharmurthy D, Lapane KL, Baek J et al.. “Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data.” BMJ open (2022). PMID: 36549721 ↗
L4Cited in: Definition, Classification & Nomenclature - [508]
Vo Chieu VD, Vo Chieu V, Dressler F et al.. “Juvenile idiopathic arthritis of the knee: is contrast needed to score disease activity when using an augmented MRI protocol comprising PD-weighted sequences?” European radiology (2022). PMID: 36472701 ↗
L4Cited in: Definition, Classification & Nomenclature - [509]
Kunchok A, Aksamit AJ, Davis JM et al.. “Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.” JAMA neurology (2020). PMID: 32421186 ↗
L3bCited in: Definition, Classification & Nomenclature - [510]
Venerito V, Lopalco G, Morrone M et al.. “fAI-BRO: a multimodal AI decision-support system to address diagnostic delay in fibromyalgia syndrome.” RMD open (2026). PMID: 42442924 ↗
L4Cited in: Definition, Classification & Nomenclature - [511]
de Souza VA, Macedo DM, Guimarães NS et al.. “Patients with chikungunya meeting criteria for inflammatory rheumatic diseases: a systematic literature review and meta-analysis.” Advances in rheumatology (London, England) (2025). PMID: 40993769 ↗
L2aCited in: Definition, Classification & Nomenclature - [512]
Moen HV, Hänel M, Therkildsen J et al.. “Bony proliferations in rheumatoid arthritis, psoriatic arthritis and osteoarthritis using high-resolution peripheral quantitative computed tomography-A systematic literature review.” International journal of rheumatic diseases (2024). PMID: 38334245 ↗
L2aCited in: Definition, Classification & Nomenclature - [513]
Loganathan A, Kamalaraj N, El-Haddad C et al.. “Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis.” International journal of rheumatic diseases (2021). PMID: 34076348 ↗
L2aCited in: Definition, Classification & Nomenclature - [514]
Eghleilib M, Eghlileb M, Eghlileb A. “Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review.” Cureus (2026). PMID: 41822639 ↗
L1aCited in: Pathophysiology & Mechanism - [515]
Eder L, Perez-Chada L, Liao W et al.. “Psoriasis.” Lancet (London, England) (2026). PMID: 42526473 ↗
L5Cited in: Pathophysiology & Mechanism - [516]
Osunbor O, Nkeck JR, Adebajo AO. “Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review.” Expert opinion on investigational drugs (2026). PMID: 42524831 ↗
L5Cited in: Pathophysiology & Mechanism - [517]
Osunbor O, Nkeck JR, Adebajo AO. “Investigational interleukin 17A antagonists in the treatment of psoriatic arthritis.” Expert opinion on investigational drugs (2026). PMID: 42522956 ↗
L5Cited in: Pathophysiology & Mechanism - [518]
Cattalini M, Amerio P, Bertolla D et al.. “From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin-joint interface in inflammatory diseases: a narrative review.” Current opinion in immunology (2026). PMID: 42520363 ↗
L5Cited in: Pathophysiology & Mechanism - [519]
Madsen N, Coates LC, Merola JF et al.. “Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care.” RMD open (2026). PMID: 42457215 ↗
L5Cited in: Pathophysiology & Mechanism - [520]
Conforti A, Russo V, Lucchetti L et al.. “Ketogenic diet in rheumatoid arthritis, psoriatic arthritis and psoriasis: A scoping review of clinical and mechanistic evidence.” Autoimmunity reviews (2026). PMID: 42456869 ↗
L5Cited in: Pathophysiology & Mechanism - [521]
Kemeness C, Garcia-Hernandez ML, Schandua H et al.. “Pathogenesis of psoriasis and psoriatic arthritis: Insights from animal models and single-cell and spatial transcriptomic analyses of skin, synovium and entheses.” Best practice & research. Clinical rheumatology (2026). PMID: 42173724 ↗
L5Cited in: Pathophysiology & Mechanism - [522]
Cohen S, Winthrop KL. “Advances in the use of Janus kinase inhibitors.” Current opinion in rheumatology (2026). PMID: 41841670 ↗
L5Cited in: Pathophysiology & Mechanism - [523]
Bazsó A, Szodoray P, Shoenfeld Y et al.. “Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction.” Autoimmunity reviews (2026). PMID: 41839428 ↗
L5Cited in: Pathophysiology & Mechanism - [524]
Kulyk M, De Vlam K. “The promise of biomarkers in Psoriatic Arthritis: Moving towards precision medicine.” Best practice & research. Clinical rheumatology (2026). PMID: 41832134 ↗
L5Cited in: Pathophysiology & Mechanism - [525]
Gibson M, Allen V, Adas M et al.. “Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.” Annals of the rheumatic diseases (2026). PMID: 42431784 ↗
L1aCited in: Epidemiology, Etiology & Risk Factors - [526]
Armstrong AW, Lebwohl M, Warren RB et al.. “Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.” American journal of clinical dermatology (2026). PMID: 42563042 ↗
L1bCited in: Epidemiology, Etiology & Risk Factors - [527]
Webers C, Smits ML, Renet E et al.. “Definition and prevalence of residual disease in inflammatory arthritis: a systematic literature review and meta-analysis.” Seminars in arthritis and rheumatism (2026). PMID: 42485861 ↗
L2aCited in: Epidemiology, Etiology & Risk Factors - [528]
Dons M, Sengeløv M, Skaarup KG et al.. “Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2026). PMID: 42466607 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [529]
Ricigliano VAG, Masmoudi I, Boudot de la Motte M et al.. “Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.” Therapeutic advances in neurological disorders (2026). PMID: 42344942 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors - [530]
Ungureanu RD, Bita CE, Voicu MN et al.. “Fibrinogen-to-Platelet Ratio and Hematologic Inflammatory Indexes in Spondylarthritis.” Journal of clinical medicine (2026). PMID: 42074729 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors - [531]
Wang Z, Zhou Z, Jiang R et al.. “Development and validation of a predictive nomogram for osteoporosis in patients with psoriasis.” Frontiers in medicine (2026). PMID: 42500518 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [532]
Zaręba W, Szeląg M, Batko K et al.. “Comorbidity Profiles at Diagnosis in Rheumatoid Arthritis Versus Psoriatic Arthritis: A Nationwide Polish Claims-Based Study.” Journal of clinical medicine (2026). PMID: 42452709 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [533]
Chacón C, Toledano E, Queiró R et al.. “Central sensitization in psoriatic arthritis: prevalence, clinical correlates, and association with therapeutic refractoriness in an unselected cohort excluding fibromyalgia.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42222658 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [534]
Parchão A, Monteiro C, Araújo-Andrade L et al.. “Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort.” Journal of clinical medicine (2026). PMID: 42194695 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [535]
Wu SL, Pan SY, Weng CH et al.. “Janus Kinase inhibitors associated with reduced anterior uveitis risk in autoimmune diseases.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 41961254 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [536]
Mahajan A, Bates DW, Doria A et al.. “Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes.” ACR open rheumatology (2026). PMID: 42415363 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [537]
Zhuo X, Wang J, Wang X et al.. “Association Between Psoriasis and Overactive Bladder Among US Adults: A Study Based on 2005-2006 and 2009-2014 National Health and Nutrition Examination Survey.” Neurourology and urodynamics (2026). PMID: 42554142 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [538]
Tosato S, Bonetto C, Maggioni L et al.. “Prevalence and determinants of state and trait anxiety in inflammatory rheumatic diseases.” Journal of psychosomatic research (2026). PMID: 42537270 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [539]
Coates LC, Gladman DD, Merola JF et al.. “Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.” Rheumatology (Oxford, England) (2026). PMID: 42384964 ↗
L1bCited in: Clinical Presentation - [540]
Perton FT, Pouw JN, Spierings J et al.. “Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial.” Arthritis research & therapy (2026). PMID: 42204623 ↗
L1bCited in: Clinical Presentation - [541]
Qiu Z, Chen Z, Yang Z et al.. “Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies.” Frontiers in medicine (2026). PMID: 42440529 ↗
L2aCited in: Clinical Presentation - [542]
Abdul Jalil NA, Chinoy H, Jani M et al.. “Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways.” Rheumatology (Oxford, England) (2026). PMID: 41987562 ↗
L2bCited in: Clinical Presentation - [543]
Oliver M, Mosesso K, Weiss PF et al.. “Clinical Disease Manifestations Associated with Tumor Necrosis Factor inhibitor non-Response in Juvenile Spondyloarthritis.” The Journal of rheumatology (2026). PMID: 42386274 ↗
L3bCited in: Clinical Presentation - [544]
Lopalco G, Del Vescovo S, Luchetti MM et al.. “Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis.” Rheumatology (Oxford, England) (2026). PMID: 41999231 ↗
L3bCited in: Clinical Presentation - [545]
Fatica M, Perrotta FM, Conigliaro P et al.. “Predicting the course: Real-world trajectories toward minimal disease activity in psoriatic arthritis.” Autoimmunity reviews (2026). PMID: 41946409 ↗
L3bCited in: Clinical Presentation - [546]
Durbin JW, Cui E, Kesick A et al.. “Outcomes Following Total Hip Arthroplasty in Patients Who Have Cutaneous Psoriasis and Psoriatic Arthritis.” The Journal of arthroplasty (2026). PMID: 41881203 ↗
L4Cited in: Clinical Presentation - [547]
He Z, Zhang YN, Wei JC et al.. “Increased risk of inflammatory bowel disease in ankylosing spondylitis compared to psoriasis.” Frontiers in immunology (2026). PMID: 41727477 ↗
L3bCited in: Clinical Presentation - [548]
Graell E, Delgado JF, Domingo Gomez A et al.. “Presence of autoantibodies targeting the shared epitope in rheumatoid arthritis and psoriatic arthritis.” Frontiers in immunology (2026). PMID: 41909691 ↗
L3bCited in: Clinical Presentation - [549]
Popescu CC, Enache L, Ștențel C et al.. “Real-World Distributions and Concordance of C-Reactive Protein and Erythrocyte Sedimentation Rate Across Rheumatic Diseases.” Clinics and practice (2026). PMID: 42041949 ↗
L3bCited in: Clinical Presentation - [550]
Corrao S, Scibetta S, Falcone F et al.. “Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders.” Frontiers in immunology (2026). PMID: 42465765 ↗
L4Cited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [551]
Carrizo-Abarza V, Mehta P, Kharouf F et al.. “Radiographic sacroiliitis progression in psoriatic arthritis.” Rheumatology (Oxford, England) (2026). PMID: 42384912 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [552]
Simon D, Minopoulou I, Bayat S et al.. “Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study.” Arthritis research & therapy (2026). PMID: 42568089 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [553]
Puig L, Tsai TF, Soriano ER et al.. “Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.” The Journal of dermatology (2026). PMID: 42226468 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [554]
Kapural L, Viradia I, Korunda S et al.. “Long-Term Effectiveness of Repeated, Single-Day Intravenous Ketamine Infusions for Severe Arthritis: A Retrospective Cohort Study.” Pain physician (2026). PMID: 42550528 ↗
L4Cited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [555]
Shields SA, Von Holle A, Padival R et al.. “Inflammatory marker profiles vary by BMI across Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis.” Frontiers in endocrinology (2026). PMID: 42539493 ↗
L3bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [556]
Anghel D, Cobilinschi CO, Prioteasă OG et al.. “Correlations between serum 25-hydroxyvitamin D levels and nailfold microvascular changes in psoriatic arthritis patients with distal interphalangeal arthritis treated with TNF inhibitors.” Frontiers in immunology (2026). PMID: 42519344 ↗
L3bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [557]
Mehta P, Yang M, Kharouf F et al.. “Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy.” Rheumatology (Oxford, England) (2026). PMID: 42281273 ↗
L3bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [558]
Ruiz-Montesinos D, Mendoza-Mendoza D, Bocio Núñez J et al.. “Role of the S1P/S1PR axis in inflammation and structural damage in psoriatic arthritis: a cross-sectional study with clinical, biochemical and imaging correlation.” RMD open (2026). PMID: 42259576 ↗
L3bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [559]
Fedkov D, Yevstifeiev D, Iaremenko O et al.. “Clinical-psychosocial archetypes predict short-term outcomes in inflammatory arthritis: an unsupervised segmentation study.” Clinical rheumatology (2026). PMID: 42207465 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [560]
Ramiro S, Capelusnik D, López-Medina C et al.. “Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.” Annals of the rheumatic diseases (2026). PMID: 42409723 ↗
L1bCited in: Severity, Disease Activity & Risk Stratification - [561]
Degerlund-Maldi K, Regardt M, Nystrand Länsman C et al.. “Construct validity and responsiveness of EQ-5D-3L and EQ VAS in psoriatic arthritis: an evaluation based on the Swedish Rheumatology Quality Register.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2026). PMID: 42493679 ↗
L3bCited in: Severity, Disease Activity & Risk Stratification - [562]
Conforti A, Gentile M, Cipolloni V et al.. “Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort.” Frontiers in medicine (2026). PMID: 42487949 ↗
L3bCited in: Severity, Disease Activity & Risk Stratification - [563]
Mukherjee J, Lakhanpal A, Smith MH et al.. “Clinical and Histopathologic Characteristics and Outcomes of Patients With Psoriatic Arthritis Undergoing Arthroplasty.” The Journal of rheumatology (2026). PMID: 42297439 ↗
L4Cited in: Severity, Disease Activity & Risk Stratification - [564]
Wilk M, Korkosz M, Haugeberg G. “Shedding light on sexuality in psoriatic arthritis: a 5-year prospective follow-up of an outpatient cohort.” Rheumatology international (2026). PMID: 42474514 ↗
L4Cited in: Severity, Disease Activity & Risk Stratification - [565]
Balay-Dustrude E, Fennell J, Baszis K et al.. “Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review.” Pediatric rheumatology online journal (2024). PMID: 39734203 ↗
L1aCited in: Acute Management: Flares & Organ-Threatening Disease - [566]
Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N et al.. “A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.” European journal of cancer (Oxford, England : 1990) (2024). PMID: 38834015 ↗
L1aCited in: Acute Management: Flares & Organ-Threatening Disease - [567]
Hoxha A, Striani G, Lovisotto M et al.. “COVID-19 vaccine and the risk of flares in inflammatory arthritis: a systematic literature review and meta-analysis.” Frontiers in immunology (2024). PMID: 39555064 ↗
L2aCited in: Acute Management: Flares & Organ-Threatening Disease - [568]
Aw NMY, Fong W, Shin K et al.. “Discontinuing or Tapering Biologic or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: A Systematic Literature Review.” International journal of rheumatic diseases (2025). PMID: 41355344 ↗
L1aCited in: Acute Management: Flares & Organ-Threatening Disease - [569]
Deodhar A, Nowak M, Ye JY et al.. “Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.” Rheumatology and therapy (2025). PMID: 40616721 ↗
L2bCited in: Acute Management: Flares & Organ-Threatening Disease - [570]
Tonutti A, Morandini P, Faeti C et al.. “Natural language processing to intercept rheumatoid and psoriatic arthritis from clinical notes in the Emergency Department.” Therapeutic advances in musculoskeletal disease (2026). PMID: 41948113 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [571]
Helliwell PS, Cañete JD, Coates LC et al.. “Further Validation of a Questionnaire to Assess Flare in Psoriatic Arthritis: Determination of Cutoff and Longitudinal Change.” The Journal of rheumatology (2026). PMID: 41833333 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [572]
Monticielo OA, Seguro LPC, de Ataíde Mariz H et al.. “Current landscape of immune-mediated inflammatory rheumatic diseases in Brazil's public and private systems: retrospective cohort study.” BMJ open (2025). PMID: 41285502 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [573]
Ippoliti E, Falco GM, Di Giorgi N et al.. “Journey of Patients with Psoriasis in an Italian Tertiary Centre, an 11-year Retrospective Analysis.” Acta dermato-venereologica (2025). PMID: 40200596 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [574]
Yazji SM, Helliwell PS, Balanescu A et al.. “Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis.” The Journal of rheumatology (2025). PMID: 39814446 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [575]
Mocanu V, Barber CEH, McLane P et al.. “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: A Population-Based Cohort Study.” The Journal of rheumatology (2025). PMID: 39814438 ↗
L3bCited in: Acute Management: Flares & Organ-Threatening Disease - [576]
Ting IPL, Teo HG, Koay BT et al.. “Population-Specific HLA Profiles in Generalised Pustular Psoriasis in Sarawak, Malaysia.” Experimental dermatology (2026). PMID: 42053151 ↗
L4Cited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [577]
Sheth ND, Ross BJ, Hrudka BT et al.. “The Effects of Disease-Modifying Anti-Rheumatic Drugs on Total Hip Arthroplasty Outcomes in Patients Who Have Inflammatory Arthropathies.” The Journal of arthroplasty (2026). PMID: 42001906 ↗
L3bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [578]
Yan T, He Q, Shi X. “Integrative Network Toxicology, Machine Learning, Single-Cell Analysis, scTenifoldKnk-Based Virtual Knockout, and Molecular Docking Suggest a Potential Molecular Link Between Aspartame and Rheumatoid Arthritis Involving HLA-DRB1.” International journal of molecular sciences (2026). PMID: 42450069 ↗
L3bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [579]
Capparelli E, Iacovantuono M, Tasso M et al.. “Diagnostic delay in the early phase of psoriatic arthritis is independently associated with adverse pain-related cognitive responses: a multicentre cross-sectional study.” Frontiers in immunology (2026). PMID: 42523834 ↗
L3bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [580]
Mulder MLM, McGagh D, Helliwell PS. “Introducing the Global Exploration of Psoriatic Arthritis Disease Activity Assessment (EXPLORE-PsA): The First Young-GRAPPA Research Initiative.” The Journal of rheumatology (2026). PMID: 42225331 ↗
L3bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [581]
Tan J, Bernatsky S, Lee JLF et al.. “COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study.” Vaccines (2025). PMID: 40006651 ↗
L2bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [582]
Rojas-Giménez M, Muñoz-Reinoso P, Arcila-Durán MD et al.. “An Analysis of Major Adverse Cardiovascular Events, Other Adverse Events, and Efficacy in Patients with Rheumatic Disease Receiving Targeted Therapy: Experience from a Third-Level Hospital.” Journal of clinical medicine (2025). PMID: 40649067 ↗
L4Cited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [583]
Gallardo-Nelson MJ, Cruces M, Gómez YM et al.. “4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.” Frontiers in immunology (2024). PMID: 39131157 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [584]
Flouda S, Grigoriou M, Sentis G et al.. “Peripheral blood transcriptomic analysis of patients with rheumatoid arthritis associated interstitial lung disease reveals: distinct molecular signature with evidence of humoral and myeloid immunity.” Arthritis research & therapy (2026). PMID: 42093034 ↗
L4Cited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [585]
Hung W, Azmi A, Katz S. “Rheumatic disease in Canada's Northwest Territories: baseline review and comparative insights.” Clinical rheumatology (2026). PMID: 42260210 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [586]
Bulut Gökten D, Ersözlü T, Gökten M et al.. “Audiometric evaluation of bone conduction thresholds reveals subclinical sensorineural hearing loss in patients with ankylosing spondylitis and psoriatic arthritis.” Brazilian journal of otorhinolaryngology (2026). PMID: 41967425 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [587]
Engel A, Xie C, Summer R et al.. “The risk of interstitial lung disease in psoriatic arthritis versus psoriasis: a retrospective nationwide database analysis (2014-24).” Rheumatology advances in practice (2025). PMID: 40520447 ↗
L4Cited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [588]
Khandwala P, Desai D, Lau A. “Prevalence of Autoimmune Diseases in Patients Treated With Immune Checkpoint Inhibitors: An Epidemiological Study Using A Global Network of Health Care Organizations.” ACR open rheumatology (2025). PMID: 39854167 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [589]
Kanaji N, Misaki N, Murota M et al.. “Prevalence and clinical features of interstitial lung disease in patients with psoriasis.” BMC pulmonary medicine (2024). PMID: 39695614 ↗
L4Cited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [590]
Ak T, Güner S, Albayrak B et al.. “Socioeconomic status in Behçet's syndrome.” Clinical and experimental rheumatology (2026). PMID: 42370509 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [591]
Lindner B, Ausserwinkler M, Siess C et al.. “[Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].” Wiener klinische Wochenschrift (2026). PMID: 41925750 ↗
L1cCited in: Complications: Disease-Driven & Treatment-Related - [592]
Mease PJ, Merola JF, Magrey M et al.. “Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.” RMD open (2026). PMID: 41807031 ↗
L2bCited in: Complications: Disease-Driven & Treatment-Related - [593]
Llorca J, Ferraz-Amaro I, Moreno-Martínez MJ et al.. “Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort.” Seminars in arthritis and rheumatism (2026). PMID: 41548490 ↗
L2bCited in: Complications: Disease-Driven & Treatment-Related - [594]
Osorio-Chávez JS, Portilla González V, Ferraz-Amaro I et al.. “Hepatotoxicity Risk of Isoniazid in Patients with Autoimmune Rheumatic Diseases and Prior Liver Injury Due to Disease-Modifying Antirheumatic Drugs: A Single-Center Experience and Literature Review.” Journal of clinical medicine (2026). PMID: 41598370 ↗
L3bCited in: Complications: Disease-Driven & Treatment-Related - [595]
Preuß SL, Olbrich H, Bieber K et al.. “COVID-19 Infection vs Vaccination and the Risk of New-onset Psoriasis.” Acta dermato-venereologica (2026). PMID: 41508833 ↗
L3bCited in: Complications: Disease-Driven & Treatment-Related - [596]
Balakrishnan K, Zangana LHM, Ajayi MR et al.. “Uptake of Shingles, Influenza, COVID-19 and Pneumococcal Vaccination in Patients with Inflammatory Arthritis: A Three-Centre Study.” Vaccines (2026). PMID: 42188773 ↗
L3bCited in: Complications: Disease-Driven & Treatment-Related - [597]
Augustin M, Sator PG, von Kiedrowski R et al.. “Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA.” Dermatology and therapy (2026). PMID: 41926037 ↗
L3bCited in: History and Evolution of Treatment - [598]
Tonutti A, Luciano N, Maizza B et al.. “Development of a confidence-based Natural Language Processing tool to identify inflammatory arthritis from non-inflammatory conditions in Rheumatology medical notes.” Arthritis research & therapy (2026). PMID: 41520124 ↗
L3bCited in: History and Evolution of Treatment - [599]
Karagianni S, Eleftheraki A, Papagoras C et al.. “Late-onset psoriatic arthritis: data from a nationwide cross-sectional study.” Therapeutic advances in musculoskeletal disease (2025). PMID: 41427120 ↗
L4Cited in: History and Evolution of Treatment - [600]
Messina OD, Clark P, Torres JM et al.. “Vitamin D in inflammatory rheumatic diseases: still a challenge.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42104141 ↗
L1bCited in: Prognosis & Natural History - [601]
Tada Y, Maeda Y, Hasegawa M et al.. “Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.” The Journal of dermatology (2026). PMID: 42504061 ↗
L3bCited in: Special Populations, Pregnancy & Prevention - [602]
Burlo F, Pastore S, Stocco G et al.. “Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology.” Arthritis research & therapy (2025). PMID: 41470033 ↗
L4Cited in: Special Populations, Pregnancy & Prevention - [603]
Ohyachi K, Takamura S, Iino K et al.. “Sex Differences in Response and Persistence to Biologic Therapy in Psoriatic Arthritis: A 52-Week Analysis With Extended Long-Term Outcomes.” The Journal of dermatology (2025). PMID: 41355591 ↗
L4Cited in: Special Populations, Pregnancy & Prevention - [604]
Miao KL, Huang MY, Guo L et al.. “Effect of biologic use on the development of psoriatic arthritis: A population-based study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41195984 ↗
L3bCited in: Special Populations, Pregnancy & Prevention - [605]
Kimpton J, Akpabio A, Watts A et al.. “Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.” RMD open (2026). PMID: 42618212 ↗
L1aCited in: Epidemiology, Etiology & Risk Factors - [606]
Nielung LM, Giuseppe DD, Hetland ML et al.. “Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries.” Annals of the rheumatic diseases (2026). PMID: 42697827 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [607]
Kougkas N, Sotiriou E, Deligeorgakis D et al.. “Biologic DMARD class influences progression from psoriasis to PsA: a real-world cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42584086 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [608]
Comdühr S, Sauer T, Deckert S et al.. “Skewed MHC Class I Peptide Presentation in Psoriatic Arthritis.” International journal of molecular sciences (2026). PMID: 42653321 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [609]
Bellis E, Gatto M, Cruciani C et al.. “Clinical and ultrasonographic features preceding a difficult-to-treat phenotype in psoriatic arthritis: a retrospective real-world exploratory cohort study.” Frontiers in immunology (2026). PMID: 42718874 ↗
L3bCited in: Clinical Presentation - [610]
Li R, Sang H, Zhang Y et al.. “Anterior-posterior topographic patterns of thoracic joint structural abnormalities on chest CT in psoriatic arthritis.” Frontiers in medicine (2026). PMID: 42718699 ↗
L3bCited in: Clinical Presentation - [611]
Li T, Zhang Z, Li D et al.. “CT-based structural phenotypes of thoracic small-joint involvement in psoriatic arthritis.” Frontiers in medicine (2026). PMID: 42662221 ↗
L3bCited in: Clinical Presentation - [612]
Guo Q, Luan H, Chen X et al.. “A Clinically Accessible Nomogram for Identifying Likely Psoriatic Arthritis Among Patients with Psoriasis: A Multicenter Cross-Sectional Study.” Journal of clinical medicine (2026). PMID: 42652619 ↗
L3bCited in: Clinical Presentation - [613]
Bikas DV, Brandon TG, Newby BN et al.. “HLA-B Associates With Distinct Disease Expression in Juvenile Spondyloarthritis: A Retrospective Cohort Study.” ACR open rheumatology (2026). PMID: 42610327 ↗
L3bCited in: Clinical Presentation - [614]
AbuJwaid YK, Assi AK, Amro AM et al.. “IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.” Frontiers in immunology (2026). PMID: 42661716 ↗
L1aCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [615]
Coates LC, Mease P, Kavanaugh A et al.. “Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.” RMD open (2026). PMID: 42660564 ↗
L1bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [616]
van der Heijde D, Mease PJ, Paul C et al.. “Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.” Annals of the rheumatic diseases (2026). PMID: 42562758 ↗
L1bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [617]
Baum H, Torgutalp M, Rios Rodriguez V et al.. “Clinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42703355 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [618]
Cai Z, Yan L, Zhang Y. “Efficacy and safety evaluation of adalimumab for psoriatic arthritis: A meta-analysis.” Medicine (2026). PMID: 42629706 ↗
L1aCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [619]
Pinto-Tasende JA, Garcia-Porrua C, Maceiras-Pan F et al.. “Treatment Persistence and Factors Associated with Bimekizumab Discontinuation in Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Multicenter Study.” Biomedicines (2026). PMID: 42652161 ↗
L2bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [620]
Charlton R, Tillett W, McHugh N et al.. “Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42565551 ↗
L3bCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [621]
Paci V, Foti R, Pantano I et al.. “IMPACT study: large real-world evaluation of guselkumab in psoriatic arthritis integrating clinical response and treatment persistence.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42719485 ↗
L1bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [622]
Villa-Gonzalez JM, Arevalo-Ortega I, Gonzalez-Hermosa MR et al.. “Potential Blood Biomarkers Predicting Treatment Response in Psoriasis: A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42590198 ↗
L2aCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [623]
Xie W, Chen T, Chen Y et al.. “Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.” American journal of clinical dermatology (2026). PMID: 42579249 ↗
L2aCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [624]
Hegazy EM, El Taieb MA, Hassan MH et al.. “TRAF3IP2 (rs13190932) polymorphism in psoriasis and psoriatic arthritis: susceptibility, systemic inflammation and response to methotrexate.” Postepy dermatologii i alergologii (2026). PMID: 42621284 ↗
L2bCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [625]
Moreira CR, de Alcântara CC, Mario Martin LM et al.. “NLRP3 genetic variants and their impact on psoriasis susceptibility, severity, and risk of psoriatic arthritis.” Human immunology (2025). PMID: 41207130 ↗
L3bCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [626]
Tankovic K, Claudepierre P, Vo TT et al.. “Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 42605840 ↗
L3bCited in: History and Evolution of Treatment - [627]
Pool IA, de Groot ADE, Keizer RJ et al.. “Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases.” Clinical pharmacokinetics (2026). PMID: 42631819 ↗
L4Cited in: Special Populations, Pregnancy & Prevention